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NHS: National Health Service 
NOAC: Novel oral anticoagulant 
NT-pro BNP: N-terminal pro-BNP 
NYHA:   New York Heart Association 
OSA: Obstructive Sleep Apnoea 
PCI: Percutaneous Coronary Intervention 
PET: Positron Emission Tomography 
PND: Paroxysmal Nocturnal Dyspnoea 
PMT: Prose Memory Test 
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
PT: Prothrombin Time 
PVD: Peripheral Vascular Disease 
PVWMC:   Periventricular White Matter Changes 
RAAS: Renin Angiotensin Aldosterone System 
RAVL:   Rey Auditory Verbal Learning Test 
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RBANS:   Repeatable Battery for the Assessment of Neurocognitive Status 
RBMT:   Rivermead Behavioural Memory Test 
RCPM:   Raven’s Coloured Progressive Matrices 
RDW: Red Cell Distribution Width 
SCWT:   Stroop Colour Word Test 
SD: Standard Deviation 
SDMT:   Symbol Digit Modalities Test 
SIGN: Scottish Intercolliegate Guidelines Network 
SLUMS: Saint Louis University Mental Status 
SOB: Shortness of Breath 
SPECT: Single Photon Emission Computerised Tomography 
SSS: Sick Sinus Syndrome 
SVD: Small Vessel Disease 
SVT: Supraventricular Tachycardia 
SW: Sulcal Widening 
SWI: Susceptibility Weighted Imaging 
TFTs: Thyroid Function Tests 
TIA: Transient Ischaemic Attack 
TMT: Trail Making Test 
TR: Tricuspid Regurgitation 
TTE: Transthoracic Echocardiography 
U&Es: Urea and Electrolytes 
VE: Ventricular Enlargement 
VJT: Verbal Judgement Test 
VST:   Visual Scanning Test 
VT: Ventricular Tachycardia 
VWST:   Verbal Word Span Test 
WAIS:   Wechsler Adult Intelligence Scale 
WBC: White Blood Cell 
WHO: World Health Organisation 
WLNS: Wechsler Letter Number Sequencing 
WMS:   Wechsler Memory Scale 
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WTAR: Wechsler Test of Adult Reading 
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Summary 
The clinical syndrome of heart failure is one of the leading causes of hospitalisation and 
mortality in older adults.  Due to ageing of the general population and improved survival from 
cardiac disease the prevalence of heart failure is rising.  Despite the fact that the majority of 
patients with heart failure are aged over 65 years old, many with multiple co-morbidities, the 
association between cognitive impairment and heart failure has received relatively little 
research interest compared to other aspects of cardiac disease.   
The presence of concomitant cognitive impairment has implications for the management of 
patients with heart failure in the community.  There are many evidence based pharmacological 
therapies used in heart failure management which obviously rely on patient education 
regarding compliance.  Also central to the treatment of heart failure is patient self-monitoring 
for signs indicative of clinical deterioration which may prompt them to seek medical assistance 
or initiate a therapeutic intervention e.g. taking additional diuretic.   Adherence and self-
management may be jeopardised by cognitive impairment. 
Formal diagnosis of cognitive impairment requires evidence of abnormalities on 
neuropsychological testing (typically a result ≥1.5 standard deviation below the age-
standardised mean) in at least one cognitive domain. Cognitive impairment is associated with 
an increased risk of dementia and people with mild cognitive impairment develop dementia at 
a rate of 10-15% per year, compared with a rate of 1-2% per year in healthy controls.1  
Cognitive impairment has been reported in a variety of cardiovascular disorders. It is well 
documented among patients with hypertension, atrial fibrillation and coronary artery disease, 
especially after coronary artery bypass grafting. This background is relevant to the study of 
patients with heart failure as many, if not most, have a history of one or more of these co-
morbidities.   
A systematic review of the literature to date has shown a wide variation in the reported 
prevalence of cognitive impairment in heart failure.  This range in variation probably reflects 
small study sample sizes, differences in the heart failure populations studied (inpatients versus 
outpatients), neuropsychological tests employed and threshold values used to define cognitive 
impairment.  The main aim of this study was to identify the prevalence of cognitive impairment 
in a representative sample of heart failure patients and to examine whether this association 
was due to heart failure per se rather than the common cardiovascular co-morbidities that 
often accompany it such as atherosclerosis and atrial fibrillation. 
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Of the 817 potential participants screened, 344 were included in this study.  The study cohort 
included 196 patients with HF, 61 patients with ischaemic heart disease and no HF and 87 
healthy control participants.  The HF cohort consisted of 70 patients with HF and coronary 
artery disease in sinus rhythm, 51 patients with no coronary artery disease in sinus rhythm 
and 75 patients with HF and atrial fibrillation.  All patients with HF had evidence of HF-REF 
with a LVEF <45% on transthoracic echocardiography.  The majority of the cohort was male 
and elderly.  HF patients with AF were more likely to have multiple co-morbidities.   
Patients recruited from cardiac rehabilitation clinics had proven coronary artery disease, no 
clinical HF and a LVEF >55%.  The ischaemic heart disease group were relatively well matched 
to healthy controls who had no previous diagnosis of any chronic illness, prescribed no regular 
medication and also had a LVEF >55%.  All participants underwent the same baseline 
investigations and there were no obvious differences in baseline demographics between each 
of the cohorts.   
All 344 participants attended for 2 study visits.  Baseline investigations including physiological 
measurements, electrocardiography, echocardiography and laboratory testing were all 
completed at the initial screening visit. Participants were then invited to attend their second 
study visit within 10 days of the screening visit.   
342 participants completed all neuropsychological assessments (2 participants failed to 
complete 1 questionnaire).  A full comprehensive battery of neuropsychological assessment 
tools were administered in the 90 minute study visit.  These included three global cognitive 
screening assessment tools (mini mental state examination, Montreal cognitive assessment 
tool and the repeatable battery for the assessment of neuropsychological status) and additional 
measures of executive function (an area we believe has been understudied to date).  In total 
there were 9 cognitive tests performed.  These were generally well tolerated.   
Data were also collected using quality of life questionnaires and health status measures.  In 
addition to this, carers of the study participant were asked to complete a measure of caregiver 
strain and an informant questionnaire on cognitive decline. 
The prevalence of cognitive impairment varied significantly depending on the 
neuropsychological assessment tool used and cut-off value used to define cognitive 
impairment.  Despite this, all assessment tools showed the same pattern of results with those 
patients with heart failure and atrial fibrillation having poorer cognitive performance than 
those with heart failure in sinus rhythm.  Cognitive impairment was also more common in 
patients with cardiac disease (either coronary artery disease or heart failure) than age-, sex- 
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and education-matched healthy controls, even after adjustment for common vascular risk 
factors. 
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CHAPTER ONE 
INTRODUCTION 
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1.1  Epidemiology and pathophysiology of heart failure 
1.1.1  Definition and classification of heart failure 
 
The European Society of Cardiology define heart failure (HF) as a clinical syndrome with typical 
signs and symptoms (including shortness of breath, ankle swelling and raised jugular venous 
pressure) that results from an abnormality of either cardiac structure or function, identified at 
rest.2  HF can therefore be viewed as the final common pathway resulting from an initial insult 
to the myocardium, rather than a diagnosis in itself and an underlying aetiology should 
therefore be sought. 
Contemporary terminology used to describe HF can be based upon left ventricular ejection 
fraction (LVEF), timing of symptoms or severity of symptoms.  The classification relating to 
LVEF is important, not only because of prognosis (the lower LVEF, the poorer the survival) but 
also because the large clinical trials that have informed our current clinical practice have 
largely been based on those patients with heart failure and reduced ejection fraction (HF-REF).  
There is a sub-group of patients that present with signs and symptoms typical of HF but with 
preserved ejection fraction on echocardiography (HF-PEF).  It has been postulated that 
inadequate myocardial relaxation preventing normal filling may be the underlying mechanism 
in these patients.  Unfortunately, clinical trials conducted over the past decade have failed to 
alter the trajectory of this condition which shares the same substantial morbidity and mortality 
as that of HF-REF. 
Some “De Novo” HF patients, experience symptoms for an indeterminate time period and 
present in a “sub-acute” or “acute” manner.  In contrast to this, those patients who have had 
signs and symptoms of HF for some time are often said to have “chronic HF” and at any time 
they may experience “decompensation” of their clinical condition. 
The most commonly used method of grading severity of HF is the New York Hospital 
Association (NYHA) classification (Table 1-1).  This categorises HF patients according to their 
functional limitation due to the principal symptoms of HF i.e. dyspnoea and fatigue.  Patients 
can change class at any time and this does not necessarily correlate with LVEF or duration of 
symptoms. 
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Table 1-1:  New York Heart Association heart failure classification 
NYHA Class Patient Symptoms 
I No limitation of physical activity.  Ordinary physical activity does not 
cause undue fatigue, palpitations or breathlessness. 
II Mild limitation of physical activity.  Comfortable at rest or with mild 
exertion but ordinary activity results in fatigue, palpitations or 
breathlessness. 
III Marked limitation of physical activity.  Comfortable at rest but any 
ordinary activity causes fatigue, palpitations or breathlessness. 
IV Symptoms of HF at rest.  Any physical activity causes exacerbation of 
symptoms. 
 
1.1.2  Epidemiology of heart failure 
 
The Framingham study published in 1971, described the natural history of HF and showed a 
prevalence of HF of 0.8% in those aged between 50 and 59, rising to 9.1% in those over 80 with 
incidence rates of 0.2% at age 54 and 0.4% at age 85.3  This study relied on a clinical diagnosis 
of HF.  However, more recent epidemiological studies have required objective evidence of HF 
to fulfil current diagnostic guidelines.4  Estimates of the incidence and prevalence of HF in the 
literature will therefore vary depending on the definition of HF used, the diagnostic criteria 
and the cohort studied.  
More recently, the prevalence of HF has been estimated between 1 to 2% of the adult 
population in developed countries increasing to ≥10% in patients over 70 years with more 
than half of these older patients having HF-PEF.5  Data from the Framingham cohort has shown 
no increase in the incidence of HF since the 1970’s, and this pattern is also broadly evident 
when looking at data from Medicare records.  In fact, these records show a reduction in 
incidence rates from 57.5/1000 to 48.4/1000 person years in the 80-84 year age group in the 
period from 1994-2003.4  However, despite the slight reduction in incidence, the prevalence 
rate rose significantly from 90/1000 to 120/1000 person years.  These trends can be explained 
in part by the ageing of the general population and improved survival from cardiovascular 
disease.    
In Scotland, a large primary care survey estimated the prevalence of HF to be 7.1 in 1000, 
increasing with age to 90.1 in 1000 among patients over 85 years of age.6  The investigators 
found the incidence of HF to be 1.8 in 1000 in men and 2.2 in 1000 in women and this figure is 
in keeping with estimates from the UK (1.4 and 1.2/1000),7 Finland (1.0 and 4.0/1000)8 and 
the USA (3.4 and 2.4/1000).9 
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1.1.3  Aetiology and pathophysiology of heart failure 
 
HF can result from a broad spectrum of structural or functional cardiac (or non-cardiac) 
disorders and is often the terminal manifestation resulting from an underlying cardiovascular 
disease process.  Table 1-2 outlines both the common and less common causes of HF.  Although 
determining the underlying aetiology can present a challenge to clinicians, it is important to do 
so for several reasons.  Determining the underlying aetiology can allow for the initiation of 
specific therapeutic disease-modifying agents, highlight the need for further investigations, 
inform longer-term prognosis and indicate a need for family screening. 
HF-REF is the best understood type of HF with regard to its underlying pathophysiology and 
treatment.  It is often sub-divided into ischaemic and non-ischaemic.  Common causes of non-
ischaemic HF-REF include hypertension, valvular heart disease, arrhythmias, and certain 
forms of cardiomyopathy.  The cardiomyopathies are a group of disorders defined by structural 
or functional abnormalities of the ventricular myocardium that are unexplained by flow 
limiting coronary artery disease or abnormal loading conditions i.e. they tend to be a diagnosis 
of exclusion.10  Historically they have been classified into primary forms in which the heart is 
the only involved organ, and secondary forms resulting from a systemic disorder.  The different 
types of cardiomyopathy include dilated, hypertrophic, arrhythmogenic right ventricular, 
restrictive and unclassified.  They can be further divided into familial and non-familial forms. 
Coronary artery disease (CAD) is the cause of approximately two thirds of HF cases.11  CAD can 
either present acutely e.g. acute myocardial infarction or insidiously e.g. chronic stable 
angina/occult disease.  Regardless of its mode of onset it triggers maladaptive physiological 
responses that eventually result in progressive impaired cardiac function. 
HF-PEF is more common in older, female patients.  It is less frequently due to CAD and is more 
often linked to hypertension and atrial fibrillation (AF) with the diagnosis being one of 
exclusion of other non-cardiac causes of breathlessness.2  HF-PEF can be a precursor to HF-
REF in certain causes of HF e.g. hypertension.12  The pathophysiological basis of HF-PEF 
remains poorly understood:  while an abnormality of diastolic function has been postulated as 
the underlying mechanism, this hypothesis has been disputed.13 
Although any cardiac pathology can ultimately lead to HF, most is known about the 
pathophysiology of HF due to myocardial contractile failure leading to left ventricular systolic 
dysfunction (LVSD).  Following on from the index event (or injury such as myocardial 
infarction), a loss of myocytes results in the reduction of stroke volume and in turn cardiac 
output (CO).  As a consequence a number of compensatory mechanisms are then triggered in 
35 
 
an attempt to maintain CO.  Although, initially effective, over time these compensatory 
mechanisms contribute to adverse remodelling of the myocardium and a further decline in 
cardiac function.  The process of remodelling is complex and involves a number of 
haemodynamic, neurohormonal and structural changes which, in combination, result in 
changes to ventricular geometry, dimensions and ultimately function.14 
The haemodynamic responses triggered by reduced CO lead to elevated left ventricular 
diastolic pressure and volume.  Initially, the increased stretch applied to cardiac myocytes 
leads to enhancement of myocardial contractile force.  This is the intrinsic adaptive process 
known as the Frank-Starling law.15-17  While, within the normal range of end-diastolic volumes 
an increased haemodynamic load will result in enhanced myocardial contraction, studies have 
shown that increased preload in the presence of high end-diastolic volumes can lead to a 
decline in cardiac performance.  This decline is often designated the descending limb of the 
Starling curve.18 
Through activation of the sympathetic nervous system and up-regulation of the renin-
angiotensin aldosterone system, neurohormonal responses act synergistically to increase 
preload (mainly through vasoconstriction and salt and water retention).   
Like other compensatory mechanisms over time, these processes too become deleterious by 
increasing myocardial afterload and stimulating further structural responses (including 
dilatation of damaged myocardium, hypertrophy of unaffected myocytes and fibrosis of 
necrotic myocardium) all of which result in further decline in cardiac function and a vicious 
cycle of progressive HF (Figure 1-1). 
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Table 1-2:  Causes of heart failure 
 
Common causes of heart failure Less common causes of heart failure 
Arrythmias 
 Atrial fibrillation 
Cardiomyopathies 
 Familial 
 Peripartum 
 Toxins (cocaine, iron, copper) 
Cardiomyopathies 
 Alcohol induced cardiomyopathy 
 Idiopathic cardiomyopathy 
 
 
Congenital heart disease 
 
Coronary artery disease 
Endomyocardial disease 
 Radiotherapy 
 Carcinoid 
 
Hypertension 
High output 
 Thyrotoxicosis 
 Anaemia 
Iatrogenic 
 Anthracyclines 
 Steroids 
Infective 
 Chagas disease 
 Viral myocarditis 
 Human immunodeficiency virus 
 Lyme disease 
Valvular heart disease 
 Degenerative 
 Rheumatic fever 
 Congenital 
Infiltrative 
 Amyloid 
 Sarcoid 
 Neoplastic 
 Metabolic 
 Endocrine (e.g. acromegaly) 
 Nutritional (e.g. thiamine deficiency) 
 Autoimmune (e.g. scleroderma) 
 Neuromuscular 
 Friedreich’s ataxia 
 Muscular dystrophy 
 Pericardial disease 
 Calcification 
 Infiltration 
 Storage disorders 
 Haemochromatosis 
 Fabry disease 
 Glycogen storage disease 
 
 
 
 
37 
 
Figure 1-1:  Pathophysiology of heart failure due to left ventricular systolic dysfunction.  
Reproduced with permission from McMurray JJ et al14 
 
 
 
 1.1.4  Diagnosis of heart failure 
 
There are three aspects to the diagnosis of HF.  Firstly, the recognition of the cardinal 
symptoms (e.g. dyspnoea/fatigue) and signs (e.g. peripheral oedema) of the HF syndrome.  
Secondly, the demonstration of an abnormality of cardiac structure or function with the patient 
at rest.  Finally, the identification of the underlying aetiology. 
There is no symptom or sign of HF that is both sensitive and specific to HF and so clinical 
evaluation, on its own, is not sufficient to confirm the diagnosis.  Many of the presenting 
symptoms are relatively insensitive in discriminating HF from other potential differential 
diagnoses and those symptoms which are more sensitive are less specific.19  Many of the clinical 
signs result from salt and water retention and so are also non-specific (Table 1-3).  In addition, 
these signs can change quickly depending on diuretic use/fluid intake and so are more difficult 
to assess in patients without clinical decompensation.  Signs and symptoms are very useful 
when assessing response to treatment and can indicate clinical deterioration; which may 
prompt escalation of therapy. 
If clinical HF is suspected, initial baseline investigations including 12 lead electrocardiography 
(ECG) and B-type natriuretic peptide (BNP) are recommended by both the European Society 
of Cardiology (ESC) and the Scottish Intercollegiate Guidelines Network (SIGN). 2;20Less than 
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8% of patients presenting acutely with HF will have a normal ECG, however, its specificity is 
relatively poor (<60% at best).21;22 With more chronic presentations, the ECG has an even 
lower negative predictive value (<10%).21  However, the ECG is also a useful tool in assessing 
the potential underlying aetiology of heart failure e.g. arrhythmia/ischaemia and in guiding 
treatment e.g. rate control/device therapy. 
The most commonly studied blood biomarker in HF is the naturally occurring, cardiomyocyte 
secreted, peptide BNP.  The prohormone, pro-BNP, is released into the circulation from the 
ventricle in response to increased myocardial stretch, and cleaved into BNP (the active 
fragment) and N-terminal pro-hormone of brain natriuretic peptide (NT-pro BNP, inactive 
fragment) both of which can be measured in the plasma.   It is well established that plasma 
levels of both BNP and NT-pro BNP are elevated in patients with LVSD23 with the degree of 
elevation proportional to the severity of chronic HF.24  Factors which may increase serum BNP 
levels include female sex, increasing age and renal impairment.  Obesity can decrease serum 
BNP levels.  The thresholds used in clinical practice are dependent on whether the patient 
presents with acute HF or with a more gradual onset.  A normal BNP level in an untreated 
patient virtually excludes cardiac disease and suggests an alternative diagnosis should be 
sought.  BNP levels can also be used to monitor response to treatment (levels fall when HF 
improves) and reflects patient prognosis (higher BNP levels are associated with increased 
mortality).  If both the plasma BNP and 12 lead ECG are normal the chances of finding 
significant LVSD is <10%.25  If either the ECG or plasma biomarkers are abnormal, the patient 
should be referred for echocardiography.2  
Cardiac imaging plays a key role in the diagnosis of heart failure providing useful information 
regarding cardiac structure (e.g. cardiac dimensions/volumes) and function (e.g. LV ejection 
fraction/valvular function).  For reasons of access, cost and accuracy transthoracic 
echocardiography is the most commonly employed cardiac imaging modality.  Comprehensive 
echocardiographic assessment of LV function is, therefore, integral to the HF diagnostic 
pathway.   
Echocardiography may be complemented by other imaging techniques depending on the 
information gained, local expertise and specific clinical questions e.g. cardiac magnetic 
resonance imaging (CMR) or computerised tomography (CT).   
Additional investigations may be employed to determine the underlying aetiology, these will 
depend on the clinical history, examination and the suspected underlying diagnosis.  These 
additional investigations may include right and left cardiac catheterisation for suspected 
constrictive or ischaemic aetiology, cardiac biopsy for suspected infiltrative diseases or genetic 
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testing for familial cardiomyopathy.  Further investigations should be chosen according to their 
ability to answer specific clinical questions and take account of contraindications to, and risks 
of, specific tests.  
Table 1-3:  Sensitivity and specificity of signs and symptoms in diagnosing chronic heart 
failure.  Adapted from 2007 SIGN guidelines “Management of chronic heart failure”20 
Symptom Sensitivity (%) Specificity (%) 
Dyspnoea 66 52 
Orthopnoea 21 81 
PND 33 76 
Oedema 23 80 
   
Sign Sensitivity (%) Specificity (%) 
Raised JVP 10 97 
3rd heart sound 31 95 
Oedema 10 93 
Tachycardia 7 99 
Crepitations 13 99 
PND, paroxysmal nocturnal dyspnoea; JVP, jugular venous pressure 
1.1.5  Treatment of heart failure 
 
The goals of treatment in HF are to reduce the burden of HF signs and symptoms, reduce HF 
hospitalisations and reduce mortality.  There is a large, robust evidence base supporting both 
the use of pharmacological and device therapy in the treatment of chronic HF-REF.  
For symptomatic relief, diuretics are the mainstay of treatment and should be initiated as soon 
as possible after a symptomatic patient presents.  Loop diuretics and thiazide diuretics are both 
used; either in isolation or combination.  These two classes of diuretic work on different parts 
of the nephron and inhibit the resorption of sodium and chloride, promoting salt and water 
diuresis.  Consequently it is important to carefully monitor the patient’s fluid status and 
urea/electrolytes. 
Prognostically, the first medication that should be commenced is an angiotensin-converting 
enzyme (ACE) inhibitor.  There is a large evidence base supporting the use of ACE-inhibitors in 
patients with HF-REF which clearly shows that their use improves morbidity and mortality.26;27 
ACE-inhibitors reduce the conversion of angiotensin I to angiotensin II (the main effector 
hormone of the renin angiotensin aldosterone system) and so reduce aldosterone release.  
Ultimately, this results in reduced sympathetic nervous system activity, reduced 
vasoconstriction and reduced inflammatory and pro-coagulant processes.  If a patient is 
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intolerant of ACE-inhibitor therapy an angiotensin receptor blocker (ARB) should be tried in 
its place.28 
Unless contraindicated and once euvolaemic all patients with HF-REF should be initiated on 
beta blocker therapy.  Beta blockers have also been shown to substantially reduce morbidity 
and mortality.29  In addition to reducing rates of sudden cardiac death, they can also improve 
left ventricular ejection fraction and have both anti-ischaemic and anti-arrhythmic 
properties.30;31  There is a consensus that ACE-inhibitor/ARB and beta blocker therapies are 
complimentary and should be started as soon as possible after a diagnosis of HF-REF is made. 
In patients who remain symptomatic despite treatment with ACE-inhibitor/ARB and beta 
blocker therapy, a mineralocorticoid receptor antagonist (MRA) should then be added; again 
to improve patient prognosis.32;33 Other evidence based HF pharmacological treatments 
include ivabradine,34 digitalis35 and (in a more select population) the combination of isosorbide 
dinitrate/hydralazine.36 
Ventricular arrhythmias are a common cause of mortality in HF patients.  Although some of the 
pharmacological therapies listed above reduce the rates of arrhythmia, they do not completely 
remove it.  Implantable cardioverter-defibrillators (ICDs) aim to prevent sudden cardiac death 
from ventricular arrhythmias.  ICDs are recommended in patients who have had previous 
symptomatic ventricular arrhythmias, who are expected to survive for longer than one year, 
irrespective of LVEF.  In terms of primary prevention, ICDs should be considered in patients 
with symptomatic HF (NYHA II-III), with LVEF ≤35%, who have had at least 3 months 
treatment with optimal medical therapy and are expected to survive for longer than one year.  
These recommendations are based on large published randomised controlled trials which all 
showed substantial reductions in mortality when ICDs are used in these subgroups of HF 
patients.37-40 
Cardiac Resynchronisation Therapy (CRT) aims to minimise interventricular and 
intraventricular dys-synchrony.  Minimising dys-synchrony increases LV filling time, decreases 
septal dyskinesis and reduces mitral regurgitation, and thus improves cardiovascular 
haemodynamics.  Several studies demonstrate the beneficial effect of CRT on HF outcomes.  
CRT use is now recommended in symptomatic patients (NYHA III/IV) who are in sinus rhythm 
with evidence of dys-synchrony on ECG, that is QRS duration ≥120 milliseconds with left 
bundle branch morphology (LBBB), an EF ≤35% and who are expected to live for longer than 
one year.41;42 In patients who do not have LBBB morphology the QRS duration should be at 
least 150 milliseconds duration.  Those patients with milder symptoms (NYHA II) are required 
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to have a LVEF of ≤30% and QRS duration of ≥130milliseconds or ≥150milliseconds, depending 
on the presence or absence of LBBB morphology, respectively.43 
No treatment has yet been shown to improve outcomes in HF-PEF and so the mainstay of 
current recommendations is symptomatic relief with diuretic therapy.44-46  Attention should be 
paid to the treatment of any associated co-morbidities, such as, ensuring adequate ventricular 
rate control in patients with atrial fibrillation and optimising blood pressure control in those 
with hypertension. 
1.1.6  Prognosis in heart failure 
 
HF reduces the quantity and quality of life for afflicted individuals and exerts a substantial 
drain on healthcare services.47  However, recent reports have suggested that the poor survival 
of patients hospitalised for HF48 (as well as those in the community)49 may be improving; 
perhaps due to the increased prescription of disease modifying agents such as beta-blockers 
and ACE-inhibitors.27;30  Despite this, 25% of patients are re-admitted with signs and symptoms 
of HF within one month of discharge and 10-20% die in the 6 months after discharge with 
prognosis in individual patients being highly variable.50  The development of a prognostic tool 
that would allow identification of those patients at greatest risk of death is therefore desired 
and is the subject of ongoing clinical research. 
To date, many potential prognostic variables have been highlighted including age, sex, 
aetiology, NYHA status, LVEF and plasma natriuretic peptide concentrations.  Overall scoring 
systems have also been developed using various combinations of parameters e.g. heart failure 
risk calculator.51  Many of these variables are inter-related and whilst they may have strong 
prognostic power in univariate models, they are competitively removed in multivariate models 
of prognosis.  These variables can change over time with a concomitant effect on prognosis.   
The ideal prognostic tool would be cost-effective, easily accessible, minimally invasive, 
reproducible and both sensitive and specific to HF.  
1.2  Heart failure and cognitive impairment 
1.2.1  Definition of cognitive impairment 
 
Cognition is the term used to describe a group of mental processes including 
attention/concentration, memory, language skills, orientation, and problem solving. It is the 
faculty for processing information, applying knowledge and changing preferences.52 These 
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various processes are known as the domains of cognition and each domain can be studied 
individually. Any one of these domains can be impaired in isolation or in combination. 
Cognitive impairment (CI) is an umbrella term that includes chronic as well as more acute 
problems, such as delirium; both of which can occur in HF. Chronic CI is a spectrum from mild 
CI (MCI) to dementia, with these two extremes sharing many of the same risk factors and 
underlying pathophysiology. There are many definitions of MCI in the literature with a division 
into those focusing on memory impairment and alternatives based on impairment of other 
domains e.g. language, orientation and attention/concentration. 
Although generally first identified by memory difficulty, CI can occur without memory 
impairment. Even if memory is impaired, the individual may still have the ability to function in 
daily life. Formal diagnosis of CI requires evidence of abnormalities on neuropsychological 
testing (typically a result ≥1.5 standard deviation below the age-standardised mean) in at least 
one cognitive domain. CI is considered a pathological entity and not a function of normal aging. 
CI is associated with an increased risk of dementia and people with MCI develop dementia at a 
rate of 10-15% per year, compared with a rate of 1-2% per year in healthy controls.1  
1.2.2  Cognitive assessment tools used to detect cognitive impairment in  
 heart failure 
 
To date, there are no tools specifically recommended for screening for CI in HF, although 
several instruments validated in the general population are potential candidates.   
Multidomain Screening Tools: 
Mini Mental State Examination (MMSE):  Although originally developed as a screening test to 
distinguish “organic” from “non-organic” (e.g. schizophrenia) cognitive disorders, the MMSE is 
now the most commonly used measure of global cognition.  Various cut-off values have been 
advocated for maximum sensitivity and specificity in differing populations and although the 
MMSE is not viewed to be sensitive at identifying earlier cognitive changes a cut-off score of ≤ 
24 is often used to define CI (Table 1-4).   When compared with the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-III) and the International Classification of Diseases 10 (ICD-
10) criteria for dementia the MMSE was reported to have a sensitivity of 94% and specificity 
of 78%.53   
Addenbrookes Cognitive Examination (ACE):  This was developed in an attempt to address the 
deficiencies of the MMSE and was designed to be sensitive to the early stages of fronto-
temporal dementia and Alzheimer’s disease (AD).  Based on a validation study, two cut-off 
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scores were suggested for clinical practice; the higher cut-off score of 88 has an increased 
sensitivity for the detection of dementia (94%) but lower specificity (89%); the lower cut-off 
score of 82 is less sensitive (84%) but was 100% accurate in correctly classifying non-
demented controls (see Table 1-4).54  
Montreal Cognitive Assessment (MoCA):  This instrument was developed to identify older adults 
who present with MCI but perform within normal range on the MMSE. The results can be 
categorised as shown in Table 1-4.  
Prolonged neurocognitive assessments are not always practical or feasible in the clinical 
setting and so the screening tests above are important in identifying patients that warrant 
further neurocognitive investigation.  Domain-specific assessments, however, remain the gold 
standard in examining cognition. 
Neuropsychological batteries:  Cognition involves multiple cognitive processes working in 
unison. Individual cognitive domains can be examined using domain-specific measures.  The 
collective term “battery” is often used when a number of these different tests are grouped 
together.  The most frequently measured individual cognitive domains in HF studies are 
attention, working memory, delayed memory, learning and psychomotor speed.  
The domain of “executive function” is an umbrella term for cognitive processes that regulate, 
control and manage other cognitive processes such as planning, problem solving, mental 
flexibility, and the initiation and monitoring of actions.52  Executive function is particularly 
important in patients with HF as this determines how a person can recognise novel situations 
and adapt to them appropriately.  Neuropsychological assessments of executive function have 
been greatly underused in studies of CI in HF to date, although in a few recent cases 
investigators have attempted to construct a neuropsychological battery to address this gap.  
For example, Bauer et al55 tested a neuropsychological battery (Repeatable Battery for the 
Assessment of Neuropsychological Status [RBANS]) assessing multiple domains, including 
immediate memory, visuospatial, language, executive function, attention and delayed memory 
in patients with HF.  Eighty community dwelling patients in NYHA class I-IV HF were enrolled, 
and although a healthy control group was not included, their results were compared with 
published age and education adjusted norms.  Validity was documented by comparing the 
RBANS scores with individual, previously validated, neuropsychological tests and test-retest 
reliability was checked by retesting a subsample of 21 participants after 12 days.  Both were 
satisfactory, supporting the use of this battery in patients with HF. 
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Informant based assessments:  Fundamental to the diagnosis of CI is neuropsychological 
change over time.  Patients themselves may struggle to make an objective assessment of 
personal change over a period of years and so one approach is to question someone familiar 
with the patient e.g. family member or friend.  Informant based interviews retrospectively 
assess change in cognitive function over time and one commonly used example of this is the 
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE).  The preferred IQCODE 
format is a 16-item questionnaire designed to retrospectively ascertain change in cognitive and 
functional performance over a 10 year time period.56  For each item the informant scores 
change on a 5-point ordinal hierarchical scale with responses ranging from 1:  “has become 
much better” to 5:  “has become much worse”.  This gives a sum score of 16 to 80 that can be 
averaged by the total number of completed items to give a final score of 1.0 to 5.0, where higher 
scores indicate greater decline.  There are no “normative values” as the IQCODE is designed to 
assess pathological cognitive decline.  A score of >3.6 is often used to differentiate “cases” and 
“non-cases”.57 
Other aspects of assessment:  Cognitive scores need to be interpreted in the context of 
mood and previous peak intelligence therefore it is important to take these factors into 
consideration at the time of patient assessment.   
The Wechsler Test of Adult Reading (WTAR) is intended as a measure of pre-morbid 
intelligence allowing us to classify an individual’s pre-morbid IQ as low, average, high.  This 
can then be used as a comparison to see the extent of cognitive decline on current testing – 
based on where they would have been, had they not had some kind of cerebral insult.  The test 
typically takes 5-10 minutes and consists of 50 words with irregular spelling e.g. gnat.  Each 
word is individually presented and examinees are asked to pronounce each.  The total raw 
score is the maximum number of words correctly pronounced (0-50).  The obtained raw score 
is converted to a standard score that is then compared to a predicted score.  The predicted 
score is derived from demographic data based on the test’s normative sample and then 
subtracted from the obtained WTAR score in order to assess the magnitude of difference.58 
Cognitive defects within mood disorders have been studied extensively.59-61  Although results 
have not always been consistent, an overall pattern of specific impairment has become evident.  
Patients with mood disorders have shown impaired performance specifically in tests of 
attention, executive function and memory.62  Evidence that cognitive decline may develop in 
conjunction with mood disorders was demonstrated in a 7 year study following 600 healthy, 
elderly participants on measures of cognition and mood.63  Participants with no depressive 
symptoms at baseline presented mild, yet progressive cognitive decline annually.  With each 
additional depressive symptom present at baseline, the annual rate of cognitive decline 
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increased by 24%.  Therefore the number of depressive symptoms at baseline was associated 
with increased risks of developing Alzheimer’s Disease (AD). 
The Hospital Anxiety and Depression Scale (HADS) is a brief (14 item), self-report measure of 
anxiety and depression.  It was initially developed for use in the general medical outpatient 
clinic but is now widely used in both clinical practice and research.64  Interpretation of the 
HADS is based primarily on the use of cut-off values and the tests authors recommend that, for 
both the anxiety and depression scales alike, raw scores of between 8 and 10 identify mild 
cases, 11-15 moderate cases and 16 or above severe cases.65 
Clinical assessment:  The gold standard method for diagnosing CI remains a comprehensive 
clinical assessment performed in specialist assessment services.  This encompasses a detailed 
history and examination as well as clinical cognitive assessment using standardised 
instruments in combination with cerebral imaging where appropriate.  The World Health 
Organisation clearly outlines the necessary clinical criteria required in order to fulfil the 
diagnosis of CI in their ICD-10 classification of mental and behavioural disorders.66 
Table 1-4:  Classification of cognitive screening tools 
Screening Test Score Clinical Interpretation 
Mini Mental State 
Examination Score 
≥25 Normal 
21-24 Mild Cognitive Impairment 
10-20 Moderate Cognitive Impairment 
≤9 Dementia 
 
Montreal Cognitive 
Assessment Score 
>26 Normal 
23-26 Mild Cognitive Impairment 
17-22 Moderate Cognitive impairment 
≤16 Dementia 
 
Addenbrookes Cognitive 
Examination Score 
 
<88 Cognitive Impairment 
<82 Dementia 
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1.2.3  Potential pathophysiology of cognitive impairment in heart failure 
  
 1.2.3.1  Introduction 
 
Historically, research describing the pathology of dementia has been polarised, with vocal 
proponents for 'amyloid' and 'cerebral small vessel disease' aetiologies.  Increasingly these 
processes are recognised as co-existing with complex biological interactions.67  The same is 
likely true of the pathogenesis of CI in HF.  Chronic cerebral hypoperfusion and occult 
cardioembolic disease are examples of potential mechanistic explanations that have 
dominated the literature on cognition in HF.  Both processes have face validity, have strong 
supporting scientific and observational data and yet have traditionally been studied in 
isolation.68  Although here, the potential pathological mechanisms are discussed separately; it 
seems likely that both processes frequently coexist in patients with HF and may exert 
pathological synergy.   
Although most of the postulated mechanisms are described in the context of HF-REF, issues of 
cerebral hypoperfusion, thrombotic disease and concomitant cardiovascular disease are also 
seen in HFPEF2 and it seems likely they will factor in the pathogenesis of any cognitive decline 
seen in this syndrome.  
 1.2.3.2  Confounding from other disease 
 
Co-existence of dementia and CI has been reported in a variety of cardiovascular disorders, 
including CAD, myocardial infarction and valvular heart disease.  Midlife exposure to the 
common vascular risk factors of diabetes, hypertension and smoking is associated with later 
life cognitive decline.69  This background is relevant to the study of patients with HF as many 
have a history of one or more of these co-morbidities.  As discussed previously, dissecting the 
contribution of HF from concomitant vascular risk and disease is challenging but is essential 
for future studies that wish to describe the cognitive component of HF. 
AF is a potential confounding condition worthy of separate discussion.  The association of AF 
with cognitive decline is compelling.70;71  Much of the CI associated with AF is driven by 
cardioembolic stroke.  However, cognitive decline is also seen in patients with AF and no 
history of clinical stroke, possibly representing occult embolic disease.70  AF is common in HF 
and the prevalence increases with severity of disease. Up to 50% of patients with 'end-stage' 
HF have AF.72  Increasing use of ambulatory monitors is discovering substantial undetected 
paroxysmal AF and so these figures may be underestimates. While AF is a factor in the 
pathogenesis of some HF-related CI, it is probably not the sole explanation.  Where studies have 
47 
 
controlled for the presence of AF in their HF patient population, there remains substantial 
prevalent CI.69;73-76  
With the increasingly sophisticated interventional toolkit available to cardiologists, the effect 
of invasive and interventional procedures on cognition should be considered.  Acute and 
chronic neurological deficits associated with cardiac surgery are well described77 while 
interventions such as cardiac catheterisation and transcatheter aortic valve replacement have 
also been associated with post-procedure CI.78  The mechanism of neurological insult 
associated with these procedures is likely a combination of reduced cerebral perfusion and 
embolic disease. 
As well as 'physical' conditions, mood disorder may also represent an important confounder of 
association between HF and CI.  Clinically important depression and anxiety are common in 
patients with HF.  Depression is found in nearly 30% of HF patients and is associated with poor 
outcomes.79  There is a complex interplay between cognitive decline (particularly in the context 
of 'small vessel disease'), mood disorder and systemic vascular disease that is poorly 
understood but likely to be relevant to HF.  Mood disorders are particularly important to detect 
as they can respond to intervention, making mood disorder in HF a potentially treatable form 
of cognitive decline.  
 1.2.3.3  Systemic inflammation and amyloid 
 
Several recent studies have demonstrated the formation of tangle and plaque-like structures 
and fibrillar deposits (that is, the 'hallmark' lesions of Alzheimer’s disease (AD) dementia) 
within the myocardium of patients with hypertrophic cardiomyopathy and idiopathic dilated 
cardiomyopathy.80  Mis-folded proteins in the form of intermediate oligomers have also been 
described in cardiac tissue, with a distribution similar to that observed in the brain of patients 
with AD,80 raising the possibility of a common myocardial and cerebral pathology in a subset 
of patients with HF. 
The systemic inflammatory state recognised in patients with HF may also contribute to CI.81  It 
is postulated that inflammatory mediators influence cognition via diverse cytokine-mediated 
interactions between neurons and glial cells. In vitro and animal models support the 
inflammation and cognitive decline hypothesis and studies in humans with HF are emerging, 
although data are far from definitive at present.81 
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 1.2.3.4  Acute and chronic hypoperfusion 
 
A mechanistic link between hypotension and CI, mediated via chronic cerebral hypoperfusion 
and loss of the normal autoregulation of cerebral perfusion pressures, has been postulated.  
Many diseases, including diabetes mellitus and depression, are associated with impaired 
reactivity of cerebrovascular perfusion autoregulatory systems and this state seems to confer 
a higher risk of cognitive decline.82  HF patients often have systemic hypotension and in the 
context of disordered autoregulation this could lead to further insults to cerebral perfusion.  
Cerebral perfusion abnormalities have been demonstrated in HF patients, with reactivity more 
impaired in patients with greater severity of HF.68   
These hypoperfusion cognitive problems are not necessarily 'vascular' dementia.  In animal 
models, reduced cerebral blood flow triggers a neurotoxic cascade that culminates in 
accumulation of amyloid and hyperphosphorylated tau proteins, the classical precursors of AD.  
If chronic hypoperfusion is causative, then improving cerebral blood flow should reduce 
cognitive decline.   
There is some evidence to support this view in patients with severe HF who have undergone 
cardiac transplant, pacemaker or cardiac resynchronisation therapy, and in whom measures 
of cognition have stabilised or improved post-procedure.83-85  
 1.2.3.5  Thrombosis and cerebral infarction 
 
The potential importance of AF-related cardioembolism has been discussed.  Cardioembolism 
is also seen in HF with sinus rhythm where ventricular function is the most important 
determinant of thrombus formation and potential embolic cerebral infarction.86  Down 
regulation of thrombomodulin, structural changes in the cardiac chambers and potential blood 
stasis in the context of reduced myocardial contractility are associated with thrombus 
formation that may in turn lead to arterial events of clinical stroke or occult cerebral 
infarction.86  This systemic prothrombotic phenotype increases risk of all thrombo-embolic 
diseases and HF is also associated with venous thromboembolism.87;88  This is not surprising, 
as abnormalities in all three constituents of Virchow’s Triad (abnormal blood constituents, 
abnormal vessel wall and abnormal blood flow) are present in HF.  Neurohormonal activation 
seen in HF is associated with increased production of thrombogenic factors such as von 
Willebrand factor, thromboxane A2 and endothelin.  The end result is a hypercoagulable state 
with increased serum levels of circulating fibrinogen, fibrinopeptide A and D-dimer (amongst 
others) resulting in platelet and thrombin activation and ultimately leading to plasma 
hyperviscosity and thrombosis.89  A relationship between all these circulating markers of 
thrombosis and haemostasis and cognitive decline, particularly 'vascular dementia', has been 
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described.90  It would seem intuitive that anticoagulation may prevent sequelae of thrombosis; 
however, studies of formal anticoagulation in HF with sinus rhythm have been equivocal.  To 
date, no large study of anticoagulation in HF describing cognitive outcomes has been published. 
1.2.4  Treatment implications of cognitive impairment in heart failure 
 
There is an impressive evidence base to support pharmacological interventions in HF-REF.  
Historically HF trials have described clinical outcomes such as death, vascular events and 
hospitalisation with decompensated HF.  There has been little focus on cognition or dementia 
as trial outcome or as a case mix adjuster.  In fact for many of the trials that inform the HF 
evidence base, dementia or CI will have been an exclusion criterion.  Where trialists have 
attempted to describe cognitive effects of HF treatment, results have been neutral.91 
Central to the treatment of HF is relatively complex multi-drug pharmacological treatment 
with attendant need for careful biochemical surveillance and self- monitoring.  To achieve 
optimal outcomes requires strict adherence to prescribed evidence-based therapy.2  Poor 
adherence is linked to an elevated risk of hospitalisation and death, whereas appropriate self-
management may reduce these risks.2  It seems intuitive that ensuring adherence and self-
management would be especially challenging in the context of CI. 
Interventions with ACE-inhibitors have been a mainstay of HF-REF therapy for decades.  ACE 
is also important in neurotransmitter modulation and there are theoretical reasons to believe 
that ACE-inhibitors may have an effect on cognitive decline.  Cognitive sub-studies of the 
Cardiovascular Health Study and the Italian Longitudinal Study on Ageing92;93 both reported 
that subjects treated with ACE-is had equivalent rates of incident dementia compared with 
those treated with other anti-hypertensives.  However, there were intriguing within-class 
differences in cognitive outcomes - for example, between centrally and non-centrally active 
agents and between differing drug potencies.93  The other pillars of HF-REF therapy, beta-
blockers and MRA’s, may also influence cognition.  Although no studies specific to HF are 
available, there is hypertension literature suggesting theoretical cognitive effects of beta-
blockade but inconclusive evidence that this is clinically important.94  Cognitive effects of MRAs 
have been demonstrated in animal models but human data are limited.95 
Novel approaches to pharmacological intervention in HF are being developed, with the 
natriuretic peptide system a key therapeutic target.  These peptides possess differing degrees 
of haemodynamic, neurohormonal, renal and cardiac effects which may be favourable in the 
HF setting and may augment the effects of RAAS blockade.  Studies using inhibitors of 
neprilysin (also known as neutral endopeptidase), an enzyme involved in the breakdown of 
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endogenous natriuretic peptides, have yielded encouraging results.96  Based on this experience 
a phase III trial comparing the angiotensin receptor neprilysin inhibitor molecule LCZ696 to 
the ACE-i enalapril was undertaken in chronic HF-REF (PARADIGM-HF).  This trial was recently 
stopped for benefit of LCZ696 over enalapril.97  However, cardiac optimism must be tempered 
by caution regarding potential non-cardiac, cognitive adverse effects.  Mutations in the 
neprilysin gene have been associated with familial forms of AD and neprilysin-deficient mice 
show an AD phenotype.98  
In the light of non-definitive data, how should we treat a patient with HF and CI? Cognitive 
enhancing medication such as acetylcholinesterase inhibitors have recognised effects on the 
cardiac conduction system, occasionally causing bradycardia, sick sinus syndrome or other 
arrhythmias (including torsades de pointes) resulting from QT prolongation through excessive 
cholinergic stimulation.  One recent study showed donepezil to be safe in patients without 
symptomatic heart disease and actually reduced levels of plasma brain natriuretic peptide in 
patients with subclinical HF.99 
Although there are no data to suggest cognitive benefits of standard HF therapy, there are 
equally no signals of harm.  Given the beneficial effects of pharmacological therapy on mortality 
and hospitalisation, it would seem sensible to consider these evidence-based medical 
interventions for all HF patients, tailoring the intervention to suit the patient.  A 
multidisciplinary approach with frequent review and medication titration seems to work well.  
Prescribers need to be alert to the potential effects of CI on concordance with sometimes 
complex drug regimens.  Early use of compliance aids and involvement of family or carers may 
help in this regard.  The goal of management of HF is to provide 'seamless care' in both the 
community and hospital to ensure the treatment of every patient is optimal.   
Despite the plethora of publications and guidelines, the data consistently show a lower uptake 
of evidence-based investigations and therapies in older patients with consequent higher rates 
of HF hospitalizations and mortality.100  The current shift away from concentration on 
individual drug therapies to a focus on systems of care that allow effective treatment delivery 
is welcomed. 
1.3  Aims of study 
CI is well documented in a range of cardiovascular disorders such as CAD,101 hypertension102 
and AF.103  This is relevant to the study of HF patients, as we know that many, if not most, have 
a history of one or more of these co-morbidities.  The documented prevalence in of CI in HF in 
current literature varies hugely – from 30 to 80% (see chapter 2).  This variation probably 
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reflects variation in study design, HF severity, sample size, neuropsychological assessment 
tools and the diagnostic criteria employed in the various studies. 
This study aims to provide a more comprehensive evaluation of cognition in HF by using larger 
sample sizes, performing an extensive neuropsychological assessment using a “domain-based” 
battery of tools and including both cardiac and healthy control participants.  Particular 
attention has been paid to the domain of executive function which is involved in the handling 
of novel situations.  It enables an individual to recognise a new situation, process the 
information and formulate a plan accordingly.  This is obviously key to patients involved in 
symptom recognition and self-management and has been understudied in HF literature to date.  
The hypotheses of this study are three-fold. 
Firstly we hypothesise that patients with HF will attain lower cognitive scores than those age 
and sex matched healthy control participants.  Secondly, HF patients will attain lower cognitive 
scores than age and sex matched cardiac controls.  Thirdly, not with-standing the first two 
hypotheses, patients with a combination of HF and AF (either permanent or paroxysmal) will 
have poorer cognition than those with HF and no history of AF.   
The aims of this study are: 
 To determine the prevalence of CI in the stable, CHF outpatient population. 
 To determine if the underlying cause of HF (ischaemic versus non ischaemic) affects 
the prevalence of CI in CHF. 
 To determine if the presence of AF affects the prevalence of CI in CHF.  
 To determine if the “pattern” of CI differs between cohorts i.e. global CI versus impaired 
executive function. 
 To compare different cognitive assessment tools including MMSE, MoCA and RBANS 
 To determine if CI is associated with: 
 Mood 
 Carer burden 
 Markers of self-care 
Ultimately, this study aims to determine whether CI is a feature of HF per se rather than the 
cardiovascular co-morbidity characterising HF. 
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CHAPTER TWO 
 
SYSTEMATIC REVIEW OF THE LITERATURE 
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2.1  Introduction 
The clinical syndrome of HF imposes an immense burden of symptoms on patients, reduces 
quality of life and is one of the leading causes of hospitalisation and mortality, particularly in 
more developed countries.5 Due to aging of the population  and improved survival from CAD 
prevalence of HF is expected to double within the next 40 years.104  These arguments of high 
symptomatic and economic burden and increasing absolute numbers in the context of an 
ageing population equally apply to the syndromes of cognitive impairment CI and in particular, 
dementia. 
CI has been reported in a variety of cardiovascular disorders. It is described in  patients with 
hypertension,102 AF103 and CAD, especially after coronary artery bypass grafting (CABG).101  
Many patients with HF, if not most, have a history of one or more of these co-morbidities.  The 
pathogenesis of CI remains poorly described but putative mechanisms such as cerebral 
hypoperfusion; cumulative cerebrovascular insults and systemic inflammation may all be 
relevant in cardiac disease. Central to the treatment of HF is a relatively complex multi-drug 
pharmacological treatment which requires careful biochemical surveillance, strict adherence 
and high level self-management.2  Successful self-management may be jeopardised by CI. 
Thus, there are plausible reasons to suspect an association between HF and cognitive decline.  
Understanding this association is important, particularly as CI may impact on HF management.  
A literature describing CI in the HF population is available but papers are published in 
disparate specialty medical journals (cardiology, neurology, psychiatry), sample sizes can be 
modest and results are inconsistent.  Individually these papers provide little insight into the 
link between the two conditions.  In this situation a comprehensive synthesis of all published 
literature with summary statistics can give useful information. 
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2.2  Methods 
This systematic review was designed, conducted and reported according to the “Preferred 
Reporting Items for systematic reviews and meta-analyses” (PRISMA) guidelines.105  A search 
protocol was created and is available on an open access web-based resource (PROSPERO, 
registration number CRD42014015485).106   
The primary aim was to describe an association between HF and CI (where CI is a syndrome 
including mild cognitive impairment, multi-domain cognitive impairment and varying 
severities of dementia).  Two independent researchers trained in systematic review, 
performed all aspects of searching, selection, extraction and assessment (J.A.C & P.M) any 
disagreements were referred to a third arbitrator (T.J.Q).   
2.2.1  Inclusion/exclusion criteria 
 
The eligibility criteria were defined prior to any literature searches and were outlined as 
follows: 
1.   Studies published in English.  
2.   Studies with at least 50 human participants. 
3.   Original research published in peer reviewed scientific journals.  
4.  Studies presenting data on CI and HF with the following study designs:  
 prospective  cohorts, cross sectional population studies and case-control  studies. 
5.   Studies using at least one validated measure of cognition or clinical diagnosis 
 made according to recognized criteria.  
6. Studies including patients with a formal clinical diagnosis of HF. 
 
Randomized controlled trials that collected cognitive data as primary or secondary outcome 
were excluded as the included participants may not be generalizable to an unselected HF 
population.  Abstracts were included in the search but, for the final selection of studies only 
those that had been fully published in peer reviewed journals were included.  Papers were not 
excluded on the basis of year of publication. 
2.2.2  Search strategy 
 
A sensitive search strategy based around concepts of [heart failure] and 
[cognition/dementia/cognitive testing] was created.  Where available validated search strings 
were used and supplemented with MeSH terms and other controlled vocabulary.  (figure 2-1 
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outlines the search strategy and review profile).  Multidisciplinary databases were searched 
from inception until 31st May 2015:  MEDLINE (OVID), EMBASE (OVID), CINAHL (EBSCO), 
PsychINFO (EBSCO), Web of Science (Thomson Reuters) and CENTRAL (Cochrane Library).  
Where the facility was available, the “explode” function was used in those databases.  
Bibliographies of included papers and relevant reviews were searched for further possible 
titles and the process was repeated until no new titles were found.  Where the same data were 
presented in more than one publication the primary (first) publication was used. 
After de-duplication, titles generated from the initial database searches were screened and if 
felt to be relevant, then the full text was reviewed.   
2.2.3  Data extraction  
 
For papers eligible for inclusion, data were extracted to a pre-specified and piloted proforma.  
Information regarding diagnosis of HF, with particular focus on subtypes of HF (HF-PEF or HF-
REF); severity of HF (symptomatic or objective marker); sampling frame (outpatient or 
inpatient/mixed) and cognitive assessment or criteria employed were collated.  
2.2.4  Risk of bias and generalizability assessment   
 
Internal and external validity were assessed using the approach outlined in critical appraisal 
skills (CASP) guidance.105  The CASP checklists were used for cohort and case-control studies 
and domains were assessed relating to sampling frame, case ascertainment (dementia and HF) 
and confounding to create a semi-quantitative assessment.    A paper was defined as low risk 
of bias where the following criteria were met: samples recruited had robust diagnosis of HF 
based on current ESC guidelines; cognitive function was assessed using standardized cognitive 
assessment tools or diagnosis made using validated classification system; confounding factors 
taken into account in the analyses of results.    
For longitudinal studies a follow up period of 18 months was deemed to be an appropriate 
timescale to assess for the development of cognitive impairment. For each study external 
validity was considered including whether the results could be applied to a contemporary HF 
population. 
2.2.5  Data analyses 
 
A summary of key findings were formatted into tables to inform a narrative synthesis of the 
included papers. Meta-analyses were performed to give summary estimates in those instances 
where more than 3 papers used a similar study design and contained comparable cognitive 
assessments.  Heterogeneity was assessed through visual inspection of forest plots and 
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quantitatively using Higgins I2 and potential publication bias was assessed using a funnel plot.   
All meta-analyses were run with both a fixed and random effects model.   
Differing statistical approaches were pre-specified depending on the study design.  For case-
control data we calculated relative risks comparing proportions with CI in the HF population 
versus the healthy control population.  For cross-sectional studies point estimates of 
prevalence of CI / dementia were described. It was intended to assess rates of incident 
CI/dementia and calculate summary hazard ratios in prospective studies. 
A sensitivity analysis was pre-specified, restricted to those studies judged as low risk of bias 
on validity assessment and subgroup analyses were pre-specified restricted to outpatient 
populations only.  All analyses were performed using Stata version 14 (Stata Corp, College 
Station, Texas).  
2.3  Results 
From 18000 titles identified, 350 abstracts were selected for review, 87 full manuscripts were 
assessed and 37 papers (n=8411 participants) were eligible for inclusion in the final review.  
Figure 2-1 outlines the search strategy and review process. 
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Figure 2-1:  Search strategy and review profile for systematic review 
125 no original data 
38 less than 50 participants 
36 repeat citations 
22 no formal diagnosis of heart failure 
15 no multidomain cognitive 
assessment 
23 review papers 
4 non-English articles 
 
 
 
 
Databases searched 
Ovid Medline 1950 - 2015 
EMBASE 1980-2015 
CINAHL 1981-2015 
PsychINFO 1967-2015 
Web of Science 
Cochrane Library 
 
Concept 1 
cognition OR confusion OR dementia OR (cognition adj5 
(disorder$ or deficit$ or defect$ or disabilit$ or decline or 
function or measures or dysfunction or scores)) OR 
(neuropsych$ adj5 (test$ or battery or deficit$)) OR psychologic 
test OR Alzheimer Disease* OR Leukoencephalopath* OR 
Vascular dementia OR organic brain syndrome OR Cognition 
Disorders OR Cognition* OR Cognitive ability OR Cognitive 
characteristics OR Cognitive function* OR Cognitive style OR 
cognitive deficit OR intellectual ability* OR Intelligence* OR IQ 
OR intellectual impairment OR Language test* OR Memory OR 
Memory Disorders OR Mental abilit* OR Mental capacity OR 
Mental Recall OR mental deficiency OR amnesia OR 
Neuropsychological Tests OR Problem solving OR OR 
Intelligence measure* OR Intelligence test* OR Intelligence tests 
statistics & numerical data OR psychologic* assessment OR 
neuropsychological test OR problem-solving OR Psychological 
performance 
Concept 2 
Heart Failure OR cardiac failure OR ((myocardial or 
myocardium or cardiac or cardial or heart or ventric*) OR  
(failure* or decompensation or insufficient* or dysfunction*)) 
Concept 1 terms AND concept 2 
terms.  Limited to humans 
18,000 titles identified 
350 abstracts selected for 
review 
87 full manuscripts 
reviewed 
37 papers included in final 
analysis 
21 no full paper available 
12 results not generalizable 
8 required to have CI for 
inclusion 
9 repeat citations 
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2.3.1  Narrative review of included studies 
 
7 case control studies were included (representing 1781 participants),55;107-112 4 of which 
included healthy participants as the control group107-110 with the other 3 comparing rates of CI 
between HF cohorts i.e. between those with HF-PEF and HF-REF.55;111-113  26 cross-sectional 
studies were included73;74;100;114-136 (representing 4177 participants) the majority of which 
(n=18) recruited patients from the outpatient setting.100;114-118;121-123;127-129;131-136  Only 4 studies 
(with 2513 participants) examined for incident cognitive function/ dementia in patients with 
HF over prospective longitudinal follow up.137-140  All key study characteristics are summarised 
in tables 2-1 - 2-3. 
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Study Sample Population CV Measures/Criteria Cognitive assessment tool used 
Bauer et al 201155 
 
51 HF-REF patients 
29 HF-PEF patients 
Outpatients only LVEF 
NYHA 
RBANS  
Neuropsychological battery 
Bratzke-Bauer et al 
2013112 
47 HF-REF patients 
33 HF-PEF patients 
Outpatients only LVEF 
NYHA 
 
MMSE 
RBANS 
Neuropsychological battery  
Callegari et al 2002107 64 HF patients 
321 healthy control participants 
Consecutive 
admissions 
LVEF<50% 
NYHA I-III 
CPET 
Right heart 
catheterisation 
Neuropsychological battery 
Festa et al 2011111 
 
169 HF-REF patients 
38 HF-PEF patients 
Outpatients only LVEF Neuropsychological battery 
Pressler et al 2010110 
 
 
249 HF patients 
63 healthy control participants 
102 general medical patients 
Outpatients only NYHA 
LVEF 
MMSE 
Neuropsychological battery 
Sauvé et al 2009108 50 HF patients 
50 healthy control participants 
Outpatients only LVEF≤40% 
NYHA II-IV 
Neuropsychological battery 
Trojano et al 2003109 149 HF NYHA II patients 
159 HF NYHA III/IV patients 
207 non HF control patients 
Consecutive 
admissions 
No measure of LV 
function 
NYHA II-IV 
MMSE 
Neuropsychological battery 
 
Table 2-1:  Design of case-controlled studies 
  
60 
 
Study Sample Population CV Measures 
/Criteria 
Cognitive assessment tool used 
Alosco et al 2014114 
 
110 CHF patients Outpatients LVEF 
NYHA II-IV 
3MS 
 
Alosco et al 2012117 
 
157 CHF patients Outpatients 2 minute step test 
NYHA 
Neuropsychological battery 
Alosco et al 2013116 
 
52 CHF patients Outpatients Cardiac Index MMSE 
RBANS 
Alosco et al 2014115 
 
179 CHF patients Outpatients LVEF 
NYHA II-IV 
Neuropsychological battery 
Antonelli et al 2003119 369 CHF patients Consecutive admissions NYHA MMSE 
Neuropsychological battery 
Arslanian- Engoren et al 
2014120 
53 CHF patients Inpatients NYHA Cogstate battery 
 
Athilingam et al 2011121 
 
90 CHF patients Outpatients NYHA 
LVEF 
Cardiac index & 6 minute walk test 
MMSE 
MoCA 
Baldasseroni et al 2010122 
 
 
80 CHF patients Outpatients NYHA 
6 minute walk test 
LVEF 
MLHFQ 
MMSE 
 
Cacciatore et al 1998123 92 CHF participants Outpatients NYHA MMSE 
Cameron et al 2010124 
 
93 CHF patients Consecutive admissions LVEF 
NYHA 
Self-care HF index 
MMSE 
MoCA   
Debette et al 200774 83 HF patients Consecutive admissions LVEF<45% 
NYHA I-IV 
MMSE 
Dodson et al 2013125 
 
282 decompensated HF 
patients 
Non-consecutive admissions HF diagnosis based on documentation in 
medical records 
MMSE 
Feola et al 200773 60 CHF patients Inpatients LVEF 
NYHA II-IV 
BNP 
 
Neuropsychological battery 
Table 2-2:  Design of cross sectional studies 
1b.  Design of cross-sectional studies 
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Feola et al 2013126 
 
 
 
 
303 CHF patients 
 
 
Consecutive admissions LVEF 
NYHA 
BNP 
6 minute walk test 
Non-invasive CO 
MMSE 
 
Gallagher et al 2013127 128 CHF patients Outpatients NYHA 
MLHFQ 
MoCA 
Garcia et al 2011128 116 CHF patients Outpatients NYHA 
2 minute step test 
3MS 
Neuropsychological battery 
Ghanbari et al 2013129 239 CHF patients Outpatients NYHA 
LVEF 
MMSE 
 
Hajduk et al 
2013130 
577 CHF patients Inpatients Not specified MoCA 
Neuropsychological battery 
Harkness et al 2013100 100 CHF patients Outpatients LVEF ≤45% 
NYHA I-III 
Self-care in HF index 
MMSE 
MoCA 
 
Hawkins et al 2014131 231 CHF patients Outpatients NYHA Neuropsychological battery 
Hawkins et al 2012132 250 CHF patients Outpatients LVEF RBANS 
Neuropsychological battery 
Hjelm et al 2013133 
 
137 CHF patients Outpatients NYHA 
LVEF 
BNP 
MMSE 
Neuropsychological battery 
Jesus et al 2006134 83 CHF patients Outpatients LVEF MMSE 
Miller et al 2012118 140 HF patients Outpatients only No measure of LV function 
No NYHA classification 
2 minute step test 
Neuropsychological battery                                               
Steinberg et al 2011135 55 HF patients Outpatients only LVEF≤45% 
NYHA I-III 
6 Minute Walk Test 
MMSE 
Neuropsychological battery 
Vogels et al 2007136 
 
58 CHF patients Outpatients LVEF 
NYHA 
MMSE 
Neuropsychological battery 
 
BNP, brain natriuretic peptide; CHF, chronic heart failure; CO, cardiac output; HF, heart failure; LV, left ventricular; LVEF, left ventricular 
ejection fraction; MLHFQ, Minnesota living with heart failure questionnaire; MMSE, mini mental state examination; MoCA, Montreal cognitive 
assessment tool; 3MS, modified mini mental exam; NYHA, New York heart association; RBANS, repeatable battery for the assessment of 
neuropsychological status 
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Table 2-3:  Design of longitudinal studies 
 
 
 
 
 
 
Study Sample Population CV Measures /Criteria Cognitive assessment tool 
used 
Follow up 
period 
Almeida et al 
2012137 
 
77 CHF patients with LVEF <40% 
73 CAD patients with LVEF >60% 
81 controls with no CAD/CHF 
Outpatients LVEF 
6 minute walk test 
MMSE 
Neuropsychological battery 
 
24 months 
Hjelm et al 2012138 
 
95 HF patients 
607 non-CHF controls 
Outpatients HF diagnosis based on 
documentation in medical 
records 
Neuropsychological battery 10 years 
Qiu et al 2006139 
 
205 CHF patients 
1096 controls 
 
Outpatients Not specified MMSE 9 years 
Riegel et al 
2012140;141 
279 consecutive  
HF patients (HF-REF & HF-PEF) 
 
Outpatients NYHA I-IV 
LVEF  
Neuropsychological battery 6 months 
 
CAD, coronary artery disease; CHF, chronic heart failure; HF, heart failure; HF-PEF, heart failure preserved ejection fraction; HF-
REF, heart failure reduced ejection fraction; LVEF, left ventricular ejection fraction; MMSE, mini mental state examination; NYHA, 
New York heart association;  
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Available longitudinal studies included ambulatory patients with HF followed for between six 
months and ten years.138;141  Within the prospective study rubric, various study designs were 
employed including comparison of HF-PEF and HF-REF and comparison of HF with healthy 
controls. The heterogeneity precluded any attempt at meta-analysis.  Three studies compared 
HF and non-HF groups,137-139 where follow-up was longer than two years the HF group seemed 
to have greater decline in cognition.  (table 2-4). 
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Table 2-4:  Results from longitudinal studies 
 
 
 
Study Sample Age 
(Years) 
Hazard Ratio (at 
last follow-up) 
Follow up 
period 
Cognitive outcome Change over time 
Almeida et al 
2012137 
 
77 CHF patients with LVEF <40% 
73 CAD patients with LVEF >60% 
81 controls with no CAD/CHF 
68 (10) 
68 (10) 
69 (11) 
N/A 24 months CAMCOG CAMCOG scores in CHF group declined by 
0.9 points over 2 years 
 
No other differences between groups 
Hjelm et al 
2012138 
 
95 HF patients 
607 non-CHF controls 
84(3) 1.258 (95%CI: 
0.95-1,66) 
10 years Neuropsychological 
battery 
HF patients: Significant decline in episodic 
memory & spatial performance compared 
with controls. 
Qiu et al 
2006139 
 
 
 
205 CHF patients 
1096 Controls  
83 (5) 
81 (5) 
1.84  
(95%CI: 1.35-
2.51) 
9 years Dementia  
(DSM diagnosis)  
Over 9 years 85% CHF patients developed 
CI & 65% of controls developed CI 
 
 
Riegel et al 
2012140 
 
279 consecutive  
HF patients  (HF-REF & HF-PEF) 
62 (12) N/A 6 months DSST No significant change in cognition over 6 
months (HF-REF and HF-PEF) 
 
Minimal improvement in DSST (53 (18)- 58 
(18)) in both groups likely due to learned 
effect 
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2.3.2  Quantitative analyses 
 
Of all eligible studies n=20 (n=2290 participants) cross-sectional73;116;142,74;100;118;118;121-130;132-136 
and n=4 (n=1414 participants) case-control were suitable for quantitative summary 
analyses.107-110  There was substantial heterogeneity across all analyses (I2: 98.5% for cross-
sectional; 71.5% for case-control) and random effects data are preferentially reported in the 
text (both models presented in the forest plots).   
For cross-sectional studies describing prevalence of CI; there was a spread in reported values 
from 0.1 (95% CI: 0.07-0.14) to 0.79 (95% CI: 0.75-0.82).  Summarising the data, overall 
prevalence was 0.43 (95%CI: 0.30-0.55).  For subgroup analysis restricted to those studies 
including only outpatients (n=14 papers; 1620 participants),100;116;118;121-123;127-129;132-136 results 
were similar 0.40 (95% CI: 0.28-0.52); as were summary results in the sensitivity analysis 
restricted to low risk of bias studies (n=13 papers; 2012 participants) 0.44 (95%CI:  0.29-
0.59).100;116;121-124;127-130;132;133;136  (Figures 2-2 – 2-4).  There were insufficient studies to allow 
for the proposed subgroup analysis looking at HF-PEF and HF-REF. 
For case-controlled studies, n=4 papers (1414 participants) compared rates of CI and dementia 
in HF versus non-HF controls.107-110  Overall the random effects model showed a 1.55 relative 
risk (95% CI:  1.23- 1.95) of CI in the HF cohort (figure 2-5). There were insufficient data to 
allow comparison between those case controlled studies comparing HF-PEF and HF-REF.  
A funnel plot showing effect estimates against study size for the cross sectional data is shown 
in figure 2-6.  This shows a relatively symmetrical funnel shape suggesting publication bias was 
not a major issue. 
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Figure 2-2:  Forrest plot of all cross-sectional studies (N=20) showing overall 
point estimate of 0.32 (95% CI: 0.31 – 0.33) for the risk of cognitive impairment 
in heart failure. 
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Figure 2-3:  Forrest plot of cross sectional studies which recruited from 
outpatient populations only (N= 14) showing point estimate of 0.38 (95% CI:  
0.36 -0.39) for the risk of cognitive impairment in heart failure. 
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Figure 2-4:  Forest plot of cross sectional studies which were found to have a “low 
risk” of study bias (N=13) showing overall point estimate of 0.38 (95% CI:  0.36-
0.39) for the risk of cognitive impairment in heart failure. 
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Figure 2-5:  Forrest plot showing case controlled studies comparing heart failure 
cohort vs. healthy controls 
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Figure 2-6:  Funnel plot of cross-sectional data 
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2.4  Discussion 
A strong association between HF and cognitive problems have been demonstrated in this 
systematic review.  Summary data suggest that in an unselected HF population around 40% 
will have CI or dementia.  Subgroup and sensitivity analyses confirm that this high prevalence 
is robust and not driven by poor quality studies or by inclusion of significant numbers who 
were unwell with decompensated HF.  Case-control data suggest that compared to matched 
controls with no HF, those with HF have significantly increased risk of CI. 
Observational data are susceptible to a variety of biases.  The variability of the prevalence rates 
for CI that are reported in the reviewed studies probably results from the differences in the 
populations studied and the differences in the range and specificity of the instruments used to 
assess cognition.  The heterogeneity of samples including patients and control subjects who 
had previous neurological injuries poses an additional limitation on the samples in most of the 
studies included.     
The ideal study design looking at the association between HF and CI would involve longitudinal 
follow up of a group of patients with HF (but free of CI at inception) with regular administration 
of standardised cognitive assessment tools and comparison with a group of age-, sex- and 
education-matched control cardiac patients as well as healthy control participants.  For 
completion a group of cardiac patients (without HF) should be included to control for 
underlying cardiac conditions such as AF and CAD.  No study using that specific design was 
found in this review. 
The strengths of this review include a comprehensive search strategy based on validated 
search terms and interrogation of cross-disciplinary electronic databases.  All papers were 
quality assessed using a robust method tailored specifically to the study question.   Due to lack 
of information in some of the manuscripts included, it was not possible to include all of the 
papers in the pre-specified analyses.  A further limitation of the summary analyses is the 
substantial clinical heterogeneity between studies and participants.  
To put the prevalence estimate of 40% into context, the estimated prevalence of CI/ dementia 
in the UK in adults over 65 years old is 7.1% (based on 2013 data).  The total number of people 
with dementia in the UK is forecast to increase to over 1 million by 2025 and over 2 million by 
2051 if age-specific prevalence remains stable.  This increasing prevalence is driven by ageing 
of the general population and existence of other co-morbid factors – of which HF could be an 
important contributor. 
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Data generated from this review are in keeping with previously published reviews describing 
the prevalence of CI in HF.  Vogels et al published a systematic review looking at this association 
in 2007.143  Across 22 studies, HF was associated with an increased risk of CI (reported 
prevalence between 30-80%).  Whether the increased risk of CI in HF is due to the clinical 
syndrome of HF itself – or the atherosclerotic risk factors commonly underlying it remains less 
clear.  Other systematic reviews have shown associations between CI and other cardiovascular 
disorders such as AF,144 stroke145 and CAD.146  Many potential confounding variables are 
relevant to these groups of patients and so although the association with impaired cognition is 
clear, a causal relationship is harder to prove - or disprove.   
Preserving cognitive function and quality of life within the growing population of elderly 
patients with heart failure requires an awareness of this potential complication in the early 
stages of heart disease.  Although the idea of concomitant CI and HF will be familiar to most 
clinicians it is not routinely screened for in the cardiology outpatient setting.  Cognitive 
screening is not currently recommended in the European Society of Cardiology heart failure 
guidelines and this is in part due to the lack of standardised screening tools that are accessible, 
easy to administer in a timely fashion and that have clear clinical cut-off scores.  Although this 
systematic review clearly shows a high prevalence of CI in the HF population recent 
observational data suggests that informal assessment of cognition by a cardiologist is 
insufficiently sensitive with 3 in 4 patients with CI not recognised as such in routine 
consultations. Cognitive assessment tools may have a role in research and practice, although 
first we should reach a consensus on appropriate assessment score cut-offs in this population 
and outline specific cognitive profiles in these patients. Although clearly important, systematic 
data on cognitive impairment in heart failure does not remove the need for prospective studies 
and experimental models to clarify the pathogenesis of this condition.   
In conclusion, much of the heterogeneity in the prevalence of cognitive impairment/dementia 
seen in the HF population can be explained by differences in study methodology and case mix.  
Although numerous studies assessing prevalence were found, there was a dearth of studies 
investigating the incidence of CI in HF which should be addressed in future research. Once the 
incidence and prevalence of CI in HF are better defined the consequences of this association 
and the possible underlying mechanisms also need to be evaluated.   
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Chapter 3:  Methods 
3.1  Introduction 
 
This chapter will outline the methods used in this clinical cross sectional study.  Ethical 
approval for the study was gained from the West of Scotland Research Ethics Service in 
November 2012 and an overview of the individual patient journey is shown in Figure 3-1.  The 
methods used for patient identification, recruitment, data collection and data analysis will all 
be described. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1:  Flow diagram of patient assessments 
Cohort 3: 
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and EF ≤45% 
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aetiology & AF  
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Age and 
gender 
matched CAD 
controls  
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of ischaemic 
aetiology  
 
Cohort 5: 
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matched 
healthy 
controls  
 
Outpatient visit 1 at BHF-GCRC  
 History & physical examination 
 Laboratory Testing 
 Urine sample taken 
 ECG 
 Written informed consent 
obtained 
Duration: 30 minutes 
 
Outpatient visit 2 at BHF-GCRC 
 Formal neuropsychological 
testing 
 HADS 
 Quality of life questionnaires 
 Zarit burden interview 
administered 
 IQCODE 
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Outpatient participants 
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 Cerebral MRI 
Duration:  90 minutes 
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non-ischaemic 
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3.2  Participant identification and recruitment 
 
3.2.1  The outpatient heart failure cohorts 
 
All HF patients in this study were recruited via the heart failure liaison service (HFLS) at the 
Royal and Western Infirmaries in Glasgow, the Royal Alexandra Hospital in Paisley and Stobhill 
Hospital, Glasgow.  The Western Infirmary, Glasgow had a catchment population of over 
250,000 people and covered the North-West of the city.  Glasgow Royal Infirmary also has a 
catchment population of over 250,000 people from the North East of the city and part of East 
Dumbartonshire.  Ambulatory care is shared between Glasgow Royal Infirmary and Stobhill 
Hospital – with cardiology outpatient clinics being held at both sites.  The Royal Alexandra 
hospital in Paisley is a large district general hospital with a wide catchment area ranging from 
Renfrewshire to Oban and Argyll.  All participant recruitment took place between March 2013 
and December 2014.  
NHS Greater Glasgow and Clyde has one of the largest, most comprehensive and longest 
running community based specialist HF nurse services which allowed access to a city-wide 
population of patients with systolic HF.  This service serves a total population of approximately 
one million inhabitants.  Any patient identified as having systolic HF (defined by EF ≤45% on 
echocardiography, radionuclide ventriculography or angiography) can be referred to the HFLS 
for follow up in the community; either from primary or secondary care.   
I screened all patients referred to the HFLS between March 2013 and December 2014 and 
patient contact was made if the patient fulfilled the study inclusion criteria (listed below).   
3.2.2  The outpatient coronary artery disease cohort 
 
The CAD cohort was recruited from cardiac rehabilitation teams based at the same four 
hospital sites listed above.  Patients admitted to hospital with an uncomplicated MI, unstable 
angina or following (either elective or emergency) coronary angiography +/- percutaneous 
coronary intervention (PCI) are followed up by a cardiac rehabilitation team.  All patients 
referred for cardiac rehabilitation between March 2013 and December 2014 were screened 
and contacted if the enrolment criteria were fulfilled (see below).       
3.2.3  The healthy control cohort 
 
Generation Scotland is a Scottish Government funded initiative which draws from 
collaboration between Scottish university medical schools, the NHS and willing volunteers.  It 
is a research resource which has recruited over 21,000 healthy volunteers from all over 
Scotland to participate in the Scottish Family Health Study.  Age and sex matched healthy 
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controls from within the same geographical area as our HF and CAD groups were recruited 
from this database.  These participants had all previously given consent to Generation Scotland 
for re-contact in future studies. 
Inclusion Criteria 
All participants were required to be able to provide written, informed consent and be over 60 
years of age.  Otherwise, the inclusion criteria varied depending on the particular study cohort 
as outlined below: 
Cohort 1:  Heart failure of ischaemic aetiology in patients in sinus rhythm 
 
This cohort included ambulatory subjects with CHF and a reduced LVEF (≤45%) secondary to 
CAD without the exclusions listed below.  The presence of CAD was defined as previous MI 
(documented in medical notes) or ≥50% stenosis in ≥1 epicardial coronary artery either on CT 
or invasive coronary angiography.   
Cohort 2:  Heart failure of non-ischaemic aetiology in patients in sinus rhythm 
 
This cohort included ambulatory subjects with CHF and a reduced LVEF (≤45%) of non-
ischaemic aetiology, without the exclusions listed below.  Non-ischaemic aetiology was defined 
by the absence of CAD on coronary angiography (either CT or invasive) or myocardial 
perfusion/ischaemia imaging (including stress echocardiography, single photon emission 
computerised tomography [SPECT], positron emission tomography [PET] or CMR) with no 
previous clinical history of MI.   
Cohort 3:  Heart failure of any aetiology and atrial fibrillation 
 
This cohort included ambulatory subjects with CHF and a reduced LVEF (≤45%) of any 
aetiology without the exclusions listed below.  These patients were required to have a 
documented diagnosis of AF (either paroxysmal or permanent).   
Cohort 4:  Coronary artery disease control group 
 
This cohort included ambulatory subjects with known CAD, LVEF >55% and no clinical HF, 
without the exclusions listed below.  CAD was defined as either previous documented MI or 
CAD of ≥50% stenosis in ≥1 epicardial coronary artery on either CT or invasive coronary 
angiography. 
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Cohort 5:  Healthy control group 
 
This cohort included ambulatory subjects with no history of chronic illness, on no regular 
medication without the exclusions listed below.   
Exclusion criteria 
 History of hospital discharge within the past 3 months 
 Previous cardiac arrest 
 Previous cardiac surgery 
 History of stroke 
 Significant hearing/visual impairment or language barrier preventing completion of 
study assessments 
 AF on 12 lead ECG or a history of paroxysmal AF (except cohort 3) 
 Depression as defined by HADS score >10 or clinically evident depression/anxiety 
 Participants younger than 60 years of age 
 Known neurodegenerative disease including known dementia 
 History of alcohol excess (i.e. >21 units/week for men and >14 units/week for females) 
 Inability to provide informed consent 
Any patient with a co-morbid diagnosis that could potentially result in altered cognition were 
excluded e.g. alcohol excess, previous cardiac arrest, previous cardiac surgery and stroke.  It is 
well documented that mood interacts with cognition and so patients with clinically significant 
anxiety or depression (either listed in their past medical history or defined by HADS score>10) 
were also excluded.  Although there are recent data suggesting that delirium can persist for up 
to 12 months post hospital discharge, the ICD-10 classification defines delirium as “transient 
and of fluctuating intensity with most cases recovering within four weeks or less”.147;148  Any 
patient discharged from hospital within the past 3 months was therefore excluded – in an 
attempt to minimise inclusion of patients with delirium.  The other exclusion criteria listed 
pertain to the participant’s ability to provide written, informed consent. 
Consent 
Initial contact was made by a member of the patients “usual care” team i.e. a member of the 
HFLS or cardiac rehabilitation team for cohorts 1-4.  In the case of cohort 5, contact was initially 
made by a member of Generation Scotland.  Potential eligible participants were given basic 
information regarding the study protocol and if there were no objections, a written patient (or 
participant) information sheet was then sent (appendices I&II, pages 199-207).  After 72 hours 
the potential participant was re-contacted and if at that stage they remained willing to 
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participate, an appointment card detailing the time and location of the first study visit was sent 
(appendix III).  Informed, written consent was obtained at study visit one (appendices IV&V).  
In addition to study participation, permission was also requested for future re-contact 
regarding further research related to this study and  for participant details to be “flagged” for 
follow-up with Information Services Division(ISD) of NHS Scotland, allowing identification of 
deaths and readmissions to hospital. 
3.3  Study visit 1 
 
3.3.1  Data collection 
 
Every participant recruited into this study was allocated a unique and anonymous study 
identification number.  They were invited to attend 2 study visits (with an optional third study 
visit) held at the British Heart Foundation Glasgow Cardiovascular Research Centre (BHF-
GCRC).  A large amount of clinical data was collected at each study visit and so the components 
of each visit will be discussed separately. 
At study visit 1, data were obtained by a thorough review of the patients’ medical case notes as 
well as from clinical history and examination.  Other methods of obtaining data included 
searching various hospital database systems for echocardiography, coronary angiography and 
radiological reports.  Data were recorded under the following headings on the case report form 
(CRF) for study visit 1; participant demographics, HF symptoms, aetiology of HF, medical 
history, medications, vital signs, CV examination, recent echocardiography results and results 
from baseline investigations performed at visit 1 which included ECG, urinalysis and blood 
tests (appendix VI). 
Demographic details collected included participant age, sex, race and date of most recent 
hospital discharge.  Although direct age and sex comparisons have been made in previous study 
populations other variables are also known to influence cognition.  Data were therefore 
collected regarding whether the participant lived alone or with a family member, marital 
status, functional ability with activities of daily living and years of education; all of which are 
known to have an impact upon cognition. 
The clinical assessment of HF involved both detailed patient history and thorough clinical 
examination.  Patients were asked about the burden of HF symptoms using the NYHA 
classification system (Table 1-2) in addition to other surrogate markers of HF severity 
including; HF duration, previous HF hospitalisation and specialist healthcare professionals 
coordinating care.  A detailed family history, past medical history and drug history were also 
recorded.   
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The underlying aetiology of HF was recorded in the CRF.  To fulfil the criteria for ischaemic 
cardiomyopathy the patient was required to have had a definite previous MI recorded in their 
clinical notes or >50% stenosis in ≥ 1 epicardial coronary artery demonstrated on either 
invasive or CT coronary angiography.  If an ischaemic cause was excluded, other potential 
causes listed in the CRF included; idiopathic dilated cardiomyopathy (DCM), hypertension, 
alcohol, valvular, unknown or other.  The recorded underlying aetiology was based on 
information from the patients’ medical notes, clinical history and echocardiographic findings. 
All participants were required to have had a transthoracic echocardiogram (TTE) performed 
in the 6 months prior to enrollment.  If this had not been performed as part of routine care an 
echocardiogram was requested prior to study visit 1 at the participants’ local cardiology 
outpatient services.  All study subjects had a TTE performed by an accredited British Society of 
Echocardiography (BSE) sonographer.  Data from the most recent TTE was recorded in the CRF 
(appendix VI).  Specific information documented included; left ventricular end-diastolic 
diameter (LVEDD), the presence or absence of left ventricular hypertrophy (LVH), the grade of 
LVSD (categorized as mild/mild-moderate/moderate/moderate-severe/severe), 
documentation of any valvular heart disease (including a qualitative assessment of severity) 
and calculated EF by Simpson’s biplane method (where available).   
During clinical examination, objective evidence of HF was noted and this was summarised 
using the Killip classification system (Table 2-1).  The Killip score was introduced in 1967 for 
clinical assessment of patients following acute MI, stratifying them according to the severity of 
their post-MI HF.  The original report by Killip and Kimball demonstrated poorer prognosis in 
those patients with a higher Killip score.149 In addition to a detailed cardiovascular 
examination, vital signs including height, weight, blood pressure, heart rate, temperature, 
oxygen saturations and respiratory rate were recorded.  It has previously been hypothesised 
that larger neck circumference may confer higher risk of obstructive sleep apnoea which may, 
in turn impact on cognition.150  Neck circumference was therefore also documented in the CRF.   
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Table 3-1:  Killip classification of heart failure 
 
Killip class Clinical examination findings 
I No clinical signs of heart failure 
II Findings of mild-moderate heart failure e.g. lung crackles/gallop 
rhythm/ third heart sound/raised JVP 
III Frank pulmonary oedema 
IV Cardiogenic shock – hypotension and evidence of peripheral 
vasoconstriction 
 
 
3.3.2  Baseline investigations 
 
Although there are no clear data to support or refute the use of “routine” laboratory tests in 
the assessment of patients with suspected dementia, the American Academy of Neurology does 
recommend screening for any potentially reversible causes of CI including vitamin B12 
deficiency and hypothyroidism.151  In contrast to this, a number of laboratory tests are 
considered mandatory in the ongoing assessment and monitoring of patients with HF and can 
provide valuable information regarding patient prognosis.152   
Each participant in this study therefore had a full panel of biochemical and haematological 
blood tests taken.  These results provided information regarding HF severity and prognosis 
and highlighted any biochemical or haematological potentially reversible cause of CI.  The 
following blood tests were taken at study visit 1;  Urea and electrolytes (U&E), liver function 
tests (LFT), thyroid function tests (TFT), glucose, bone profile, C-reactive protein (CRP), lipid 
profile, BNP, full blood count (FBC), haematinics, erythrocyte sedimentation rate (ESR) and 
coagulation screen.   All bloods except BNP were analysed in the Western Infirmary 
haematology and biochemistry laboratories within 4 hours of collection.  The BNP samples 
were collected in potassium ethylene diamine tetra acetic acid (EDTA) tubes and sent to the 
department of biochemistry at Gartnavel General Hospital in Glasgow for testing. Plasma BNP 
was measured using the Architect Assay (Abbott Laboratories, Abbott Park, IL, USA).  These 
samples were analysed in batches once a week.  
Although advances in the identification of genetic markers of AD and other dementias have 
raised awareness of the familial nature of some dementias, there are currently no genetic 
markers recommended for routine diagnostic purposes.  Over recent years there has been 
intense interest in developing markers related to the neuropathology of AD in the 
cerebrospinal fluid (CSF) e.g. CSF β-amyloid1-42 and CSF tau.153;154  Examination of CSF was out-
with the scope of this study and no serum biomarkers have yet been identified in the detection 
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of CI.  In addition to the blood tests listed above, each participant also had a urine dipstick test 
and if this was abnormal, full urinalysis and microscopy was performed. 
Every participant in this study has a 12 lead ECG performed at study visit 1.  The ECG is a useful 
tool in the diagnosis of HF and can allude to the underlying aetiology e.g. 
ischaemia/arrhythmia.  There are a number of ECG abnormalities that may be relevant in a 
patient with HF and specific ECG abnormalities confer prognostic information in HF.  Specific 
ECG parameters were recorded in the CRF (appendix VI).  Particular attention was paid to the 
cardiac rhythm on the ECG as this had implications with regards to which study cohort 
participants were recruited into.  In addition to rhythm, ventricular rate, QRS duration, QRS 
morphology, the presence of changes suggesting myocardial ischaemia and the presence of 
LVH was also documented. 
Eligible participants (based on the inclusion and exclusion criteria) without any obvious 
potential causes of reversible CI were then invited to attend study visit 2.  The second study 
visit was also held at the BHF-GCRC within 7 days of visit 1. 
3.4  Study visit 2 
   
3.4.1  Assessment of global cognition 
 
On arrival to study visit 2, participants were asked about any change in their medical condition 
or symptom burden.  They were asked regarding hospital re-admission or any change to their 
current medication.  Their vital signs (including BP, HR and weight) were recorded and a 
focused cardiovascular examination was performed.  These findings were all recorded in the 
CRF (appendix VII).  Provided there was no change in their medical condition or any recent 
hospital admission a full battery of neuropsychological assessments were then administered. 
The same neuropsychological assessments were administered to each participant in the same 
order lasting up to 90 minutes.  The time of day that the tests were completed was recorded on 
the CRF as it has been suggested this can have an impact on performance.  In the design of this 
study we included cognitive assessment tools that focused on global cognition as well as more 
specialist assessment tools looking at the individual domains of cognition.  Each will be 
discussed in turn below. 
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 3.4.1.1  Mini mental state examination 
 
The Mini mental state examination (MMSE) is the most commonly used clinical measure of 
global cognition.  Developed in 1975 by Folstein et al, it was originally intended as a brief 
screening test to quantitatively assess the severity of CI and to document changes in cognition 
over time.155 It was not intended as an isolated diagnostic tool to identify patients with 
dementia.   
The MMSE is divided into 2 sections with a maximum score of 30 (appendix VII).  The first 
section requires only verbal responses and assesses temporal and spatial orientation, memory 
(registration, repetition and recall of 3 objects) and attention (spelling “world” backwards).  
The second section tests language and visuospatial functions.  It requires the subject to name 
simple objects, follow verbal and written commands, write a sentence and copy two 
intersecting pentagons. 
In the original study by Folstein et al, the MMSE score differed significantly in 69 patients with 
dementia syndromes, affective disorder (major depressive disorder) and affective disorder 
with CI when compared to 63 age matched controls.155  Good concurrent validity was also 
demonstrated when compared to the verbal and performance intellectual quotient of the 
Wechsler adult intelligence scale (WAIS) as well as good test-re-test and inter-rater 
reliability.155  
The threshold score taken as the “cut-off” normative value for the MMSE has a large impact on 
its clinical interpretation and the commonly used classification is outlined in Table 1-4.  The 
MMSE was shown to be sensitive to age and years of education in a population study of 18,056 
participants.156  In this study sample, ages ranged from 18 to greater than 85 years old and 
from people with no education to those having several years of higher education.  The 
researchers reported MMSE scores as mean, median and percentile distributions specific for 
age and education level.  They found an inverse relationship between MMSE score and age 
ranging from a median of 29 for those 18 to 24 years of age, to 25 for individuals greater than 
80 years old.  The median MMSE score was 29, 26 and 22 for those with at least 9 years of 
education, 5 to 8 years of education and less than 5 years of education, respectively.  Therefore 
age and years of education must also be taken into consideration when interpreting results of 
the MMSE.157 
The MMSE has several limitations.  It lacks sensitivity to pick up subtle changes in cognition 
and as such has a “ceiling effect”; possibly resulting in false-negative diagnoses.158  In addition 
to this the MMSE does not include any measure of executive function and this domain has been 
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found to be altered early in the course of Alzheimer’s disease.  In addition to possible “ceiling 
effects”, it is sometimes described as having ”floor effects” with the difficulty in assessing 
memory, language and perceptual problems in patients with severe CI.  As with many of these 
cognitive assessment tools, there is also the issue of a “learned effect” which may occur if they 
are administered repeatedly at short time intervals.159  
 3.4.1.2  Montreal cognitive assessment tool 
 
The Montreal Cognitive Assessment tool (MoCA) was initially developed in 1996 by Ziad 
Nasreddine in Montreal, Quebec.160  It can be administered in under 10 minutes and has a total 
possible score of 30.  The cut-off score indicating MCI is 26 (Table 1-4).  In contrast to the 
MMSE, the MoCA corrects for low educational attainment by adding one point to the 
participants final score for ≤12 years of formal education.  It assesses a number of individual 
cognitive domains including short term memory recall, visuospatial ability, executive function, 
attention, concentration, working memory, language and orientation to time and place.  See 
appendix VIII.   
The original validation study, found the MoCA to have better sensitivity for detecting MCI when 
compared to the MMSE (90% and 18% respectively).160  In this study these 2 cognitive 
screening tools were used in the assessment of 94 patients meeting mild cognitive impairment 
clinical criteria supported by psychometric measures.  Both the MMSE and MoCA 
demonstrated good specificity (100% and 87% respectively).  Subsequently this tool has been 
shown to be a sensitive screening measure for MCI in patients with cardiovascular disease,161 
in patients with CHF162;163 and neurocognitive problems.164;165 When the MoCA was directly 
compared to the MMSE in a cohort of CHF patients it detected in excess of a third more CHF 
patients with cognitive scores suggestive of MCI than the MMSE.166 
3.4.2  Assessment of individual cognitive domains 
 
 3.4.2.1  Repeatable battery for the assessment of                      
 neuropsychological status 
 
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is a brief, 
individually administered test consisting of 5 indexes.  These include attention, language, 
visuospatial/constructional abilities, and immediate and delayed memory.  The test comprises 
12 subtests which yield 5 index scores and a total scale score and can be administered by 
trained examiners in approximately 40 minutes (Table 3-2).  Appendix IX illustrates the RBANS 
scoring sheet onto which the final scores are entered under the separate cognitive domains.   
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Index/Subtest Description 
 
List learning 
 
 
Story memory 
Immediate Memory 
A list of 10 semantically unrelated words is orally presented, and the 
examinee is asked to recall as many words as he or she can.  This 
process is repeated over 4 learning trials. 
A short story is orally presented, and the examinee is asked to retell 
the story from memory.  The same story is presented a second time, 
and the examinee is again asked to retell the story from memory. 
 
Figure copy 
 
 
Line orientation 
Visuospatial/Constructional 
The examinee is shown a multipart geometric drawing and is asked 
to make an exact copy while the drawing remains on display. 
The examinee is presented with a drawing that consists of 13 equal 
lines radiating out from a single point to form a semi-circular fan 
shaped pattern.  All lines are numbered (1-13).  Below this drawing 
are 2 lines that match 2 of the lines in the array above.  The examinee 
is asked to identify which 2 lines they match.  10 trials are given, 
with different sets of test lines on each trial. 
 
Picture naming 
  
 
Semantic fluency 
Language 
The examinee is presented with a series of pictured objects and is 
asked to name each one.  A semantic cue is provided only if an object 
is obviously misperceived. 
The examinee is given one minute to name as many exemplars as 
possible from a given semantic category. 
 
Digit span 
 
 
Coding 
Attention 
The examiner reads a string of digits and asks the examinee to 
repeat the digits in the same order.  The length of the digit string 
increases by one on each trial. 
The examinee is presented with a page filled with rows of boxes 
with a number from 1 to 9 above each box (in a random sequence), 
and a blank space below the number.  At the top of the page is a key 
with a unique, simple, geometric shape beneath each of the 
numbers, 1 to 9.  Using the key, the examinee is asked to fill in the 
number corresponding to each shape, for as many boxes as the 
examinee can complete in 90 seconds. 
 
List recall 
 
List recognition 
 
 
Story memory & figure 
recall 
Delayed Memory 
The examinee is asked to recall the list of 10 words learned in the 
list learning subtest. 
The examinee is read 20 words (10 targets, 10 distractors) and 
asked to indicate whether each word was on the word list. 
The examinee is asked to re-tell the story they learned earlier and 
draw the figure shown earlier from memory. 
Table 3-2:  Description of repeatable battery for the assessment of             
neuropsychological status subtests 
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The normative information from the RBANS manual, which is used to calculate the index and 
total scores, was based on 540 healthy adults who ranged in age from 20 to 89 years old.167  
RBANS was developed with a three-fold purpose:    
 As a stand-alone “core” battery for the detection and characterisation of dementia in 
the elderly  
 As a neuropsychological “screening” battery for use when lengthier standardised 
assessments are inappropriate 
 For repeat evaluations when an alternate form is desirable in order to control for 
content practice effects. 
 
Available normative RBANS data were then extended by a study which looked at a population 
of 718 community dwelling older adults in the USA.168  This study provided age- and education 
-corrected subtest, index and total scale scores for each domain of cognition.  Results from this 
study were similar to the original RBANS standardisation sample and are presented in table 3-
3.  Based on all of these data, the current clinical accepted thresholds are shown in table 3-4.  
For index and total scale scores a mean score of 100 with a standard deviation of 15 is accepted 
as “average range”.  Patients scoring 2 standard deviations below the mean score for the 
population sample are classed as “impaired”. 
Table 3-3:  Repeatable battery for the assessment of  neuropsychological status  
index scores for total study sample and by each midpoint age range from the 
Oklahoma Longitudinal Assessment of Health Outcomes in Mature Adults 
(OKLAHOMA) study168 
 Duff et al final 
sample 
Midpoint 
age 70 
Midpoint 
age 75 
Midpoint 
age 80 
Midpoint 
age 85 
Immediate memory 95.2 
(18.0) 
95.9 
(17.6) 
95.5 
(17.3) 
94.0 
(18.4) 
94.4 
(19.7) 
Visuospatial 102.7 
(17.5) 
103.3 
(17.2) 
102.2 
(17.4) 
101.9 
(18.5) 
101.0 
(18.9) 
Language 95.4 
(11.2) 
95.3 
(11.0) 
94.7 
(11.6) 
95.8 
(11.7) 
96.7 
(13.0) 
Attention 99.9 
(16.1) 
100.5 
(15.6) 
99.8 
(15.9) 
99.3 
(16.6) 
99.1 
(18.3) 
Delayed memory 98.9 
(17.0) 
100.5 
(16.2) 
98.5 
(17.7) 
95.7 
(18.1) 
95.7 
(18.1) 
Total scale 97.9 
(15.9) 
98.8 
(15.4) 
97.6 
(16.1) 
96.6 
(17.1) 
96.8 
(18.1) 
Data are presented as means (SD)  
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Table 3-4:  Repeatable battery for the assessment of  neuropsychological status 
          clinical classification threshold scores 
Clinical classification Total scale score 
Very superior ≥130 
Superior ≥120 & ≤129 
High average ≥110 & ≤119 
Average ≥90 & ≤110 
Low average ≥80 & ≤89 
Borderline ≥70 & ≤79 
Extremely low ≤69 
 
After this comprehensive battery was constructed, its feasibility was then documented in a 
group of patients with chronic HF by Bauer et al.55  The final sample consisted of 80 community 
dwelling NYHA class I-IV individuals with HF and reliability and validity measures documented 
by this study supported the continued use of this battery in the HF population.55 
3.4.3  Additional measures of executive function 
 
The cognitive domain of executive function has been understudied in the HF population to date.  
This is relevant to patients with HF, as “executive function” is an umbrella term used to 
describe various cognitive processes involved in the handling of novel situations.  It is a faculty 
for recognising these situations, processing information and formulating plans accordingly.  
This is obviously key to patients involved in symptom recognition and self-management.  
Individual “bolt-on” assessments of executive function were therefore added to the other 
standard measures of global and domain-specific cognition. 
 3.4.3.1  Wechsler letter number sequencing 
 
The Wechsler Adult Intelligence Scale (WAIS) intelligence quotient (IQ) tests are the primary 
instruments used to measure adult intelligence in clinical practice.  The original WAIS (Form 
I) was published in 1955 by David Wechsler and has been updated over recent years.169  
The current version of the test, the WAIS-IV, was released in 2008 and is composed of 10 core 
subtests one of which is the test of Wechsler Letter Number Sequencing (WLNS).  This subtest 
assesses attention and executive function by asking examinees to repeat sequences of number 
and letters in both numerical and alphabetical order (see appendix VII).  The WAIS-IV has been 
standardised on a sample of 2,200 people in the United States ranging from 16 to 90 years of 
age.170  In a normal distribution, the IQ range of one standard deviation above and below the 
mean is where approximately 68% of all adults would fall.171  
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 3.4.3.2  Trail making test parts A and B 
 
The Trail Making Test (TMT) is one of the most popular neuropsychological assessment tools 
used to assess speed of processing, mental flexibility and executive function.  The TMT consists 
of 2 parts; A and B.  TMT-A asks an individual to draw lines sequentially connecting 25 
encircled numbers.  The requirements are similar for TMT-B except the participant now has to 
alternate between numbers and letters.  The score on each part represents the length of time 
required to complete the test (see appendix X).   
Performance on the TMT varies with age and years of education but not gender.175  Based on a 
study of 911 community dwelling individuals normative values were therefore stratified into 
11 age groups (18-89 years) and 2 education levels (0-12 and > 12 years) allowing more 
accurate interpretation of these scores and translation into clinical practice.172  These 
normative values are available in appendix XI. 
 3.4.3.3  Controlled oral word association test  
 
Original time-limited, verbal fluency tests date back to the Thurstone’s Word Fluency Test, 
which formed part of the primary mental abilities test.  This originally asked participants to 
write words beginning with a specific letter over a relatively long period of time e.g. 5 minutes.  
This has gradually evolved and in the current version this test of phonemic verbal fluency and 
executive function records the number of words beginning with the same designated letter 
said by the participant in one minute (appendix VII).  The name of the test was changed to 
controlled oral word association (COWA) test to avoid confusing the phrase “word fluency”.  
The letters F, A and S have continued to be used as a measure of verbal fluency in the 
neurosensory centre comprehensive examination for aphasia.173 
As education may play a role and because gender differences have been reported (with females 
performing at a superior rate to age-matched males) a normative sample stratified according 
to age, education and sex was examined in a study by Ruff et al in 1996.174  The total sample of 
360 normal volunteers ranged in age between 16 and 70 years and in education from 7 to 22 
years.  Care was taken to ensure the population was heterogeneous with respect to age and 
education.  To assess test-retest reliability, 30% of the sample was retested after a 6 month 
delay.  A three-way analyses of variance (age x gender x education) was carried out on the 
mean number of words for all three letters.  Age had no significant effect.   However, gender 
moderated the effect of education on the number of words produced.  The interaction of gender 
and education was ordinal, with the effect of years of education positively predicting COWA 
performance for both men and women.  Therefore the effect of education was significant 
(p<0.0001), and differences due to education alone accounted for a greater proportion of total 
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variance (8%).  The current accepted cut-off scores for COWA (F, A & S) are shown in table 3-
5. 
Table 3-5:  Normative values for F, A, S stratified for age and years of education 
 
 
 
 
        Age 16-59 years               Age 60-79years                  Age 80-95years 
     Education  (Years)            Education (Years)             Education (Years) 
   0-8        9-12     13-21  0-8          9-12      13-21    0-8        9-12     13-21 
Percentile  
Score 
90 
80 
70 
60 
48 
   45 
   42 
   39 
   36 
   35 
   34 
   30 
   27 
38.5 
(12) 
56 
50 
47 
43 
61 
55 
51 
49 
39 
36 
31 
27 
54 
47 
43 
39 
59 
53 
49 
45 
33 
29 
26 
24 
42 
38 
34 
31 
56 
47 
43 
39 
50 
40           
30 
40 
38 
35 
45 
42 
38 
25 
22 
20 
35 
32 
28 
41 
38 
36 
22 
21 
19 
29 
27 
24 
36 
33 
30 
20           32 35 17 24 34 17 22 28 
10 28 30 13 21 27 13 18 23 
Mean 40.5 44.7 25.3 35.6 42.0 22.4 29.8 37.0 
(SD)                    (10.7) (11.2) (11.1) (12.5) (12.1) (8.2) (11.4) (11.2) 
SD, standard deviation 
 3.4.3.4  Animal naming test 
 
Semantic fluency is another method of assessing verbal fluency.  Individuals are asked to 
generate names from a specified category in one minute and the category of animals is most 
frequently employed (see appendix VII).  Tombaugh et al stratified normative values by age 
(16-59, 60-79 and 80-95 years) and years of education (0-8, 9-12 and 13-21) in 735 community 
dwelling volunteers.175  Unlike with the phonemic verbal fluency tests, age accounted for more 
variance than years of education in this assessment tool (education 13.6% vs. age 23.4%) and 
gender was found to account for less than 1% of the variance.   Table 3-6 shows the accepted 
normative values for the animal naming test stratified by age and years of education. 
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         Age 16-59 years               Age 60-79years                  Age 80-95years 
     Education  (Years)            Education (Years)             Education (Years) 
   0-8        9-12     13-21  0-8          9-12      13-21    0-8        9-12     13-21 
Percentile  
Score 
90 - 
    - 
    - 
    - 
    - 
26 30 20 22 25 18 19 24 
75             23 25 17 19 22 16 17 20 
50 20 23 14 17 19 13 14 16 
25             17 18 12 14 16 11 12 14 
10 15 16 11 12 13 9 11 12 
Mean 19.8 21.9 14.4 16.4 18.2 13.1 13.9 16.3 
(SD)                     (4.2) (5.4) (3.4) (4.3) (4.2) (3.8) (3.4) (4.3) 
SD, standard deviation 
  
 3.4.3.5  Frontal assessment battery 
 
The frontal assessment battery (FAB) is a bedside tool that takes approximately 10 minutes to 
administer and is used in the assessment of executive function.  It consists of six questions 
which explore both cognitive and behavioural domains under the control of the frontal lobes.  
The FAB was initially designed in 2000 in a study of 42 normal subjects and 121 patients with 
various degrees of frontal lobe dysfunction.176  They found a cut-off score of 12 had a sensitivity 
of 77% and a specificity of 87% in differentiating between frontal lobe dementia and 
Alzheimer’s dementia.  A copy of the FAB is shown in appendix XII. 
3.4.4  Measure of pre-morbid intelligence quotient 
 
 3.4.4.1  Wechsler test of adult reading 
 
The Wechsler test of adult (WTAR) reading provides a tool for estimating premorbid 
intellectual functioning.  When assessing individuals for possible CI, it is necessary to know 
whether their current cognitive state represents a decline from their pre-morbid level.  The 
inclusion of a marker of pre-morbid IQ is something which has been neglected in current HF 
and cognition literature to date.   
The WTAR is based on a reading-recognition paradigm, requiring the reading and 
pronunciation of words that have irregular phonetic translation but not requiring knowledge 
of word meaning.  Examinees are given a card with 50 words written on it.  They are asked to 
read these words aloud and given one mark for each word pronounced correctly (see appendix 
XIII).  The use of words with irregular pronunciation minimises the assessment of the 
examinee’s current ability to apply standard pronunciation rules and maximises the 
assessment of the examinee’s previous learning of the word.  Pronunciation guidance is given 
Table 3-6:  Normative values for animal naming test stratified for age and years 
of education 
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to the examiner both in written and audio format (see appendix XIV).  The raw score is 
converted to a standard score based on age, sex and years of education normative values.177  
The standard score is then compared to the predicted score for each examinee.  Predicted 
scores are derived from the individuals’ level of education.  The UK standardisation sample and 
demographic-predicated WTAR scores are shown in Appendix XV.    
3.4.5  Informant questionnaire on cognitive decline in the elderly 
 
The informant questionnaire on cognitive decline in the elderly (IQCODE) was developed as an 
alternative way of measuring cognitive decline from a pre-morbid level using informant 
reports.178  This is useful in patients who are unable to undergo direct testing because of lack 
of co-operation, acute illness or low levels of literacy.  There are a large number of informant 
questionnaires available and of these the IQCODE is the most commonly used.  
26 items are included in the questionnaire which asks the informant to comment on any 
perceived changes in cognition over the past 10 years.  Each item is rated on a 5 point scale 
from 1 – “much improved” to 5 – “much worse” (see appendix XVI).  The ratings are then 
averaged over the 26 items to give an overall score from 1-5.  A variety of cut-off values have 
been proposed for use in cognitive screening and these vary depending on whether the study 
population are inpatient or outpatient.  A cut-off of 3.6 or above has been generally accepted 
as abnormal.179 
This scale was designed to reflect improvement in cognition as well as decline, to allow for the 
questionnaire to be used in treatment trials and following acute illness.  The IQCODE has high 
reliability and is relatively unaffected by education and as it provides information 
complimentary to cognitive tests, harnessing them together improves screening accuracy.179   
3.4.6  Measures of symptom burden and self-care  
 
The following 3 questionnaires were administered to all patients in each of the HF cohorts.  
Patients were given these questionnaires at the end of study visit 2 and asked to complete them 
at their leisure and return them by post to the BHF-GCRC (see appendix XVII & XVIII). 
 3.4.6.1  Kansas City Cardiomyopathy Questionnaire 
 
One of the most commonly used disease-specific health related quality of life questionnaires 
(HRQoL) in HF is the Kansas City Cardiomyopathy Questionnaire (KCCQ).180  This 23-point 
questionnaire quantifies physical limitation, symptoms (frequency, severity and change over 
time), quality of life, knowledge and social function (see appendix XVII).  It is scored by 
assigning each response an ordinal value, beginning with 1 for the response that implies the 
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lowest level of functioning and adding together the scores within each domain.  Scale scores 
are transformed into a 0-100 range by subtracting the lowest possible scale score, dividing by 
the range of the scale and multiplying by 100.  To aid the interpretation of scores, two summary 
scores have been developed.  A functional status score includes the physical limitation and 
symptom domains and a clinical summary score can be calculated by combining the functional 
status with the quality of life and social limitation domains.    
 3.4.6.2  Self-Care of Heart Failure Index 
 
The self-care of heart failure index was initially published in 2004 and assesses a patient’s 
ability to monitor their symptoms, implement a treatment strategy based on their symptoms 
and assess their response to that treatment strategy.181  The questionnaire is divided into 3 
sections looking at maintenance actions (e.g. low salt diet), management actions (e.g. taking 
extra diuretic) and patient confidence in their actions (see appendix XVIII).  Each of the 3 scales 
is standardised to a 0-100 range and results should be interpreted individually.  A score of ≥70 
can be used as the cut-point to judge self-care adequacy in research.  A change in scale more 
than one half of a standard deviation is considered clinically relevant.182   
 3.4.6.3  EQ-5D 
 
The EQ-5D is a standardised instrument for use as a measure of health outcome.  The EQ-5D 
descriptive system can be converted to a single index value for health status, based on the 
respondent’s responses to the various questions.  It records the level of self-reported problems 
on mobility, self-care, usual activities, pain/discomfort and anxiety/depression.  The index 
values, presented in country specific value sets, are a major feature of the EQ-5D instrument, 
facilitating the calculation of quality-adjusted life years.  Index values were derived from the 
descriptive system using the crosswalk link function online calculator.  In addition to this, there 
is a visual analogue scale which records the respondent’s self-rated health status from 0-100, 
where the endpoints are labelled “best imaginable health state” and “worst imaginable health 
state” (see appendix XVII). 
3.4.7  Measure of care-giver strain 
 
 3.4.7.1  Zarit Burden Interview 
 
Community care of patients with chronic illness has many advantages but often places a major 
burden on family members and other care-givers.  Increased care-giver burden has been 
associated with increased hospital admissions, higher incidence of elder mistreatment and 
increased clinical depression amongst family care-givers.183;184  The identification of risk 
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factors associated with negative care-giving outcomes therefore has important clinical 
implications for quality of care and service utilisation. 
The Zarit Burden Interview was initially developed in 1980 and revised in 1985.185  It is a 22-
item scale developed to assess the severity of caregiver perceptions of burden or stress in 
caring for a patient.  Each item is answered on a 5 point scale:  o for never, 1 for rarely, 2 for 
sometimes, 3 for quite frequently and 4 for nearly always.  The scores for each item are added 
and the total ranges from 0 to 88 with higher scores indicating greater burden (see appendix 
XIX).  Although the use of absolute cut-off values does not replace the need for comprehensive 
clinical evaluation, a study by Rankin et al in 1994 identified a cut-off score as 10 as both 
sensitive and specific in identifying care-givers experiencing depressive symptoms and in need 
of further support in the community.183 
3.4.8  Assessment of mood 
 
Mood disorder is common among patients with HF.186  A recent meta-analysis published in the 
Journal of the American College of Cardiology found approximately 1 in 5 patients meet the 
criteria for major depression based on clinical interviews and substantially higher rates of 
clinically significant depression are present among patients assessed with questionnaires.187  
Rates of mortality, clinical events, rehospitalisation and general health care use are markedly 
higher among HF patients diagnosed with mood disorder and the current HF ESC guidelines 
include the provision of adequate psychological support to patients and family and/or 
caregivers.188 
The HADS questionnaire (described in chapter 1.2.2) was administered to all participants in 
this study as a measure of anxiety and depression (see appendix XVI).  It is recommended that, 
for both the anxiety and depression scales alike, raw scores of between 8 and 10 identify mild 
cases, 11-15 moderate cases and 16 or above severe cases.65 
3.5  Database construction 
 
All paper copies of the case record forms were kept in a locked filing cabinet at the BHF Glasgow 
Cardiovascular Research Centre. An electronic database was created in the Robertson Centre 
for Biostatistics at the University of Glasgow to store these data. Data were manually entered 
into the electronic database and verified by two independent database managers working in 
the Robertson Centre. No patient identifying material was entered into the electronic database; 
patients were anonymised and identified by their unique study identification number. All data 
were checked manually and also underwent pre-specified electronic data validation checks 
which resulted in the production of a large number of queries. All queries were investigated 
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and data appropriately amended in the central database. This robust system ensured quality 
control of the data processed. 
3.6  Power calculation and statistical analyses 
 
The sample size of approximately 240 patients with HF and 160 participants without HF has 
90% power at a 5% significance level to detect differences between groups for a continuous 
outcome measure of 0.36 standard deviation (SD) units, based on a two-sample t-test.  This 
compares favourably with the differences in cognitive measures previously found between HF 
patients and controls of 0.5-0.8 SD units. 
Categorical variables are summarised with the number and proportion of participants falling 
within each category.  Continuous variables are summarised using the number available, mean, 
SD, median, 25th and 75th quartiles and minimum and maximum values.  Analyses were 
performed using R for windows v3.0.0 or SAS for Windows v9.3, or higher versions of these 
programs.  A probability value of p<0.05 was considered significant. 
To assess whether cognition differed between patients with HF and healthy controls, or HF and 
cardiac controls, Generalised Linear Models (GLM) were used to compare cases and the 
healthy/cardiac controls for each of the cognitive assessment tools.  Models were fitted with 
various levels of adjustment: 
1.  Model adjusted for age and sex only 
2. As for model 1, with the addition of general demographic and clinical confounders (co-
morbidity count, race, education level [using WTAR], medication count) 
3. As for model 2, with the addition of cognitive confounders (history of depression, HADS 
score, antidepressant use) 
4. As for model 3, with the addition of vascular risk factors (smoking, systolic blood 
pressure, diabetes mellitus, BMI, previous MI, chronic kidney disease [defined as 
eGFR<60], hypertension) 
GLM’s were also fitted to assess whether cognition differed between the HF cohorts for the 
cognitive assessment tools.  Models were adjusted according to the same covariates 
specified above in models 1-4 along with additional covariates supplied in a fifth model: 
5. As for model 4, with the addition of HF clinical severity covariates (NYHA class, CHF 
>2years, previous HF hospitalisation, BNP and specialist co-ordinating care) 
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The HF groups were compared in the following two analyses: 
(a)  HF with AF versus HF without AF (here HF was included irrespective of CAD 
status) 
(b) HF with CAD versus HF groups without CAD (here HF was included irrespective of 
AF status) 
Using established binary and multiple cut-point definitions for each questionnaire, comparable 
analysis using the covariates from the continuous outcomes indicated above were done using 
either binary or ordinal logistic regression, as appropriate. Results for all analyses are 
presented as the estimated difference between groups alongside corresponding 95% 
confidence intervals and p-values. 
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CLINICAL CHARACTERISTICS OF HEART 
FAILURE COHORTS 
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Chapter 4:  Clinical characteristics of heart failure cohorts 
4.1  Introduction 
 
This chapter will outline the recruitment of ambulatory patients with chronic, stable heart 
failure into this study and detail the reasons for exclusion from participation.  The main focus 
of this chapter is to describe in detail their clinical characteristics including demographic 
details, signs and symptoms of heart failure, past medical history, medication use and 
examination findings.  The results of basic investigations including electrocardiography, 
echocardiography and blood tests will also be described.  Significance testing was not routinely 
performed for each variable – only in certain pre-selected variables where a significant 
association was postulated.  
4.2  Results     
 
4.2.1  Recruitment of study cohort   
 
Recruitment into this study took place between March 2013 and December 2014.  Heart failure 
patients attending outpatient clinics at Glasgow Royal Infirmary, Western Infirmary Glasgow, 
Royal Alexandra Hospital and Stobhill hospital were screened for eligibility.  Patients with 
heart failure were recruited into 1 of 3 HF cohorts: 
Cohort 1.  Heart failure of ischaemic aetiology in sinus rhythm (HF CAD) 
Cohort 2.  Heart failure of non-ischaemic aetiology in sinus rhythm (HF no CAD) 
Cohort 3.  Heart failure of any aetiology and atrial fibrillation (HF AF) 
 
The final numbers recruited into each of these HF cohorts is illustrated in figure 4.1. 
 
A total of 520 patients with heart failure were screened for inclusion however 324 were 
excluded from participation.  The main reasons for exclusion are illustrated in figure 4.2.  The 
reasons for exclusion included:  History of AF (for HF cohorts 1&2), previously diagnosed 
neurological illness (including previous stroke, traumatic brain injury, cerebral palsy and 
former diagnosis of cognitive impairment / dementia),  age <60 years, recent discharge from 
hospital, previous cardiac surgery (including CABG and valve replacement surgery), patient 
refusal, history of alcohol excess, previous cardiac arrest, ejection fraction >45%, terminal 
illness and inability to provide informed consent (due to language barrier / sensory 
impairment).  
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Figure 4-1:  Final numbers recruited into each heart failure cohort 
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Figure 4-2:  Breakdown of reasons for exclusion into study for heart failure 
patients 
4.2.2  Demographics of heart failure cohorts 
 
The clinical demographics of patients recruited into HF cohorts 1-3 are shown in table 4-1.  The 
3 HF groups were relatively well matched for age and sex.  The majority of HF patients 
recruited into the study were male (70%) with an overall mean (SD) age of 71 (8) years and a 
wide overall range in age from 60-94 years.  99% of the total HF population were white with 
the remaining 1% being South-Asian.  Education status was also well matched between the HF 
cohorts as assessed by total years of education and full scale IQ.  A higher proportion of those 
with HF secondary to CAD were current smokers (60%) with approximately half of the 3 HF 
cohorts drinking alcohol within recommended limits.   
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Table 4-1:  Basic demographics of patients recruited into heart failure cohorts  
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
 
Total HF 
(n=196) 
Age (years) 
71.0 ± 8.1 69.4 ± 7.5 71.0 ± 8.6 
 
70.6 ± 8.1 
 
Age range 
(years) 
 
60-86 60-87 60-94 60-94 
Sex (% males) 
49 (70) 32 (63) 56 (75) 
 
137 (70) 
 
Education  
(total years) 11 
[10, 14] 
11 
[10, 14] 
12 
[10, 15] 
 
11 
[10, 14] 
 
Full scale IQ 104 
[79, 118] 
 
100 
[70, 117] 
100 
[70, 118] 
103 
[70, 118] 
Smoker 
42 (60) 24 (47) 35 (47) 
 
101 (52) 
 
Current alcohol 
36 (51) 24 (47) 39 (52) 
 
99 (51) 
 
Data are presented as means ± SD or median [Q1, Q3] for continuous data and N (%) for 
categorical data.  
 
4.2.3 Diagnosis of heart failure   
 
To fulfil the entry criteria into this study, HF patients were required to have objective evidence 
of reduced left ventricular ejection fraction on echocardiography in addition to documented 
clinical evidence of HF, thus fulfilling the current ESC definition of HF-REF.  Therefore, all 
patients recruited into HF cohorts 1-3 had an ejection fraction of <45% on transthoracic 
echocardiography, performed within 6 months of entry into this study.  In addition to EF I also 
looked at other surrogate measures of HF severity including HF duration, prior hospital 
admissions with HF, specialist co-ordinating care and serum BNP concentration.  See table 4-
2.   
Of the 70 patients recruited into HF cohort 1 (HF CAD) 66 (94%) had ≥50% stenosis in one or 
more coronary artery on invasive coronary angiography with the remaining 4 having a 
documented prior myocardial infarction based on clinical history, cardiac enzymes and ECG 
findings.   
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CAD was excluded on invasive coronary angiography in 32 (63%) of the 51 patients recruited 
into HF cohort 2 (HF of non-ischaemic aetiology).  The remaining 19 patients had CAD excluded 
on stress echocardiography (n=7), CMR (n=3) and CT coronary angiography (n=9).  After 
exclusion of CAD no cause of HF was found in 25% of this cohort.  The other underlying 
aetiologies recorded listed in table 4-3. 
Table 4-2:  Heart failure characteristics 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
Ejection fraction 
34.1 ± 6.7 33.7 ± 7.1 
 
34.9 ± 7.1 
 
HF duration >2 years 
42 (60.0) 18 (35.3) 
 
52 (69.3) 
 
Previous HF hospitalisation 
52 (74.3) 34 (66.7) 
 
61 (81.3) 
 
HF specialist co-ordinating care 
 
64 (91.4) 45 (88.2) 67 (89.3) 
BNP (pg/ml) 
162 
[11, 3425] 
208 
[12, 2271] 
 
214 
[13, 1160] 
 
Data are presented as means ± SD or median [Q1, Q3] for continuous data and N (%) for 
categorical data.  
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Table 4-3:  Aetiology of heart failure 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
Ischaemic aetiology 70 (100) 0 (0) 42 (56) 
 
Idiopathic dilated 
cardiomyopathy 
 
0 (0) 16 (31) 2 (3) 
Hypertensive cardiomyopathy 0 (0) 6 (11) 0 (0) 
 
Cardiomyopathy secondary to 
valvular heart disease 
 
0 (0) 7 (13) 2 (3) 
Unknown aetiology 0 (0) 13 (25) 15 (20) 
 
Other aetiology of heart failure 
 
0 (0) 10 (19) 14 (18) 
Data are presented as means ± SD or median [Q1, Q3] for continuous data and N (%) for 
categorical data.  
 
 
4.2.4  Heart failure symptom burden 
 
Study participants were asked about symptoms of HF when they attended the initial screening 
visit and at return visit 1.  Table 4-4 displays the frequencies of HF symptoms recorded at 
return visit 1.  Most HF patients recruited had NYHA class II HF with smaller proportions 
having NYHA I or NYHA III HF.  No patients with NYHA class IV were recruited into this study. 
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Table 4-4:  Symptoms of heart failure 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
NYHA I 19 (27.1) 18 (35.3) 16 (21.3) 
 
NYHA II 37 (52.9) 21 (41.2) 45 (60.0) 
 
NYHA III 14 (20.0) 12 (23.5) 14 (18.7) 
 
Orthopnoea 16 (22.9) 10 (19.6) 11 (14.7) 
 
PND 16 (22.9) 10 (19.6) 17 (22.7) 
 
Ankle swelling 33 (47.1) 20 (39.2) 41 (54.7) 
 
Wheeze 15 (21.4) 11 (21.6) 18 (24.0) 
 
Palpitations 10 (14.3) 5 (9.8) 8 (10.7) 
 
Data are presented as N (%)  
4.2.5  Medical history 
 
Table 4-5 illustrates the common co-morbid conditions found in the HF cohorts.  Common risk 
factors for cardiovascular disease are displayed including treated hypertension, 
hypercholesterolaemia and diabetes mellitus.  Since cerebrovascular disease was an exclusion 
to this study, none of the study participants had a documented past history of previous stroke 
or TIA.  Although, as previously discussed, mood disorder is common in patients with HF only 
2% of this HF population had a prior history of depression.  Due to the interaction between 
mood and cognition, patients with clinically significant depression were excluded from this 
study.  Those patients with a historical past medical diagnosis of depression documented in 
medical casenotes but not being actively treated were allowed to participate. 
Arrhythmias are a common cause of morbidity and mortality in HF.  Of 196 patients with HF 
enrolled, over one third (38.8%) had a previously documented arrhythmia.  Documented 
arrhythmias included supraventricular arrhythmia (SVT), ventricular tachycardia (VT), sick 
sinus syndrome (SSS) and atrioventricular (AV) block.  The prevalence of device therapy was 
relatively low, with the highest proportion of complex cardiac devices being present in those 
with ischaemic cardiomyopathy. 
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A family history of cardiac disease was recorded for each patient enrolled into this study.  
Between 24 and 51% of each cohort gave a family history of CAD with less aware of any history 
of cardiomyopathy. 
As part of the past medical and social history taken, participants were asked about their living 
arrangements (whether they lived independently or with someone) and regarding any input 
from social services supplying help with activities of daily living.    
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Table 4-5:  Prevalence of co-morbid conditions in heart failure cohorts 
 HF CAD 
(n=70) 
HF no CAD 
(n=51) 
HF AF 
(n=75) 
Previous MI 68 (97.1) 0 (0) 37 (49.3) 
 
Treated hypertension 61 (87.1) 29 (56.9) 71 (94.7) 
 
Hypercholesterolaemia 61 (87.1) 21 (41.2) 61 (81.3) 
 
Diabetes Mellitus 19 (27.1) 10 (19.6) 20 (26.7) 
 
        Diet controlled 3 (4.3) 2 (3.9) 3 (4.0) 
 
        Oral therapy 12 (17.1) 6 (11.8) 13 (17.3) 
 
        Insulin 4 (5.7) 2 (3.9) 4 (5.3) 
 
Hypothyroidism 3 (4.3) 5 (9.8) 3 (4.0) 
 
Peripheral arterial disease 10 (14.3) 3 (5.9) 4 (5.3) 
 
Prior arrhythmia 10 (14.3) 4 (7.8) 62 (82.7) 
 
        SVT 
 
3 (4.3) 0 (0) 46 (61.3) 
        VT 
 
3 (4.3) 1 (2.0) 7 (9.3) 
        SSS 
 
2 (2.9) 0 (0) 8 (10.7) 
        AV Block 
 
2 (2.9) 3 (5.9) 1 (1.3) 
Conventional pacemaker 4 (5.7) 1 (2.0) 8 (10.7) 
 
CRT-D 2 (2.9) 1 (2.0) 5 (6.7) 
 
CRT-P 9 (12.9) 2 (3.9) 1 (1.3) 
 
Primary prevention ICD 4 (5.7) 0 (0) 5 (6.7) 
 
Valvular heart disease 26 (37.1) 25(49.0) 39 (52.0) 
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Depression  
 
2 (2.9) 2 (3.9) 0 (0) 
Family history CAD 36 (51.4) 13 (25.5) 18 (24.0) 
 
Family history  
cardiomyopathy 
 
5 (7.1) 13 (25.5) 3 (4.0) 
Lives alone 24 (34.3) 
 
14 (27.5) 30 (40.0) 
Employed carers 
 
5 (7.1) 1 (2.0) 7 (9.3) 
Data are presented as N (%).  AV, atrioventricular; CAD, coronary artery disease;  
CRT-D, cardiac resynchronisation therapy – defibrillator; CRT-P,  cardiac resynchronisation 
therapy – pacemaker; ICD, implantable cardioverter defibrillator; MI, myocardial infarction; 
SVT, supraventricular tachycardia; VT, ventricular tachycardia; SSS, sick sinus syndrome 
 
4.2.6  Medication use 
 
Table 4-6 shows the frequencies of prescription of HF medication in each HF cohort.  166 out 
of the total 196 (85%) patients with HF were prescribed regular diuretic (including both loop 
and thiazide diuretics).  Most patients were treated with either ACE inhibitor or ARB (89.9% 
of the total HF population) with slightly fewer patients established on regular beta blocker 
therapy (84.7%).  Less than half of the HF patients (42.3%) were prescribed a 
mineralocorticoid receptor antagonist (MRA).  Digoxin was more commonly used in the HF 
with AF cohort, probably reflecting its use as a rate-control agent. 
Previous systematic reviews have looked at the association between cognition and 
antiplatelet/anticoagulant medication use.189;190  I therefore collected data on the prescription 
of any antiplatelet or anticoagulant and these data are presented in table 4-7.  84% of those 
patients with HF and AF were formally anticoagulated with warfarin (73.3%) or a novel oral 
anticoagulant [(NOAC) 10.7%]. 
Other cardiovascular and non-cardiovascular medications are presented in table 4-8.  A range 
of other medications were prescribed reflecting the large number of co-morbidities frequently 
associated with HF.  Recent data have highlighted antihistamine and incontinence medications 
as potential cognitive confounders.  These were not frequently prescribed in our HF 
cohorts.191;192 
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Table 4-6:  Heart failure medication use 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
Diuretic 62 (88.6) 44 (86.3) 60 (80.0) 
 
Beta blocker 64 (91.4) 41 (80.4) 61 (81.3) 
 
ACE or ARB 63 (90.0) 48 (94.1) 65 (86.7) 
 
ACE Inhibitor 50 (71.4) 39 (76.5) 50 (66.7) 
 
ARB 13 (18.6) 12 (23.5) 16 (21.3) 
 
MRA 32 (45.7) 18(35.3) 33 (44.0) 
 
Ivabradine 2 (2.9) 0 (0) 1 (1.3) 
 
Digoxin 1 (1.4) 1 (2.0) 22 (29.3) 
 
Hydralazine 3 (4.3) 0 (0) 2 (2.7) 
 
Data are presented as N (%). ACE, angiotensin converting enzyme; ARB, angiotensin receptor 
blocker; MRA, mineralocorticoid receptor antagonist 
 
Table 4-7:  Antiplatelet and anticoagulant use 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
Any antiplatelet therapy 57 (81.4) 28 (54.9) 21 (28.0) 
 
Aspirin 49 (70.0) 22 (43.1) 17 (22.7) 
 
Clopidogrel 20 (28.6) 6 (11.8) 4 (5.3) 
 
Any anticoagulant therapy 9 (12.9) 13 (25.5) 63 (84.0) 
 
Warfarin 8 (11.4) 11 (21.6) 55 (73.3) 
 
NOAC 1(1.4) 2 (3.9) 8 (10.7) 
 
Data are presented as N (%). NOAC, novel oral anticoagulant 
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Table 4-8:  Other medication use 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
Calcium channel blocker 4 (5.7) 2 (3.9) 9 (12.0) 
 
Nicorandil 10 (14.3) 3 (5.9) 7 (9.3) 
 
Long acting nitrate 14 (20.0) 2 (3.9) 9 (12.0) 
 
Oral hypoglycaemic 15 (21.4) 8 (15.7) 18 (24.0) 
 
Statin 56 (80.0) 29 (56.9) 52 (69.3) 
 
Any lipid lowering drug 59 (84.3) 29 (56.9) 52 (69.3) 
 
Anxiolytic 4 (5.7) 1 (2.0) 3 (4.0) 
 
Antidepressant 4 (5.7) 2 (3.9) 2 (2.7) 
 
Incontinence medication 4 (5.7) 1 (2.0) 11 (14.7) 
 
Antihistamine 1 (1.4) 0 (0) 0 (0) 
 
Bronchodilator 
 
18 (25.7) 8 (15.7) 12 (16.0) 
Data are presented as N (%)  
4.2.7  Clinical examination findings 
 
 4.2.7.1  Routine physiological measurements 
 
Routine physiological measurements were taken for each study participant at the initial 
screening visit and again at return visit 1.  Table 4-9 lists the physiological measurements taken 
at return visit 1.  From height and weight measurements, body mass index (BMI) was 
calculated for each patient.  According to the World Health Organisation (WHO) BMI 
classification, the mean BMI of patients in HF cohorts 1 & 2 (27.4, 28.4) fell into the overweight 
range (BMI >25) with the mean BMI of the HF and AF cohort (30.4) falling into the obese 
category (BMI >30). 
Neck circumference is thought to play a role in the pathogenesis of obstructive sleep apnoea 
(OSA).  Due to the potential link between OSA and cognition I recorded neck circumference for 
each participant.  A neck circumference over 16cm in females and 17cm in males is associated 
with an increased risk of developing OSA.   
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Table 4-9:  Physiological measurements taken at return visit 1 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
Height                                        Median 
 (cm)                                      Mean (SD) 
167 
166.5 (9.3) 
168 
166.3 (9.3) 
170 
167.2 (13.6) 
 
Weight                                      Median 
 (Kg)                                      Mean (SD)  
75.9 
78.8 (19.6) 
75.5 
81.2 (22.0) 
85.0 
87.7 (17.9) 
 
BMI                                             Median 
                                               Mean (SD) 
27.4 
28.3 (5.9) 
28.4 
29.0 (6.1) 
30.4 
31.5 (7.1) 
 
Neck circumference males                 
 (cm)                                         Median 
                                               Mean (SD) 
17.4 
17.2 (1.7) 
17.8 
17.9 (2.5) 
18.0 
17.8 (2.0) 
 
Neck circumference females 
(cm)                                                Median 
                                                    Mean (SD) 
15.8 
15.0 (2.5) 
15.2 
14.6 (2.2) 
16.0 
15.9 (2.1) 
 
Systolic BP                                Median 
(mmHg)                                Mean (SD) 
135 
136.9 (23.1) 
133 
138.2 (24.3) 
137 
137.9 (21.3) 
 
Diastolic BP                                 Median 
(mmHg)                                Mean (SD) 
70 
72.1 (9.9) 
76 
75.7 (11.5) 
79 
77.7 (11.6) 
 
Heart rate                                Median 
(BPM)                                    Mean (SD) 
69.5 
69.5 (12.5) 
70.0 
72.1 (12) 
70.0 
71.5 (12.3) 
 
SpO2                                           Median  
(%)                                            Mean (SD)                                           
97 
96.6 (2.0)
97 
97.1 (1.4) 
97 
96.9 (1.7) 
 
Respiratory rate                        Median 
 (BPM)                                  Mean (SD) 
16 
15.5 (1.7) 
16 
15.2 (1.8) 
16 
15.3 (1.8) 
 
Temperature                            Median 
 (˚C)                                       Mean (SD) 
 
36.0 
36.3 (0.8) 
36.5 
36.5 (0.7) 
36.2 
36.2 (0.8) 
 
Data are presented as means (SD) or median [Q1, Q3].  BP, blood pressure; BPM, beats per 
minute; cm, centimetres; Kg, kilogram; mmHg, millimetres of mercury 
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 4.2.7.2  Cardiovascular examination signs 
 
Each study participant had a full cardiovascular examination performed at return visit 1.  The 
main findings are presented in table 4-10.  Of the physical signs of heart failure listed below, 
peripheral oedema, followed by pulmonary crackles were most commonly found.  Over 50% 
of patients in each cohort had a murmur on auscultation of their heart. 
Table 4-10:  Cardiovascular examination findings 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
Elevated JVP 1 (1.4) 4 (7.8) 3 (4.0) 
 
Palpable apex 5 (7.1) 9 (17.6) 8 (10.7) 
 
Displaced apex 2 (2.9) 5 (9.8) 7 (9.3) 
 
Third heart sound 0 (0) 0 (0) 1 (1.3) 
 
Cardiac Murmur 36 (51.4) 30 (58.8) 49 (65.3) 
 
Pulmonary crackles 27 (38.6) 24 (47.1) 32 (42.7) 
 
Pleural effusion 1 (1.4) 0 (0) 2 (2.7) 
 
Peripheral oedema 25 (35.7) 25 (49.0) 35 (46.7) 
 
Ascites 1 (1.4) 0 (0) 0 (0) 
 
Carotid bruit 1 (1.4) 5 (9.8) 3 (4.0) 
 
Data are presented as N (%).  JVP, jugular venous pressure 
4.2.8  Electrocardiography 
 
Each study participant had a 12 lead ECG performed at their initial screening visit.  This was 
performed on a calibrated ECG machine by an operator competent in the recording of an 
electrocardiogram.  The most common ECG findings are presented in table 4-11 below.  Of the 
patients recruited into the HF and AF category, n= 55 (73%) had evidence of AF on their 
baseline study ECG.  n=15 (20%) were in normal sinus rhythm and n=5 (7%) had a paced 
rhythm on surface ECG.  The remaining 121 patients with HF had no evidence (past or present) 
of AF.  The overall mean ventricular rate was higher in those with AF on their ECG compared 
to those in SR (71±14bpm vs.  67±11bpm).  The highest proportion of LBBB morphology was 
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found in those patients with HF and CAD (21%).  The HF cohort with the longest mean QRS 
duration was those with non-ischaemic cardiomyopathy. 
Table 4-11:  Electrocardiographic findings in heart failure cohorts 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
Ventricular rate (bpm) 
66.7 ± 10.2 71.1 ± 13.0 
 
71.3 ± 14.0 
 
Sinus rhythm 
58 (82.9) 48 (94.1) 
 
15 (20.0) 
 
Atrial fibrillation 
0 (0.0) 0 (0.0) 
 
55 (73.3) 
 
Paced rhythm 
12 (17.1) 3 (5.9) 
 
5 (6.7) 
 
LBBB 
15 (21.4) 13 (25.5) 
 
12 (16.0) 
 
RBBB 
1 (1.4) 1 (2.0) 
2 (2.7) 
 
 
Mean QRS duration (ms) 
115.8 ± 27.6 119.4 ± 29.0 
 
118.1 ± 27.9 
 
Median QRS duration(ms)  
108.0 
[94.0, 136.0] 
 
114.0 
[94.0, 144.0] 
112.0 
[94.0, 142.0] 
Mean QTc interval (ms) 
441.7 ± 27.4 440.7 ± 28.5 
 
437.3 ± 33.5 
 
Median QTc interval (ms)  
437.5 
[422.0, 465.0] 
 
439.0 
[421.0, 464.0] 
441.0 
[415.0, 457.0] 
 
Data are presented as means ± SD or median [Q1, Q3] for continuous data or N (%) for 
categorical data. BPM, beats per minute; LBBB, left bundle branch block; ms, 
milliseconds; RBBB, right bundle branch block 
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4.2.9  Echocardiography 
 
All HF patients recruited into this study had a transthoracic echocardiogram performed within 
6 months of recruitment by an accredited British Society of Echocardiography sonographer.  
These were performed at the patient’s local cardiology outpatient department and were 
requested at the time of recruitment (if they had not had one performed in the 6 months prior 
to recruitment).  All HF patients recruited into this study had a left ventricular ejection fraction 
<45% and the other common echocardiogram findings are presented in table 4-12.   
Left ventricular ejection fraction was relatively well matched across the 3 HF cohorts.  A higher 
proportion of those with non-ischaemic cardiomyopathy had significant valve pathology 
(defined as at least moderate), a higher proportion of severe LVSD and left ventricular 
dilatation. 
Table 4-12:  Echocardiographic findings in heart failure cohorts 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
Dilated LV 39 (55.7) 41 (80.4) 38 (50.7) 
 
LVH 8 (11.4) 9 (17.6) 17 (22.7) 
 
Mild LVSD 9 (12.9) 10 (19.6) 14 (18.7) 
 
Moderate LVSD 33 (47.1) 19 (37.3) 31 (41.3) 
 
Severe LVSD 28 (40) 22 (43.1) 30 (40) 
 
At least moderate AS 1 (1.4) 3 (5.9) 1 (1.3) 
 
At least moderate AR 0 2 (3.9) 1 (1.3) 
 
At least moderate MS 0 0 0 
 
At least moderate MR 13 (18.6) 17 (33.3) 18 (24.0) 
 
At least moderate TR 4 (5.7) 2 (3.9) 3 (4.0) 
 
Data are presented as N (%) for categorical data. AR, aortic regurgitation; AS, aortic stenosis; 
LV, left ventricle; LVH, left ventricular hypertrophy; LVSD, left ventricular systolic dysfunction; 
MR, mitral regurgitation; MS, mitral stenosis; TR, tricuspid regurgitation 
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Figure 4-3:  Distribution of left ventricular ejection fraction by heart failure cohort 
4.2.10  Biochemistry 
 
All HF patients (n= 196) enrolled into this study had a full battery of biochemical blood tests 
checked at their initial screening visit.  The following biochemical tests were performed in each 
patient:  U&E, LFT, CRP, BNP, TFT, glucose, calcium, phosphate, urate and cholesterol.  All 
biochemical analyses were performed at the Western Infirmary Glasgow within 4 hours of 
collection, with the exception of plasma BNP which was batched and sent to the department of 
biochemistry at Gartnavel General Hospital in Glasgow for testing. 
There were a mixture of normally distributed and skewed data, therefore mean and median 
values are both presented in this section.  Biochemical parameters measured were similar 
across the 3 HF cohorts.  The BNP and U&E results are shown in table 4-13.  eGFR was 
calculated using the 4-variable MDRD formula and severe renal dysfunction was categorised 
by an eGFR <30ml/min/1.73m2.  Most patients enrolled had normal (eGFR 
>60ml/min/1.73m2) or mildly impaired renal function (eGFR ≥30 & <60ml/min/1.73m2).  See 
figure 4-4.  
 Median plasma BNP was elevated in each of the 3 separate HF groups (>35 pg/mL for patients 
presenting in a non-acute manner) with an overall median plasma BNP of 204.5g/mL for the 
total HF population.  There was a large range in concentrations of plasma BNP which is 
illustrated in figure 4-5.  
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Figure 4-4:  Distribution of eGFR by heart failure cohort 
 
 
 
Figure 4-5:  Distribution of BNP by heart failure cohort 
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Table 4-13:  BNP and renal function results in heart failure cohorts 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
Reference 
range/Units 
Mean BNP 
 
298.4  
(480.2) 
358.8  
(421.8) 
326.8  
(289.8) 
<35 pg/ml 
Median BNP 
 
162 
[68, 305] 
208 
[98, 470] 
214 
[105, 493] 
<35 pg/ml 
Mean sodium 
 
138.0  
(2.8) 
138.3  
(3.1) 
138.1  
(3.0) 
133-146 mmol/l 
Median sodium 138 
[137, 140] 
138 
[137, 140] 
138 
[137, 140] 
133-146 mmol/l 
 
Mean potassium 4.3  
(0.4) 
4.4  
(0.3) 
4.3  
(0.5) 
3.5-5.3 mmol/l 
 
Median potassium 4.3 
[4.1, 4.6] 
4.4 
[4.2, 4.6] 
4.3 
[4.1, 4.6] 
3.5-5.3 mmol/l 
 
Mean urea  9.9  
(4.4) 
7.8  
(3.2) 
8.8  
(3.8) 
2.5-7.8 mmol/l 
 
Median urea 8.9 
[7, 11.2] 
7.0 
[5.5, 10.3] 
7.9 
[6.3, 10.3] 
2.5-7.8 mmol/l 
 
Mean creatinine 112.7  
(36.9) 
93.3  
(34.8) 
104.1  
(33.9) 
40-130 µmol/l 
 
Median creatinine 112 
[81, 135] 
85 
[67, 110] 
102 
[74, 125] 
40-130 µmol/l 
 
Mean eGFR 61.9  
(23.6) 
75.4  
(27.0) 
67.4  
(22.1) 
>60ml/min/1.73m2 
 
Median eGFR 56.9 
[26.3, 115.0] 
74.8 
[28.2, 161.8] 
65.2 
[27.8, 110.9] 
>60ml/min/1.73m2 
 
Data are presented as means (SD) or median [Q1, Q3].  BNP, brain natriuretic peptide; eGRF, 
estimated glomerular filtration rate  
 
 
The mean concentration of liver enzymes bilirubin, aspartate transaminase (AST), alanine 
transaminase (ALT), alkaline phosphatase and albumin were within normal local reference 
ranges and are shown in table 4-14.  
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Table 4-14:  Liver function test results in heart failure cohorts 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
Reference range 
/Units 
Mean bilirubin 11.2  
(4.3) 
13.2  
(7.8) 
15.0  
(8.4) 
<20 mmol/l 
 
Median bilirubin 10 
[8, 14] 
11 
[8, 15] 
14 
[9, 17] 
<20 mmol/l 
 
Mean AST 20.7  
(8.8) 
22  
(8.2) 
23.5  
(8.1) 
<40 mmol/l 
 
Median AST 19 
[16, 23] 
21 
[16, 25] 
22 
[18, 28] 
<40 mmol/l 
 
Mean ALT 18.4  
(9.2) 
19.5  
(8.6) 
22.1  
(11.7) 
<50 mmol/l 
 
Median ALT 16 
[12, 22] 
18 
[13, 26] 
18 
[15, 26] 
<50 mmol/l 
 
Mean alkaline 
phosphatase 
89.5  
(29.5) 
93.9  
(42.2) 
92.2  
(35.1) 
30-130 mmol/l 
 
Median alkaline 
Phosphatase 
83.5 
[71, 107] 
83 
[69, 106] 
82 
[68, 106] 
30-130 mmol/l 
 
Mean albumin 37.1  
(2.8) 
37.3  
(3.8) 
36.9  
(2.7) 
35-50 mmol/l 
 
Median albumin 37 
[35, 39] 
38 
[35, 40] 
37 
[35, 39] 
35-50 mmol/l 
 
Data are presented as means (SD) or median [Q1, Q3].  ALT; alanine transaminase AST; 
aspartate transaminase 
 
The other biochemical tests measured at the initial screening visit are shown in table 4-15.  All 
HF patients had normal thyroid function test results.  Due to the interaction between thyroid 
function and cognition, abnormal thyroid function would have been a potential confounder and 
so these patients would not have been eligible for participation.  Mean and median CRP values 
were within normal limits in each of the HF groups.  Random glucose levels were checked with 
the highest mean values found in those patients with non-ischaemic cardiomyopathy.  Fasting 
blood glucose levels were not checked. In patients receiving lipid lowering therapy, mean and 
median total cholesterol levels were less than 5mmol/l.  Of those patients not receiving lipid 
lowering therapy, patients with both ischaemic and non-ischaemic cardiomyopathy had total 
mean and median cholesterol levels outwith the reference range.  All groups had slightly 
elevated mean urate levels. 
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Table 4-15:  Results of other biochemical tests measured in heart failure cohorts 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
Reference range/ 
Units 
Mean TSH 2.1  
(2.1) 
2.1  
(3.2) 
1.8  
(1.1) 
0.35-5.00 mU/L 
 
Median TSH 1.6 
[1.1, 2.6] 
1.5 
[1.1, 2.0] 
1.7 
[1.1, 2.4] 
0.35-5.00 mU/l 
 
Mean T4 14.1  
(2.3) 
14.2  
(2.4) 
14.2  
(1.9) 
9.0-21.0 pmol/l 
 
Median T4 13.6 
[12.3, 15.7] 
14.0 
[12.8, 15.0] 
14.0 
[12.6, 15.9] 
9.0-21.0 pmol/l 
 
Mean urate 0.5 
(0.1) 
1.2 
(5.3) 
0.5  
(0.2) 
0.2-0.43 mmol/l 
 
Median urate 0.5 
[0.4, 0.5] 
0.4 
[0.4, 0.5] 
0.5 
[0.4, 0.6] 
0.2-0.43 mmol/l 
 
Mean CRP 8.1  
(12.2) 
4.9  
(5.5) 
6.5  
(11.6) 
0-10 mg/l 
 
Median CRP 3.5 
[2.0, 9.0] 
3.0 
[1.0, 6.0] 
4.0 
[3.0, 8.0] 
0-10 mg/l 
 
Mean glucose 
 
6.9  
(3.5) 
7.3  
(4.9) 
7.0  
(3.1) 
3.5-6.0 mmol/l 
Median glucose 
 
5.6 
[5.1, 6.8] 
5.5 
[4.8, 7.0] 
5.8 
[5.2, 7.8] 
3.5-6.0 mmol/l 
Mean total 
cholesterol  
on lipid lowering 
therapy 
4.1  
(0.8) 
4.3  
(1.2) 
3.8  
(0.8) 
<5.0 mmol/l 
 
Mean total 
cholesterol 
not on lipid 
lowering therapy 
5.5  
(1.2) 
5.2  
(1.4) 
4.8  
(1.1) 
<5.0 mmol/l 
Median total 
cholesterol  
on lipid lowering 
therapy 
4.0 
[3.6, 4.7] 
4.1 
[3.4, 4.9] 
3.7 
[3.2, 4.2] 
<5.0 mmol/l 
 
Median total 
cholesterol  
not on lipid 
lowering therapy 
5.3 
[4.8, 6.0] 
5.1 
[4.4, 6.3] 
4.7 
[3.9, 5.3] 
<5.0 mmol/l 
Data are presented as means (SD) or median [Q1, Q3].  CRP, C-reactive protein; TSH, thyroxine 
stimulating hormone 
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4.2.11  Haematology 
 
Full blood count, haematinics and coagulation screens were checked for each patient recruited 
into this study.  There were a mixture of normally distributed and skewed data, therefore mean 
and median values are both presented in this section.  These results are shown in tables 4-16 
– 17. 
Table 4-16:  Full blood count results in heart failure cohorts  
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
Reference range/ 
Units 
Mean WBC count 7.7  
(1.9) 
8.1  
(3.0) 
8.0  
(2.1) 
4.0-11.0 x109/l 
 
Median WBC 
count 
7.5 
[6.7, 8.6] 
7.7 
[6.0, 9.1] 
7.8 
[6.5, 9.3] 
4.0-11.0 x109/l 
 
Mean Hb 129.1  
(20.0) 
133.6  
(14.9) 
134.3  
(15.1) 
115-165 g/L 
 
Median Hb 130.5 
[116, 144] 
135.0 
[125, 146] 
137.0 
[123, 143] 
115-165 g/L 
 
Mean RDW 16.3  
(12.1) 
15.0  
(2.5) 
14.7  
(1.4) 
11.6-14.6 % 
 
Median RDW 14.1 
[13.2, 15.0] 
14.2 
[13.4, 15.3] 
14.4 
[13.8, 15.4] 
11.6-14.6 % 
 
Mean platelet 
count 
239.3  
(82.1) 
228.3  
(89.4) 
213.9  
(60.2) 
150-400 x109/l 
 
Median platelet 
count 
225.5 
[187, 274] 
211 
[160, 263] 
205 
[180, 253] 
150-400 x109/l 
 
Mean lymphocyte 
count 
1.9  
(0.7) 
1.8  
(0.7) 
1.9  
(0.9) 
1.5-4.0 x109/l 
Median 
lymphocyte count 
1.9 
[1.4, 2.3] 
1.7 
[1.3, 2.3] 
1.8 
[1.3, 2.1] 
1.5-4.0 x109/l 
Mean ESR 16.4  
(13.9) 
9.0  
(7.0) 
13.9  
(13.8) 
1-12 mm/h 
 
Median ESR 13.5 
[6, 22] 
8.0 
[2, 12] 
10.0 
[5, 18] 
1-12 mm/h 
 
Data are presented as means (SD) or median [Q1, Q3].  ESR, erythrocyte sedimentation rate; 
Hb, haemoglobin; RDW, Red Cell Distribution Width; WBC, White Blood Cell 
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Table 4-17:  Haematinic results in heart failure cohorts  
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
Reference range/ 
Units 
Mean vitamin B12 417.1 (187.3) 367.1 (183.6) 399.8  
(135.5) 
200-900 pg/ml 
 
Median vitamin 
B12 
364 
[302, 488] 
324 
[239, 425] 
377.5 
[292, 460] 
200-900 pg/ml 
 
Mean serum folate 6.2  
(4.5) 
5.3  
(2.8) 
6.2  
(4.4) 
3.1-20 µg/L 
 
Median serum 
folate 
4.5 
[3.5, 7.2] 
4.8 
[3.1, 7.0] 
4.6 
[3.4, 7.4] 
3.1-20 µg/L 
 
Mean serum 
ferritin 
185  
(172) 
168.8 (177.1) 154  
(171.5) 
15-200 ng/mL 
 
Median serum 
ferritin 
153 
[68, 238] 
126 
[45, 225] 
98 
[39, 212] 
15-200 ng/mL 
 
Data are presented as means (SD) or median [Q1, Q3]  
All patients with HF recruited into this study had a normal haemoglobin, lymphocyte count, 
WBC count and platelet count.  In keeping with no evidence of anaemia, there was also no 
evidence of vitamin B12 deficiency, iron deficiency nor folate deficiency seen when 
haematinics were checked.  All 3 HF cohorts had an elevated mean red blood cell distribution 
width with both the ischaemic cardiomyopathy cohort and HF and AF cohort having elevated 
mean ESR levels.   
85 out of a total of 196 HF (43%) patients were formally anticoagulated with either warfarin 
or a novel oral anticoagulant.  Coagulation results therefore varied significantly.  The overall 
mean prothrombin time (PT) for those receiving formal anticoagulation versus those not on 
anticoagulation was 27.8s (8.6) vs. 11.5s (2.1) respectively.  These results are demonstrated in 
figure 4-6. 
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Figure 4-6:  Mean pro-thrombin time on anticoagulation vs. no anticoagulation by heart 
failure cohort 
4.3  Summary 
 
This chapter described in detail the process of study recruitment as well as the clinical 
characteristics of the HF cohort recruited into this study.  Of the 520 HF patients screened in 
the cardiology outpatient department, 196 fulfilled the criteria for inclusion.  All of these HF 
patients had evidence of HF-REF with a LVEF <45% on transthoracic echocardiography.  They 
were a cohort of stable, community-dwelling HF patients who had not been recently 
discharged from hospital. 
In keeping with results from published studies of HF epidemiology,5 the mean age of our 
population was 71 years with 70% of our total HF population being male.  Those a history of 
AF had a higher proportion adverse HF prognostic indicators including longer duration of heart 
failure, higher rates of previous HF hospitalisation and higher concentrations of plasma BNP.  
Of those patients with non-ischaemic cardiomyopathy 22% had no clear cause of their HF 
identified.   
Although a significant proportion of this cohort were elderly, with significant co-morbidities 
and polypharmacy, over one third (35%) lived at home alone and less than 10% (6.7%) had 
any employed carers to help with activities of daily living.  The majority of these patients were 
on treatment with regular diuretic for symptomatic relief in addition to disease modifying 
medication.  84% of those patients with AF were formally anticoagulated – the majority with 
warfarin.   
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Consistent with an outpatient sampling frame, basic physiological measurements were stable 
for each of the HF groups.  The majority of patients were in NYHA class II with lung crepitations 
and peripheral oedema being commonly found on physical examination.  Across the 3 HF 
cohorts, most patients had objective evidence of either moderate or severe LVSD based on 
LVEF.  Those with non-ischaemic cardiomyopathy in sinus rhythm were more likely to have a 
dilated left ventricle and prolonged QRS duration – most frequently with a left bundle branch 
block morphology on ECG.  Apart from elevated plasma BNP levels there were no significant 
biochemical or haematological findings on laboratory testing.  This is indicative of the fact that 
any potentially reversible causes of cognitive impairment precluded enrolment into this study.  
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CHAPTER FIVE 
 
 
CLINICAL CHARACTERISTICS OF CONTROL 
COHORTS 
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5.1  Introduction 
 
This chapter will discuss the recruitment of both disease and healthy control groups into this 
study.  Their clinical characteristics including demographic details, past medical history, 
medication use and examination findings will be described in detail.  Results of basic 
investigations including electrocardiography, echocardiography and blood tests will also be 
described with the differences between these 2 control groups highlighted.  Significance testing 
was not routinely performed for each variable – only in certain pre-selected variables where a 
significant association was postulated.  I chose to include both healthy controls (HC) and 
cardiac controls (CAD CONT) into this study to allow us to control for underlying cardiac 
conditions that often are present in HF.  In my literature review (outlined in chapter 2) I found 
no study that has previously used this specific design. 
5.2  Results 
 
5.2.1 Recruitment of study control cohorts 
 
 5.2.1.1  Cardiac control cohort 
 
Patients attending cardiac rehabilitation clinics between March 2013 and December 2014 at 
Glasgow Royal Infirmary, Western Infirmary Glasgow, Royal Alexandra Hospital and Stobhill 
hospital were screened for eligibility.  These patients were required to have coronary artery 
disease on CT or invasive coronary angiography (defined as >50% stenosis in ≥1 coronary 
artery) or a clinical history of previous myocardial infarction with supporting evidence 
including elevated serum cardiac enzymes, dynamic ECG changes and clinical history 
consistent with acute myocardial ischaemia.  They could not have any clinical history of heart 
failure and were required to have a LVEF >55% on transthoracic echocardiography. 
Of the 197 patients screened at the cardiac rehabilitation clinic 61 were included in the final 
sample.  136 patients were excluded for a variety of reasons and these are shown in table 5-1.   
The most common reason for exclusion was age<60 years old followed by patient refusal to 
participate.  In contrast to the HF cohorts, no patients were excluded because of previous 
cardiac arrest or inability to provide informed consent due to sensory or language difficulties.   
Some patients are referred for cardiac rehabilitation following cardiac surgery and in this 
cohort 13% of those screened had to be excluded due to previous cardiac surgery.  Those who 
develop LVSD following acute myocardial infarction are often followed up at the HF clinic 
rather than by the cardiac rehabilitation team and so only 4% of those screened were excluded 
on the basis of having a reduced LVEF. 
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Table 5-1:  Reasons for exclusion into study for cardiac control patients 
Reason for exclusion Number (% of those excluded) 
 
Age <60 years 64 (47) 
 
Alcohol excess 4 (3) 
 
AF 8 (6) 
 
Cardiac surgery 18 (13) 
 
Ejection fraction< 55% 5 (4) 
 
Hospital discharge within 3 months 5 (4) 
 
Neurological illness 10 (7) 
 
Patient refusal 21 (15) 
 
Terminal illness 1 (1) 
 
Data are presented as N (%) for categorical data.  AF, atrial fibrillation. 
 5.2.1.2  Healthy control cohort 
 
The healthy control cohort was recruited from the Generation Scotland database (see chapter 
3).  These are healthy participants who have previously volunteered to take part in clinical 
research projects and whose details are held in a central database.  Participants recruited into 
this cohort were required to have no previous history of heart failure or coronary artery 
disease.  They were required to have no diagnosis of any chronic illness and to be on no regular 
medication.  Candidates who fulfilled these criteria were contacted by the Generation Scotland 
team and asked if they were willing to participate.   
The first 100 participants to reply were invited to attend for an initial screening visit.  13 of 
these volunteers were then excluded because of prescription of regular medication and 
previously undisclosed past medical history including previous stroke, hypertension, diabetes 
and connective tissue disease.  The remaining 87 healthy volunteers gave written informed 
consent and participated in the study visits. 
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5.2.2  Demographics of control cohorts 
 
5.2.2.1  Demographics of control cohorts 
 
The clinical demographics of the control cohorts are shown in table 5-2.  The two control 
cohorts had participants of similar age range.  Those recruited into the healthy control cohort 
were more likely to be female, non-smokers with higher average years of education and higher 
full scale IQ. 
Table 5-2:  Basic demographics of participants recruited into control cohorts 
 CAD CONT 
(n=61) 
HC 
(n=87) 
Age (years) 67.5 ± 6.3 
 
70.3 ± 6.7 
 
Age range (years) 60-92 
 
59 – 85 
 
Sex (% males) 43 (71) 
 
55 (63) 
 
Education (total years) 
 
13 
 [11, 15] 
15 
 [12, 18] 
Full scale IQ 
 
103 
[70, 117] 
112 
[75, 117] 
Smoker 37 (61) 
 
13 (15) 
 
Current alcohol 41 (67) 
 
65 (75) 
 
Data are presented as means (SD), median [Q1, Q3] or N (%) for categorical data.  
5.2.2.2  Comparison between control and HF cohorts 
 
When compared, the mean age of patients with CAD and no HF was lower than the mean age 
of those with HF (67.5 versus 70.6, p=0.0149) as was the mean age of the healthy control 
participants (70.3 versus 70.6, p= 0.8613).  70% of HF patients recruited into this study were 
male compared to 71% of patients recruited into the cardiac control group and 63% of healthy 
volunteers.  These differences were not statistically significant when between group 
comparisons were made - firstly between HF patients and CAD controls (p=1.0000) and 
secondly between HF patients and healthy controls (p=0.3310).  Healthy control participants 
were more likely to be female, have longer years of education, were less likely to smoke and 
more likely to consume alcohol.  Table 5-3 shows a summary of the statistically significant p-
values when between group comparisons of baseline characteristics were made. 
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Table 5-3:  Summary of statistically significant differences in baseline 
demographics between groups 
 Total HF 
(N=196) 
CAD 
CONT 
(N=61) 
HC 
(N=87) 
HF vs CAD 
CONT 
p-value 
HF vs 
HC 
p-value 
Age (years) 70.6 ± 8.1 
 
67.5 ± 6.3 70.3 ± 6.7 0.0149 0.8613 
Education 
(total years) 
 
11 
[10, 14] 
 
13 
[11, 15] 
15 
[12, 18] 
0.0169 <0.0001 
Current 
alcohol 
 
99 (51) 41 (67) 65 (75) 0.0323 0.0002 
Data are presented as means (SD), median [Q1, Q3] or N (%) for categorical data.  
5.2.3  Medical history 
 
As previously described, those participants recruited into the healthy control cohort could not 
have any past medical history of chronic disease.  Figure 5-1 shows the common co-morbid 
conditions found in the cardiac control cohort. 
Patients recruited into the cardiac control cohort were required to have coronary artery 
disease confirmed either on CT or invasive coronary angiography (defined as >50% stenosis 
in ≥1 coronary artery) or a clinical history of previous myocardial infarction.  60 out of the 61 
patients included had undergone previous coronary angiography (with invasive or CT) with 
45 of them having going on to have percutaneous coronary intervention performed.  52 
patients had a previous diagnosis of myocardial infarction and 36 (59%) described ongoing 
symptoms of angina. 
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Figure 5-1:  Prevalence of co-morbid conditions in the cardiac control population 
Other cardiovascular risk factors including hypertension, hypercholesterolaemia and diabetes 
were also common in this cohort.  Of the 12 patients diagnosed with diabetes 9 were treated 
with oral hypoglycaemic therapy only, 2 were diet controlled and only one was on insulin 
therapy.  Only 2 patients had a conventional pacemaker for bradyarrhythmia and there were 
no patients recruited in this cohort with implantable cardiac defibrillators or cardiac 
resynchronisation pacemakers.  
67.2% of cardiac control patients stated they had a family history of premature coronary artery 
disease.  45 patients (74%) lived with a relative and 2 (3%) patients had regular employed 
carers to assist with activities of daily living. 
5.2.4  Medication use 
 
Patients were excluded from the healthy control cohort if they were prescribed any regular 
medication.  Tables 5-3 to 5-5 present the number of cardiac control patients receiving the 
most commonly prescribed medications. 
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Over 98% of this population were prescribed some form of antiplatelet agent, 93% were on 
some form of lipid lowering therapy and no patients in this group were formally anticoagulated 
with warfarin or NOAC.  Other non-cardiovascular medications prescribed included anxiolytics 
(n=2), antidepressants (n=1), incontinence medication (n=2) and bronchodilators (n=5). 
Table 5-4:  Commonly prescribed cardiovascular medications in cardiac control 
cohort 
 CAD CONT 
(n=61) 
Statin  
59 (96.7) 
 
Any lipid lowering drug 
 
57 (93.4) 
Beta Blocker  
51 (83.6) 
 
ACE Inhibitor  
39 (63.9) 
 
Nicorandil  
12 (19.7) 
 
Diuretics  
12 (19.7) 
 
Long-acting nitrates  
11 (18.0) 
 
Calcium channel-blocker  
10 (16.4) 
 
Diabetic medication 
10 (16.4) 
 
ARB  
5 (8.2) 
 
Ivabradine  
2 (3.3) 
 
Aldosterone Blocker  
1 (1.6) 
 
Digoxin  
1 (1.6) 
 
Data are presented as N (%).  ACE, angiotensin converting enzyme; ARB, angiotensin receptor 
blocker. 
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Table 5-5:  Antiplatelet and anticoagulant use in cardiac control cohort 
 CAD CONT 
(n=61) 
Any antiplatelet therapy 60 (98.4) 
 
Aspirin 59 (96.7) 
 
Clopidogrel 17 (27.9) 
 
Any anticoagulant therapy 0  
 
Warfarin 0  
 
NOAC 0  
 
Data are presented as N (%).  NOAC, novel oral anticoagulant 
 
Table 5-6:  Other medication use in cardiac control cohort 
 CAD control 
(n=61) 
Anxiolytic 2 (3.3) 
 
Antidepressant 1 (1.6) 
 
Incontinence medication 2 (3.3) 
 
Antihistamine 0  
 
Bronchodilator 
 
5 (8.2) 
Data are presented as N (%).   
5.2.5  Clinical examination findings 
 
Routine physiological measurements were taken for each study participant at the initial 
screening visit and again at return visit 1.  Table 5-4 lists the physiological measurements taken 
at return visit 1 for those recruited into wither the cardiac or healthy control cohort.  According 
to the World Health Organisation (WHO) BMI classification, the mean BMI of participants in 
both control cohorts (28.4, 26.4) fell into the overweight range (>25).  A full cardiovascular 
examination was also performed at this time.  Participants recruited into these control cohorts 
had no clinical signs of heart failure.  The presence of a cardiac murmur was recorded for 7% 
of the cardiac control cohort and otherwise cardiovascular examinations for participants in 
these cohorts were essentially normal.  
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Table 5-7:  Physiological measurements taken at return visit 1 
 CAD CONT 
(n=61) 
HC 
(n=87) 
Height (cm)                                                 Median 
                                                                    Mean (SD) 
168 
167.1 (8.8) 
172 
169.7 (11.0) 
Weight (Kg)                                                 Median 
                                                                    Mean (SD)  
81 
82.4 (16.3) 
77 
78.0 (14.3) 
BMI                                                                  Median 
                                                                    Mean (SD) 
28.4 
 29.4 (5.0) 
26.4 
27.0 (3.9) 
Neck circumference males (cm)        Median 
                                                               Mean (SD) 
18.0 
18.5 (2.2) 
17.8 
17.5 (1.3) 
Neck circumference females (cm)     Median                                                                  
                                                                    Mean (SD) 
15.7 
15.4 (2.2) 
15.0
15.2 (2.1) 
Systolic BP (mmHg)                                 Median                                                                     
                                Mean (SD) 
133 
138.2 (24.3) 
137 
141.3 (20.6) 
Diastolic BP (mmHg)                               Median 
        Mean (SD) 
76 
75.7 (11.5) 
79 
78.4 (10.2) 
Heart rate (BPM)                                      Median 
Mean (SD) 
70 
72.1 (12) 
62 
64.3 (10.1) 
SpO2(%)                                                        Median  
                                                                    Mean (SD)                                           
97 
97.1 (1.4) 
97 
96.9 (1.4) 
Respiratory rate (BPM)                         Median 
                                                                    Mean (SD) 
16 
15.2 (1.8) 
14 
14.9 (2.1) 
Temperature(˚C)                                       Median 
                                                                    Mean (SD) 
36.5 
36.5 (0.7) 
36.1 
36.0 (0.8) 
Data are presented as means (SD) or median [Q1, Q3].  BP, blood pressure;  
BPM, beats per minute; cm, centimetres; Kg, kilogram; mmHg, millimetres of  
mercury 
 
 
5.2.6  Electrocardiography 
 
All patients recruited into cohorts 4 (cardiac control cohort) and 5 (healthy control cohort) 
were in normal sinus rhythm and this was confirmed on 12 lead ECG at their initial screening 
visit.  The mean heart rates were 62 (10) beats per minute and 69 (10) beats per minute for 
cohorts 4 and 5 respectively.  One patient in the cardiac control group had (left) bundle branch 
block on their ECG, all others had a QRS duration <120ms.  7 (11.5%) of cardiac patients had 
evidence of an old myocardial infarction on their ECG with pathological Q waves present.  
There were no acute ischaemic changes seen on any of the ECGs. 
5.2.7  Echocardiography 
 
The majority of cardiac control patients had already had transthoracic echocardiography 
performed within the past 6 months as part of routine clinical care.  Healthy control 
participants underwent transthoracic echocardiography at time of enrolment by a 
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sonographer accredited by the British Society of Echocardiography.  Study participants 
recruited into these control groups were required to have a LVEF >55% to fulfil the inclusion 
criteria.  The mean calculated ejection fractions were 66% for those with ischaemic heart 
disease and 64% for the healthy control subjects.  16% of the cardiac control patients had 
evidence of concentric LVH in keeping with a prior history of hypertension.  Otherwise, there 
were no significant echocardiographic findings and no other between group differences.  
5.2.8  Biochemistry 
 
Participants recruited into the 2 control cohorts had the same laboratory tests performed as 
those recruited into the HF cohorts.  These included U&E, LFT, CRP, BNP, TFT, glucose, calcium, 
phosphate, urate and cholesterol.  Bloods were taken from each participant at the initial 
screening visit and analysed at the Western Infirmary Glasgow within 4 hours of collection 
(with the exception of BNP which was batched and sent to the department of biochemistry at 
Gartnavel General Hospital in Glasgow for testing).  There were a mixture of normally 
distributed and skewed data, therefore mean and median values are both presented in this 
section.   
Current ESC HF guidelines recommend an optimum exclusion cut-off point of 35pg/mL for BNP 
in patients presenting in a non-acute way.  In this cohort the median BNP concentration was 
28pg/mL [15, 37] for healthy control participants and 62pg/mL [29, 106] for the cardiac 
control group.  These values were considerably lower than the median BNP for the HF cohort 
(204.5pg/mL, [81, 401]).  See table 5-5. 
The mean sodium and potassium values were similar to the mean values in the HF cohort and 
were within normal limits.  The mean urea and creatinine values were lower than those found 
in the HF cohorts (6.2mmol/l (2.8) vs. 8.9mmol/l (4.0) and 79.3µmol/l (27.9) vs. 104.4µmol/l 
(35.8) respectively).  The distribution of eGFR by control cohort is illustrated in figure 5-2 with 
the majority of patients having normal renal function (eGFR>60ml/min/1.73m2).  See table 5-
5. 
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Table 5-8:  BNP and renal function results for control cohorts 
 CAD CONT 
(n=61) 
HC 
(n=87) 
Reference range/ 
Units 
Mean BNP 
 
93.2 
(96.4) 
33.1 
(26.7) 
<35 pg/ml 
Median BNP 
 
62 
[29, 106] 
28 
[15, 37] 
<35 pg/ml 
Mean sodium 
 
138 
(3) 
139 
(2) 
133-146 mmol/l 
Median sodium 139 
[137, 140] 
139 
[137, 140] 
133-146 mmol/l 
 
Mean potassium 4.3 
(0.4) 
4.1 
(0.3) 
3.5-5.3 mmol/l 
 
Median potassium 4.3 
[4.1, 4.5] 
4.1 
[3.9, 4.3] 
3.5-5.3 mmol/l 
 
Mean urea  6.5 
(4.3) 
5.9 
(1.3) 
2.5-7.8 mmol/l 
 
Median urea 5.5 
[5.0, 6.6] 
5.6 
[5.0, 6.6] 
2.5-7.8 mmol/l 
 
Mean creatinine 83.8 
(43.3) 
74.8 
(12.4) 
40-130 µmol/l 
 
Median creatinine 73 
[67, 92] 
74 
[65, 84] 
40-130 µmol/l 
 
Mean eGFR 86.7 
(23) 
88.0 
(15) 
>60ml/min/1.73m2 
 
Median eGFR 85.6 
[15, 180] 
88.3 
[60, 126] 
>60ml/min/1.73m2 
 
Data are presented as means (SD) or median [Q1, Q3].  BNP, brain natriuretic peptide; eGRF, 
estimated glomerular filtration rate 
 
 
Figure 5-2:  Distribution of eGFR by control cohort 
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Every study participant had LFTs checked at the initial screening visit (table 5-6).  The mean 
bilirubin, AST, ALT, alkaline phosphatase and albumin concentrations were all within normal 
limits for both the cardiac control patients and healthy volunteers.   
Table 5-9:  Liver function test results for control cohorts 
 CAD CONT 
(n=61) 
HC 
(n=87) 
Reference 
range/ Units 
Mean bilirubin 11.0 
(5.0) 
11.9 
(5.4) 
<20 mmol/l 
 
Median bilirubin 10 
[8, 12] 
10 
[8, 13] 
<20 mmol/l 
 
Mean AST 22.7 
(7.7) 
22.5 
(6.3) 
<40 mmol/l 
 
Median AST 22 
[19, 26] 
21 
[18, 25] 
<40 mmol/l 
 
Mean ALT 25.6 
(14.1) 
23.4 
(10.3) 
<50 mmol/l 
 
Median ALT 22 
[17, 29] 
21 
[17, 27] 
<50 mmol/l 
 
Mean alkaline 
phosphatase 
81 
(24.3) 
75 
(18.6) 
30-130 mmol/l 
 
Median alkaline 
Phosphatase 
80 
[65, 94] 
74 
[61, 86] 
30-130 mmol/l 
 
Mean albumin 38.1 
(2.8) 
37.6 
(2.4) 
35-50 mmol/l 
 
Median albumin 38 
[37, 40] 
37 
[36, 39] 
35-50 mmol/l 
 
Data are presented as means (SD) or median [Q1, Q3].  ALT; alanine transaminase AST; 
aspartate transaminase 
 
 
In addition to these biochemical tests TFTs, glucose, CRP, urate, calcium, phosphate and 
cholesterol were also measured.  All participants recruited into either control cohort had 
normal thyroid function tests, urate levels and CRP.   
No participants in the HC cohort were on lipid lowering therapy.  Even when compared to those 
patients with ischaemic heart disease not on lipid lowering therapy, the HC population had 
higher mean cholesterol levels (5.3 versus 4.6).  Median random glucose levels were within 
normal limits.  Fasting blood glucose levels were not checked.  These results are shown in table 
5-7. 
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Table 5-10:  Results of other biochemical tests measured in control cohorts 
 CAD CONT 
(n=61) 
HC 
(n=87) 
Reference 
range/ Units 
Mean TSH 1.9 
(3.1) 
1.8 
(1.0) 
0.35-5.0 mU/L 
 
Median TSH 1.3 
[1.0, 1.7] 
1.6 
[1.2, 2.3] 
0.35-5.0 mU/l 
 
Mean T4 13.3 
(2.0) 
13.3 
(1.7) 
9.0-21.0 pmol/l 
 
Median T4 13.0 
[12.1, 13.9] 
13.0 
[12.0, 14.0] 
9.0-21.0 pmol/l 
 
Mean urate 0.4 
(0.1) 
0.4 
(0.1) 
0.2-0.43 mmol/l 
 
Median urate 0.4 
[0.3, 0.4] 
0.4 
[0.3, 0.4] 
0.2-0.43 mmol/l 
 
Mean CRP 4.4 
(5.6) 
3.4 
(10.0) 
0-10 mg/l 
 
Median CRP 3.0 
[1.0, 5.0] 
2.0 
[1.0, 3.0] 
0-10 mg/l 
 
Mean glucose 
 
6.4 
(3.1) 
5.4 
(1.0) 
3.5-6.0 mmol/l 
Median glucose 
 
5.5 
[4.8, 6.8] 
5.0 
[4.7, 5.7] 
3.5-6.0 mmol/l 
Mean total 
cholesterol  
on lipid lowering 
therapy 
4.0 
(0.8) 
N/A <5.0 mmol/l 
 
Mean total 
cholesterol 
not on lipid 
lowering therapy 
4.6 
(0.9) 
5.3 
(1.0) 
<5.0 mmol/l 
Median total 
cholesterol  
on lipid lowering 
therapy 
 
3.9 
[3.5, 4.4] 
N/A <5.0 mmol/l 
 
Median total 
cholesterol  
not on lipid 
lowering therapy 
4.5 
[3.7, 5.1] 
5.3 
[4.7, 6.1] 
<5.0 mmol/l 
Data are presented as means (SD) or median [Q1, Q3].  CRP, C-reactive protein; TSH, thyroxine 
stimulating hormone 
 
 
 
 
 
 
 
134 
 
5.2.9  Haematology 
 
Table 5-8 displays the full blood count results for the control cohorts.  Data were normally 
distributed and so mean (SD) results are presented in this section.  There were no significant 
differences between the 2 control cohorts and all mean haematological results were within the 
normal reference range. 
Table 5-11:  Full blood count results for control cohorts. 
 CAD CONT 
(n=61) 
HC 
(n=87) 
Reference 
range/ Units 
Mean WBC count 7.2 
(1.8) 
6.4 
(1.5) 
4.0 11.0 x109/l 
 
Mean Hb 137.7 
(11.9) 
143.7 
(12.7) 
115-165 g/L 
 
Mean RDW 13.3 
(0.6) 
13.3 
(1.0) 
11.6-14.6 % 
 
Mean platelet count 238 
(56.2) 
235 
(47.8) 
150-400 x109/l 
 
Mean lymphocyte 
count 
2.0 
(0.8) 
1.9 
(0.6) 
1.5-4.0 x109/l 
Mean ESR 7.2 
(7.0) 
7.6 
(8.3) 
1-12 mm/h 
 
Data are presented as means (SD).  ESR, erythrocyte sedimentation rate; Hb, haemoglobin; 
RDW, Red Cell Distribution Width; WBC, White Blood Cell 
 
Patients in the CAD control group tended to have higher serum concentrations of vitamin B12 
and folate when compared to the healthy controls, however, mean levels were within normal 
limits for both groups.  Although healthy controls had higher mean levels of serum ferritin all 
mean levels were within reference range.  See table 5-9. 
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Table 5-12:  Haematinic results for control cohorts 
 CAD CONT 
(n=61) 
HC 
(n=87) 
Reference 
range/ Units 
Mean vitamin B12 410.5 
(160.8) 
347.2 
(120.6) 
200-900 pg/ml 
 
Mean serum folate 7.0 
(4.7) 
6.3 
(3.6) 
3.1-20 µg/L 
 
Mean serum ferritin 136.3 
(129.3) 
165.0 
(141.9) 
15-200 ng/mL 
 
Data are presented as means (SD)  
5.3  Summary 
 
This chapter outlines in detail the process of recruitment into two control cohorts.  A disease 
control cohort was included to allow comparison between patients with coronary artery 
disease with and without HF.  This allows examination into whether HF per se is associated 
with certain cognitive outcomes rather than the atherosclerotic process that often underlies it.  
In our systematic review of the literature (see chapter 2) no prior studies were found that used 
this particular study design.  
61 patients with CAD, no clinical HF and LVEF >55% were enrolled from cardiac rehabilitation 
clinics.  They were relatively well matched to 87 healthy controls who had no previous 
diagnosis of any chronic illness, prescribed no regular medication and had LVEF >55%.  These 
control participants underwent the same baseline investigations as those patients with HF and 
this chapter has described their results in detail.   
Participant demographics were similar across each of the 5 study cohorts.  Only 3 statistically 
significant differences were found when between group comparisons were made.  Healthy 
control participants were on average younger, with longer years of total years of education and 
more likely to consume alcohol within recommended limits. 
Patients with HF were more likely to have renal dysfunction, elevated red blood cell 
distribution width and ESR levels than either of the 2 control cohorts.  Patients with HF had 
higher levels of plasma BNP, followed by patients with CAD and no HF.  All cohorts had normal 
liver function and thyroid function.  There was no documented anaemia nor iron, folate or 
vitamin B12 deficiency found.   
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CHAPTER SIX 
 
REPEATABLE BATTERY FOR THE 
ASSESSMENT OF NEUROPSYCHOLOGICAL 
STATUS 
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6.1  Introduction 
 
Each participant in this study underwent detailed neuropsychological testing using an 
extensive battery of cognitive assessment tools.  These assessment tools were administered to 
each participant in the same order by either Sister Meyer or I.  Both Sister Meyer and I were 
trained in their administration by Dr Niall Broomfield, consultant clinical neuropsychologist.  
The results from the neuropsychological assessment tools employed will be outlined in the 
following five chapters in the order in which they were administered to each study participant. 
This chapter will describe in detail the results of the repeatable battery for the assessment of 
neuropsychological status (RBANS) for all study participants.  This was the first cognitive test 
administered to each participant.  This assessment tool has previously been described in 
chapter 3 and the RBANS scoring sheet is shown in appendix IX.  The RBANS assesses the 
following individual domains of cognition:  immediate memory, language, attention, 
visuospatial awareness and delayed memory.   
Once individual subtests were scored, the raw scores were converted to index scores using 
normative tables provided in the RBANS stimulus booklet.167  A total scale score was then 
derived from the index scores using the reference tables again provided in the RBANS manual.  
Following their administration, the RBANS booklets were blindly scored by Dr Rosalind Lees 
with a random 20% of the sample re-scored by 2 independent consultant neuropsychologists 
(Dr Niall Broomfield and Dr John Sharp) for quality assurance.  Any disagreements in marking 
were referred to a third arbitrator (Professor Jonathan Evans). 
In this chapter, the individual scores for each cognitive domain in addition to the total scale 
scores will be described.  Difference in results between the 5 study cohorts will also be 
outlined.  Significance testing was only performed for certain pre-specified variables. At the 
end of this chapter the results presented here will be compared to other published results in 
an attempt to put these results into context. 
 
 
 
 
 
 
 
 
138 
 
6.2  Results 
 
6.2.1  RBANS total scale 
 
6.2.1.1  RBANS total scale results 
 
Table 6-1 presents the RBANS total scale results for each of the 5 study cohorts.  Patients with 
HF and AF had the lowest (worst) mean RBANS total scale scores of 82.0± 16.2 followed by 
those with HF and CAD (86.3 ± 14.3).  There were similar mean scores found in those with HF 
and no CAD (89.2 ± 14.6) and cardiac control patients (91.2 ± 15.9).  Patients with HF were at 
increased risk of CI when compared to both the healthy control cohort (odds ratio, 12.73; 95% 
confidence interval [CI], 7.14 to 22.7; p<0.0001) and the cardiac control cohort (odds ratio, 
2.05; 95% CI, 1.2 to 3.49; p=0.0081).  The relationship between CI and HF persisted even after 
adjustment for potential confounding variables as shown in tables to 6-3 and 6-4. 
Table 6-2 outlines the variables included in each of the models used in this analysis.  In addition 
to age and sex (adjusted for in model 1) model 2 also adjusted for race, co-morbidity score, 
medication count and full scale IQ (derived from the Wechsler test of adult reading and used 
as a measure of education).  Adjusting for these variables resulted in the largest difference in 
odds ratio (see tables 6-3 and 6-4) suggesting that co-morbid conditions and pre-morbid 
education are the variables which have the greatest impact on cognition.  
There was no significant difference in RBANS total scale scores between HF patients with CAD 
and those without CAD (odds ratio, 0.83; 95% CI, 0.49 to 1.40; p=0.4849).   
Table 6-1:  Repeatable battery for the assessment of  neuropsychological status 
         total scale scores by cohort 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
CAD 
CONT 
(n=61) 
HC 
(n=87) 
Mean (SD)  86.3 (14.3) 89.2 (14.6) 82.0 (16.2) 91.2 (15.9) 
 
106.9 (16.4) 
 
Median 86.0 93.0 82.0 91.0 
 
108.0 
 
Range 51.0, 116.0 59.0, 117.0 53.0, 123.0 54.0, 127.0 
 
64.0, 149.0 
 
Data are presented as means (SD)  
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Table 6-2:  Reference for model adjustment labels  
Model label Model text 
 
Covariates 
 
0 Unadjusted Model 
 
N/A 
 
1 Basic Model  
 
Sex, Age 
 
2 
Demographic 
Adjusted Model 
 
As for model 1, plus Co-Morbidity Score, Race, 
Wechsler Test of Adult Reading, Medication 
Count 
 
3 
Cognitive Adjusted 
Model 
 
As for model 2, plus History of Depression, 
HADS depression score, History of Anxiety 
 
4 
Vascular Adjusted 
Model 
 
As for model 3, plus Smoker, Systolic Blood 
Pressure, Diabetes Mellitus, BMI, Previous MI, 
Chronic Kidney Failure (defined as eGFR < 60), 
Hypertension 
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Table 6-3:  Repeatable battery for the assessment of  neuropsychological status 
          total scale results for HF cohort versus healthy controls 
 
Outcome  
 
Model Total N OR.(95% CI) p-value 
All HF vs Healthy 
controls 
0 283 12.73 (7.14, 22.7) 
 
 
<0.0001 
 
 
All HF vs Healthy 
controls 
1 283 13.17 (7.36, 23.57) 
 
 
<0.0001 
 
 
All HF vs Healthy 
controls 
2 283 4.98 (1.90, 13.07) 
 
 
0.0011 
 
 
All HF vs Healthy 
controls 
3 271 5.47 (2, 14.97) 
 
 
0.0009 
 
 
All HF vs Healthy 
controls 
4 268 4.19 (1.36, 12.87) 
 
 
0.0124 
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Table 6-4:  Repeatable battery for the assessment of  neuropsychological status 
          total scale results for HF cohort versus CAD controls 
Outcome Model Total N OR.(95% CI) p-value 
 
All HF vs  
CAD controls 
 
0 257 2.05 (1.20, 3.49) 0.0081 
 
All HF vs  
CAD controls 
 
1 257 1.96 (1.13, 3.38) 0.0158 
 
All HF vs  
CAD controls 
 
2 257 1.92 (1.06, 3.47) 0.0316 
 
All HF vs  
CAD controls 
 
3 248 2.02 (1.1, 3.71) 0.0243 
 
All HF vs  
CAD controls 
 
4 244 2.20 (1.05, 4.61) 0.036 
 
HF patients with AF were more likely to have CI than HF patients in sinus rhythm (odds ratio, 
2.00; 95% CI, 1.18 to 3.37; p=0.0098).  Patients with AF who were receiving formal 
anticoagulation (with either warfarin or a novel oral anticoagulant) had lower RBANS total 
scale scores compared to those who were not.  This is demonstrated in figure 6-1.  Although 
this may seem counterintuitive it is probably explained in part by the fact that those patients 
commenced on formal anticoagulation would be those patients identified as being at greatest 
risk of thromboembolic disease e.g. older with a history of vascular disease, hypertension or 
other cardiovascular risk factors.  There are therefore more potential confounders present in 
these patients and this may in part explain why they had poorer cognitive scores documented 
by RBANS.  
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Figure 6-1:  Repeatable battery for the assessment of neuropsychological status median 
total scale scores for the heart failure and atrial fibrillation cohort 
6.2.1.2  RBANS total scale results:  Binary analyses 
 
Formal diagnosis of cognitive impairment requires evidence of abnormality on formal 
neuropsychological testing in at least one cognitive domain.  Typically an abnormal result is 
taken as one which is ≥1.5 standard deviations below the age-standardised mean. Results from 
this study were therefore analysed using the following three RBANS total scale scores: 70 (≥2 
SD below the mean), 80 (≥1.5 SD below the mean) and 90 (≥0.75 SD below the mean) to define 
impaired cognition.  The proportion of participants categorised as having CI varied greatly 
depending on which RBANS cut-off value was used.  The results from these binary analyses are 
shown in table 6-5.   
A threshold value of <90 classified nearly 75% of patients with HF and AF as having abnormal 
cognition however only 25% of the same cohort were classified as cognitively impaired using 
the more conservative cut-off of <70.   
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Table 6-5:  Repeatable battery for the assessment of  neuropsychological status  
          binary analyses 
Variable 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
RBANS binary 
(<70 vs ≥70) 
   Normal 61 (87.1%) 46 (90.2%) 56 (74.7%) 55 (90.2%) 
 
86 (98.9%) 
 
   Abnormal 9 (12.9%) 5 (9.8%) 19 (25.3%) 9 (12.9%) 
 
1(1.1%) 
 
RBANS binary  
(<80 vs ≥80) 
   Normal 48 (68.6%) 37 (72.5%) 46 (61.3%) 50 (82.0%) 
 
83 (95.4%) 
 
   Abnormal 22 (31.4%) 14 (27.5%) 29 (38.7%) 11 (18.0%) 
 
4 (4.6%) 
 
RBANS binary 
(<90 vs ≥90) 
   Normal 29 (41.4%) 27 (52.9%) 19 (25.3%) 33 (54.1%) 
 
76 (87.4%) 
 
   Abnormal 41 (58.6%) 24 (47.1%) 56 (74.7%) 28 (45.9%) 
 
11 (12.6%) 
 
Data are presented as N(%) 
6.2.1.3  Clinical severity classified by RBANS total scale 
 
Qualitative descriptions of RBANS scores are provided in the RBANS manual.  Depending on 
results of the total scale scores study subjects are classified into the following categories:  very 
superior, superior, high average, average, low average, borderline and extremely low.  The aim 
of this qualitative classification is to aid with the clinical interpretation of the RBANS scores.   
Table 6-6 shows the proportion of participants categorised into each class.  As expected, the 
majority (43.7%) of the healthy control population were categorised as average.  Only healthy 
control participants were classified as “superior” or “very superior”.  More patients with HF 
and AF fell into the “borderline” and “extremely low” category compared to any of the other 
cohorts. 
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Table 6-6:  Qualitative descriptions of repeatable battery for the assessment of 
          neuropsychological status total scale scores 
Variable 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Very Superior 
≥130 
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
 
6 (6.9%) 
 
Superior 
≥120 & ≤129 
0 (0.0%) 0 (0.0%) 3 (4.0%) 4 (6.6%) 
 
13 (14.9%) 
 
High Average 
≥110 & ≤119 
3 (4.3%) 3 (5.9%) 1 (1.3%) 3 (4.9%) 
 
19 (21.8%) 
 
Average 
≥90 & ≤110 
26 (37.1%) 24 (41.7%) 15 (20.0%) 26 (42.6%) 
 
38 (43.7%) 
 
Low Average 
≥80 & ≤89 
19 (27.1%) 10 (19.6%) 27 (36.0%) 17 (27.9%) 
 
7 (8.0%) 
 
Borderline 
≥70 & ≤79 
13 (18.6%) 9 (17.6%) 10 (13.3%) 5 (8.2%) 
 
3 (3.4%) 
 
Extremely Low 
≤69 
9 (12.9%) 5 (9.8%) 19 (25.3%) 6 (9.8%) 
 
1 (1.1%) 
 
Data are presented as N (%) 
6.2.2  RBANS assessment of immediate memory  
 
Immediate memory is assessed using 2 subtests as part of the RBANS.  These 2 subtests are 
described below: 
1.  List learning:  A list of 10 semantically unrelated words is orally presented, and the 
examinee is asked to recall as many words as he or she can.  This process is repeated over 4 
learning trials. 
2.  Story memory:  A short story is orally presented, and the examinee is asked to recall the 
story from memory.  The same story is presented a second time and the examinee is again 
asked to retell the story from memory. 
The two individual raw scores are then converted into an index score for that domain using 
previously published normative data.167  The mean index scores for each cohort are shown in 
table 6-7.   
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Patients with both HF and AF had the lowest mean score (79.6 ± 18) in the domain of 
immediate memory followed by patients with non-ischaemic cardiomyopathy (84.9 ± 17.8) 
and then those with ischaemic cardiomyopathy (85.5 ± 15.8).  Patients with HF had poorer 
immediate memory scores than either the CAD (87.8 ± 18) or the healthy control (100.3 ± 15.6) 
groups.   
Table 6-7:  Repeatable battery for the assessment of  neuropsychological status  
         immediate memory scores 
 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Mean (SD) 85.5 (15.8) 84.9 (17.8) 79.6 (18.0) 87.8 (18.0) 
 
100.3 (15.6) 
 
Median 85.0 85.0 78.0 87.0 
 
103.0 
 
Range 49.0, 120.0 44.0, 120.0 40.0, 123.0 53.0, 126.0 
 
65.0, 136.0 
 
 
 
6.2.3  RBANS assessment of language 
 
Language is assessed as part of this neuropsychological battery by the two subtests outlined 
below: 
1.  Picture naming:  The examinee is presented with a series of pictured objects and is asked 
to name each one.  A semantic cue is provided only if an object is obviously misperceived. 
2.  Semantic fluency:  The examinee is given one minute to name as many examples as possible 
from a given semantic category (fruits and vegetables). 
The language index scores are presented in table 6-8.  Patients with HF and AF had the lowest 
mean score (89.2 ± 11.5) followed by those with ischaemic cardiomyopathy (90 ± 10.7) and 
those with non-ischaemic cardiomyopathy (94.1 ± 10.5).  Scores were similar between CAD 
control patients (92.2 ± 9.2) and those with ischaemic cardiomyopathy. 
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Table 6-8:  Repeatable battery for the assessment of  neuropsychological status  
          language scores 
 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Mean (SD) 90.0 (10.7) 94.1 (10.5) 89.2 (11.5) 92.9 (9.2) 
 
100.2 (10.9) 
 
Median 92.0 96.0 90.0 92.0 
 
101.0 
 
Range 57.0, 110.0 75.0, 120.0 51.0, 117.0 60.0, 120.0 
 
57.0, 134.0 
 
 
 
6.2.4  RBANS assessment of attention  
 
The domain of attention indicates the examinee’s capacity to remember and manipulate both 
visually and orally presented information.  Scores from the two subtests below contribute to 
this index score and the index scores are shown in table 6-9. 
1.  Digit span:  The examiner reads a string of digits and asks the examinee to repeat the digits 
in the same order.  The length of the digit string increases by one on each trial. 
2.  Coding:  The examinee is presented a page filled with rows of boxes with a number from 1 
to 9 above each box (in a random sequence), and a blank space below the number. At the top 
of the page is a key with a unique geometric shape beneath each of the numbers, 1 to 9.  Using 
the key, the examinee is asked to fill in the number corresponding to each shape, for as many 
boxes as the examinee can complete in 90 seconds.  
Poorest scores of attention were found in the HF and AF cohort followed by those with HF in 
sinus rhythm.  The healthy control participants had the highest scores of attention. 
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Table 6-9:  Repeatable battery for the assessment of  neuropsychological status  
          attention scores 
 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Mean (SD) 93.8 (14.9) 95.7 (15.3) 90.5 (19.6) 99.8 (18.7) 
 
112.0 (16.4) 
 
Median 97.0 97.0 91.0 100.0 
 
109.0 
 
Range 53.0, 122.0 60.0, 132.0 53.0, 150.0 60.0, 150.0 
 
82.0, 150.0 
 
 
 
6.2.5  RBANS assessment of visuospatial awareness 
 
Visuospatial awareness is assessed based on the examinee’s ability to perceive spatial relations 
and to construct a spatially accurate copy of a drawing.  Scores from the figure copy and line 
orientation subtests contribute to this domains assessment. 
1.  Figure copy:  The examinee is shown a geometric drawing and is asked to make an exact 
copy while the drawing remains on display. 
2.  Line orientation:  The examinee is presented with a drawing that consists of thirteen equal 
lines radiating out from a single point to form a semi-circular fan-shaped pattern.  All lines are 
numbered 1-13.  Below this drawing are two lines that match two of the lines from the array 
above.  The examinee is asked to identify which two lines they match.  Ten trials are given, with 
different sets of test lines on each trial. 
Table 6-10 shows the mean index scores for visuospatial awareness for each of the study 
cohorts.  Healthy control participants had the highest mean score (108.8 ± 19.0) followed by 
patients with non-ischaemic cardiomyopathy (98.0 ± 18.2).  Patients in the CAD control group 
had a mean score of 95.9 ± 20.0 and this was followed by those patients with ischaemic 
cardiomyopathy (90.8 ± 19.6).  Patients with HF and AF had the lowest mean scores in 
visuospatial awareness (87.8 ± 20.7). 
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Table 6-10:  Repeatable battery for the assessment of neuropsychological status 
           visuospatial scores 
 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Mean (SD) 90.8 (19.6) 98.0 (18.2) 87.8 (20.7) 95.9 (20.2) 
 
108.8 (19.0) 
 
Median 89.0 100.0 89.0 92.0 
 
112.0 
 
Range 53.0, 131.0 56.0, 126.0 50.0, 136.0 53.0, 131.0 
 
62.0, 131.0 
 
 
 
6.2.6  RBANS assessment of delayed memory 
 
Delayed memory indicates the examinee’s anterograde memory capacity and is assessed by 
the four individual subtests described below. 
1.  List recall:  The examinee is asked to recall the list of 10 words learned in the list learning 
subtest. 
2.  List recognition:  The examinee is read 20 words (10 words from the list, 10 distractors) 
and asked to indicate whether each word was on the word list. 
3.  Story memory:  The examinee is asked to retell the story they learned earlier. 
4.  Figure recall:  The examinee is asked to draw the figure shown earlier from memory. 
The lowest delayed memory scores were found in patients with HF and AF (84.4 ± 16.2).  
Overall, patients with HF had lower scores than either of the control cohorts.  These results are 
shown in table 6-11. 
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Table 6-11:  Repeatable battery for the assessment of neuropsychological status 
            delayed memory scores 
 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Mean (SD) 88.0 (18.3) 86.4 (18.9) 84.4 (16.2) 90.5 (16.9) 
 
101.9 (14.6) 
 
Median 89.0 88.0 86.0 95.0 
 
102.0 
 
Range 40.0, 129.0 44.0, 123.0 40.0, 123.0 40, 122.0 
 
56.0, 130.0 
 
 
 
6.3  Summary 
 
Chapter 6 has described the results of the repeatable battery for the assessment of 
neuropsychological status in patients with ischaemic and non-ischaemic cardiomyopathy both 
in sinus rhythm and AF, in patients with CAD without HF and in a cohort of age and sex matched 
healthy controls.  The RBANS took approximately 40 minutes to administer and was well 
tolerated by study participants, with all study subjects completing the assessments.   
Although many previously published studies have assessed cognition using the RBANS battery, 
less have used RBANS in the HF population with fewer still assessing cognition with RBANS in 
a defined group of patients with CAD in sinus rhythm with no HF.193  In an attempt to put our 
results into context, the tables below outline the results found in this study compared to other 
published studies.  Table 6-12 displays the key study characteristics and RBANS scores found 
in studies looking at healthy control populations alongside the results from the healthy control 
population in this study.194;195  The results from each RBANS subtest looking at the individual 
domains of cognition were higher (better) for the healthy control population assessed in this 
study when compared to the other two.  In keeping with this pattern, the mean total RBANS 
score from the healthy control population in this study was higher than those from the other 
studies which used RBANS in a healthy control population (106.9 versus 97.9 and 92.4).   
The RBANS manual gives a mean value of 100 for the RBANS total scale score and for each 
individual cognitive domain in the general population.196  Other studies (including the 2 shown 
below) have attempted to extend the original normative data by reporting on RBANS 
performances in community dwelling older adults.  As illustrated in table 6-12, our healthy 
control cohort tended to have higher (better) mean results than the cohorts studies by Duff 
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and Gaita.  The results from our healthy control cohort were therefore more in keeping with 
the original RBANS published normative values used in the RBANS manual. 
Table 6-12:  Repeatable battery for the assessment of neuropsychological status 
            scores for healthy control populations 
RBANS measure Duff et al194 
(N=718) 
Gaita et al195 
(N=90) 
CIHF HC 
(N=87) 
 
 
Age 
 
 
73.3 (5.8) 
 
 
59.7 (13.1) 
 
70.3 (6.7) 
 
Male sex (%) 
 
 
300 (41.8) 
 
 
68 (75.6) 
 
55 (63.2) 
 
Years of education 
 
N/A N/A 14.8 (3.6) 
 
Immediate Memory 
 
95.2 (18.0) 95.6 (17.5) 100.3 (15.6) 
 
Visuospatial 
 
102.7 (17.5) 93.8 (16.7) 108.8 (19.0) 
 
Language 
 
95.4 (11.2) 92.9 (11.4) 100.2 (10.9) 
 
Attention 
 
99.9 (16.1) 101.4 (21.2) 112.0 (16.4) 
 
Delayed memory 
 
98.9 (17.0) 93.5 (11.7) 101.9 (14.6) 
 
Total scale score 
 
97.9 (15.9) 92.4 (15.4) 106.9 (16.4) 
Data are presented as mean (SD) or N (%) 
Only 1 study was found which used RBANS in a cohort of patients with CAD and no HF and 
these results are compared to our cardiac control cohort in table 6-13.193  That study looked at 
82 patients with atherosclerotic vascular disease.  Transthoracic echocardiography was not 
performed as part of the study inclusion criteria; however, these patients had no clinical 
history of HF.  The mean age of study subjects were relatively well matched (68.0 versus 67.5).  
Our study included a higher proportion of males (70.5% versus 57.3%) who on average had 
fewer years of education (13.0 versus 14.5).  With the exception of attention, our cardiac 
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control cohort had lower (poorer) results for each individual domain and total scale score (91.2 
versus 97.0).   
The study population recruited by Moser et al was recruited from the University of Iowa.  In 
the study manuscript there was no documentation of other vascular risk factors such as 
smoking history.  Inherent heterogeneity in the two study populations may explain the 
differences in RBANS scores found.  
Table 6-13:  Repeatable battery for the assessment of neuropsychological status 
            scores in patients with CAD compared to other studies 
RBANS measure 
Moser et al193 
(N=82) 
CIHF CAD CONT 
(N=61) 
 
Age 
 
68.0 (7.7) 67.5 (6.3) 
 
Male sex (%) 
 
47.0 (57.3) 43.0 (70.5) 
 
Years of education 
 
14.5 (3.2) 13.0 (3.3) 
 
Immediate Memory 
 
99.5 (15.4) 87.8 (18.0) 
 
Visuospatial 
 
96.4 (15.1) 95.9 (20.2) 
 
Language 
 
99.7 (10.3) 92.9 (9.2) 
 
Attention 
 
95.7 (14.0) 99.8 (18.7) 
 
Delayed memory 
 
98.9 (13.0) 90.5 (16.9) 
 
Total scale score 
 
97.0 (11.4) 91.2 (15.9) 
Data are presented as mean (SD) or N (%) 
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Table 6-14 compares the scores from the HF population in this study to results from other 
studies assessing cognition in HF patients using RBANS.112;113;142  The other HF studies using 
RBANS to assess cognition did not divide the total HF cohorts into patients with AF, ischaemic 
cardiomyopathy and non-ischaemic cardiomyopathy as I did in this study. Table 6-14 therefore 
shows the scores for the individual HF cohorts as well as the total HF population.   
Our HF population had fewer average years of education compared to the study cohorts 
assessed in the other 3 HF studies.  HF patients recruited into this study had lower (poorer) 
scores in the domains of immediate memory, language, visuospatial and delayed memory when 
compared to the other 3 HF cohorts.  Overall, the total HF cohort in this study had higher 
(better) scores in the domain of attention when compared to the other study populations.  The 
mean total scale score for all HF patients was lower in our study compared to the others (85.4 
versus 94.1, 90.1 and 106.4).   
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RBANS measure 
 
Bauer et al 
(N=80)113 
Bratzke -
Bauer et al112 
(N=47) 
Alosco et al142 
(N=52) 
CIHF 
HF CAD 
(N=70) 
CIHF 
HF no CAD 
(N=51) 
CIHF 
HF AF 
(N=75) 
CIHF 
All HF 
(N=196) 
 
Age  
 
72.0 (12.0) 
 
74.7 (8.9) 
 
 
65.7 (8.9) 
 
71.0 (8.1) 69.4 (7.5) 71.0 (8.6) 70.6 (8.1) 
 
Male sex (%) 
  
51.0 (64.0) 
 
37.0 (79.0) 
 
 
21.0 (40.4) 
 
49.0 (70.0) 32.0 (62.7) 56.0 (74.7) 137.0 (69.9) 
 
Years of education 
 
N/A 
 
13.8 (3.1) 
 
 
16.1 (2.6) 
 
11.6 (3.4) 11.8 (3.7) 12.6 (4.0) 12.0 (3.7) 
 
Immediate Memory 
 
88.5 (16.11) 
 
86.5 (17.8) 
 
 
105.6 (13.5) 
 
85.5 (15.8) 84.9 (17.8) 79.6 (18.0) 83.1 (17.3) 
 
Language 
 
94.1 (10.6) 93.3 (9.1) 103.8 (11.8) 90.0 (10.7) 94.1 (10.5) 89.2 (11.5) 90.8 (11.1) 
 
Attention 
 
89.5 (18.2) 90.2 (19.3) 105.1 (13.3) 93.8 (14.9) 95.7 (15.3) 90.5 (19.6) 93.0 (17.0) 
 
Visuospatial 
 
100.1 (16.7) 102.4 (18.0) 104.8 (11.8) 90.8 (19.6) 98.0 (18.2) 87.8 (20.7) 91.5 (20.0) 
 
Delayed memory 
 
94.2 (15.4) 91.1 (16.8) 103.4 (12.5) 88.0 (18.3) 86.4 (18.9) 84.4 (16.2) 86.2 (17.7) 
 
Total scale score 
 
94.1 (14.1) 90.1 (15.8) 106.4 (12.8) 86.3 (14.3) 89.2 (14.6) 82.0 (16.2) 85.4 (15.3) 
Table 6-14:  Repeatable battery for the assessment of neuropsychological status scores in patients with HF.  Data are presented as means (SD) 
Kl; compared to other studies   
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A number of previous studies have suggested that dementias of differing aetiologies may have 
distinct neuropsychological profiles.  The most common distinction made is between “cortical” 
dementias e.g. Alzheimer’s disease and “subcortical” dementias e.g. vascular dementia.  
Typically, such studies report poor immediate memory in patients with cortical dementia 
compared to those with subcortical dementia being more impaired on tests of attention and 
executive function.197  It is therefore clinically useful to be able to profile individual domains of 
cognition.  The majority of previous studies comparing dementias of differing aetiologies on 
neuropsychological tests have employed experimental tests which often have a number of 
shortcomings including insensitivity of screening tests and lack of population based normative 
data.  The repeatable battery for the assessment of neuropsychological status appears to have 
overcome these obstacles.   
A striking finding was the impact of a co-morbid diagnosis of AF.  Those patients with AF and 
HF had the poorest cognitive outcomes.  Using the clinical qualitative descriptions of RBANS 
over half of patients with HF and AF were categorised as having cognitive impairment on 
RBANS testing.  There is a substantial body of influence linking AF with an increased risk of CI 
with a recent meta-analysis of the literature showing that AF is associated with a higher risk of 
CI with or without a clinical history of stroke.70;198-200  Results from this research support this 
(a clinical history of stroke being a reason for exclusion from this study).  I am not aware of any 
other study that has particularly examined this relationship in a HF cohort, such as I have done. 
Looking at the results of the individual cognitive domains in this study, there appeared to be 
less effect of AF on the domain of memory which perhaps suggests a subcortical rather than 
cortical pattern of CI in these patients.  The adverse effect of AF on cognitive function seen in 
these results could in part be explained by the occurrence of subclinical thromboembolism or 
may simply be a marker of more extensive CVD.  A sub-study of this research project using 
neuroimaging is currently underway to further investigate this hypothesis. 
Even using the more conservative threshold value of <70 to define cognitive impairment I 
found that a substantial proportion of those with HF had evidence of impaired cognition on 
formal neuropsychological testing.  Overall 19% of HF patients were categorised as having 
cognitive impairment in one or more cognitive domain.  This relationship persisted even after 
adjustment for other potential confounding variables including age, sex, education level, co-
morbidity score, medication count and mood disorder.   
RBANS was only one of a number of neuropsychological assessment tools that were employed 
in this study.  Over the next 3 chapters the results of the other cognitive assessment tools will 
be presented. 
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CHAPTER SEVEN 
 
MONTREAL COGNITIVE ASSESSMENT TOOL 
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7.1  Introduction 
 
The second neuropsychological assessment tool to be administered during the return study 
visit was the Montreal Cognitive Assessment Tool (MoCA).  This assessment tool is outlined in 
chapter 3 and a copy of it is shown in appendix VIII.  It was completed by every study subject 
and took approximately 15 minutes to administer. 
The MoCA was initially designed as a cognitive screening tool to assist physicians in detection 
of subtle changes in cognition.  It is a one page 30 point test providing scores for seven 
individual domains of cognition.   The MoCA adds one point for those whose educational level 
is 12 years or less.   
The individual MoCA items are as follows.  The short term memory recall task (5 points) 
involves two learning trials of five nouns and delayed recall after approximately 5 minutes.  
Visuospatial abilities are assessed using a clock drawing task (3 points) and a three-
dimensional cube copy (1 point).  Multiple aspects of executive functions are assessed using an 
alternation task adapted from the Trails making test part B (1 point), a phonemic fluency task 
(1 point), and a two item verbal abstraction task (2 points).  Attention and concentration are 
evaluated using a tapping test (1 point), a serial subtraction task (3 points) and a forward and 
backward digit task (2 points).  Language is assessed using a three-item naming task with 
animals (3 points), repetition of two sentences (2 points) and a fluency test.  Finally orientation 
to time and place is assessed (6 points).   
Following its administration, the MoCA assessment forms were blindly scored by Dr Rosalind 
Lees with a random 20% of the sample re-scored by two independent neuropsychologists (Dr 
Niall Broomfield and Dr John Sharp) for quality assurance.  Any disagreements in marking were 
referred to a third arbitrator (Professor Jonathan Evans). 
In this chapter, the individual scores for each cognitive domain as well as the total MoCA scores 
will be described for each study participant and any difference in results between the five study 
cohorts will be outlined.  Significance testing was only performed for certain pre-specified 
variables.  At the end of this chapter the results presented here will be compared to other 
published results in an attempt to put these results into context. 
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7.2  Results 
 
7.2.1  MoCA total score 
 
  7.2.1.1  MoCA total score results 
 
The Montreal Cognitive Assessment tool has a potential maximum score of 30.  The mean (SD), 
median and range of total scores are presented in table 7-1.  The healthy control participants 
had the highest mean score of 26.8 ± 2.4.  This was followed by the CAD control group with a 
mean score of 24.1 ± 4.1.  Of the three HF groups, those with HF and AF had the lowest mean 
score (22.6 ± 3.3) compared to patients with ischaemic cardiomyopathy in sinus rhythm (23.4 
± 3.7) and those with non-ischaemic cardiomyopathy in sinus rhythm (23.2 ± 4.2).  The mean 
MoCA score for patients in AF receiving anticoagulation was lower than those who were 
treated with antiplatelet therapy only (22.4 ± 3.2 versus 23.2 ± 4.2).  The distribution of total 
MoCA scores demonstrated by group is shown in figure 7-1. 
Table 7-1:  Montreal cognitive assessment tool total scores 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
CAD 
CONT 
(n=61) 
HC 
 
(n=87) 
Mean (SD) 
 
23.4 (3.7) 23.2 (4.2) 22.6 (3.3) 24.1 (4.1) 26.8 (2.4) 
Median 
 
24.0 24.0 23.0 25.0 27.0 
Range 
 
(14.0, 30.0) (12.0, 30.0) (15.0, 29.0) (5.0, 30.0) (19.0, 30.0) 
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Figure 7-1:  Montreal cognitive assessment tool total scores distributions by 
cohort 
Patients with HF were at increased risk of CI when compared to both the healthy control cohort 
(effect estimate, -3.81; 95% confidence interval [CI], -4.66 to -2.96; p<0.0001) and the cardiac 
control cohort (effect estimate, -1.12; 95% CI, -2.25 to 0.01; p=0.0524).  The same adjustment 
models were used as previously described in table 6-2.  Tables 7-2 and 7-3 show the 
relationship between CI and HF after adjustment for potential confounding variables.  Similarly 
to RBANS, the biggest difference in effect estimates was found between adjustment models 1 
and 2 suggesting that the additional factors of co-morbid conditions and education level are 
important variables in the development of CI in HF. 
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Table 7-2: Montreal cognitive assessment tool total scores for HF cohort versus 
healthy controls 
Outcome Model Total N Effect estimate 
(95%CI) 
p-value 
 
All HF vs Healthy controls 
 
 
0 
 
254 
 
-3.81 (-4.66, -2.96) 
 
<0.0001 
 
All HF vs Healthy controls 
 
 
1 
 
254 
 
-3.85 (-4.69, -3.00) 
 
<0.0001 
 
All HF vs Healthy controls 
 
 
2 
 
254 
 
-2.64 (-4.16, -1.11) 
 
0.0008 
 
All HF vs Healthy controls 
 
 
3 
 
242 
 
-2.66 (-4.22, -1.10) 
 
0.001 
 
All HF vs Healthy controls 
 
 
4 
 
239 
 
-2.36 (-4.1, -0.61) 
 
0.0088 
 
Table 7-3:  Montreal cognitive assessment tool total scores for HF cohort versus 
CAD controls 
Outcome Model Total N Effect estimate 
(95%CI) 
p-value 
 
All HF vs CAD controls 
 
 
0 
 
225 
 
-1.12 (-2.25, 0.01) 
 
0.0524 
 
 
All HF vs CAD controls 
 
 
1 
 
225 
 
-0.99 (-2.13, 0.15) 
 
0.0892 
 
 
All HF vs CAD controls 
 
 
2 
 
225 
 
-0.77 (-1.87, 0.34) 
 
0.1763 
 
 
All HF vs CAD controls 
 
 
3 
 
217 
 
-0.75 (-1.88, 0.38) 
 
0.1957 
 
 
All HF vs CAD controls 
 
 
4 
 
213 
 
-0.78 (-2.13, 0.58) 
 
0.2614 
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7.2.1.2  MoCA total score results:  Binary analyses 
 
Depending on the population being studied, a variety of threshold values for MoCA have 
previously been used to define CI in prior studies.201;202  We performed binary analyses using 
3 threshold values to define CI:  25, 26 and 27 as these are the 3 most commonly used cut-off 
values used in clinical practice.  The proportion of each cohort categorised as having CI for each 
of these threshold values are presented in table 7-4. 
Table 7-4:  Binary analyses of Montreal cognitive assessment tool total scores 
Variable 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
MoCA binary 
(<25 vs ≥25) 
   Normal 23 (41.8%) 13 (33.3%) 22 (30.1%) 31 (53.4%) 
 
76 (87.4%) 
 
   Abnormal 32 (58.2%) 26 (66.7%) 51 (69.9%) 27 (46.6%) 
 
11 (12.6%) 
 
MoCA binary 
(<26 vs ≥26) 
   Normal 18 (32.7%) 11 (28.2%) 16 (21.9%) 22 (37.9%) 
 
64 (73.6%) 
 
   Abnormal 37 (67.3%) 28 (71.8%) 57 (78.1%) 36 (62.1%) 
 
23 (26.4%) 
 
MoCA binary  
(<27 vs ≥27) 
   Normal 13 (23.6%) 8 (20.5%) 11 (15.1%) 16 (27.6%) 
 
56 (64.4%) 
 
   Abnormal 42 (76.4%) 31 (79.5%) 62 (84.9%) 42 (72.4%) 
 
31 (35.6%) 
 
Data are presented as N (%) 
Using a cut-off value of <25 to define CI, almost 70% of those patients with HF and AF were 
identified as having CI.  Even when using this more conservative threshold value to represent 
CI, almost 13% of the healthy control cohort were categorised as having some degree of CI.  
This is in comparison to 85% of patients with HF and AF being described as cognitively 
impaired when using a threshold value of <27.  Using this cut-off, over one third of the healthy 
control population were described as cognitively impaired.   
Using the cut-off value of <25, patients with HF were at increased risk of CI when compared to 
both the healthy control cohort (odds ratio, 13.72; 95% confidence interval [CI], 6.67 to 28.23; 
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p<0.0001) and the cardiac control cohort (odds ratio, 2.32; 95% CI, 1.24 to 4.32; p=0.0084).  
Those with AF were more likely to have CI than those patients in sinus rhythm, however this 
difference was not statistically significant (odds ratio, 1.49; 95% CI, 0.77 to 2.88; p=0.2339).   
7.2.2  MoCA individual domain scores 
 
The MoCA questionnaire assesses six individual cognitive domains with the individual tests 
outlined above.  Table 7-5 shows these individual domains of cognition (with the range of 
scores possible) and the mean scores for each cohort. 
Table 7-5:  Montreal cognitive assessment tool individual domain scores 
 All HF 
(N=196) 
HF.CAD 
(N = 70) 
HF.NOCA
D 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CON
T 
(N = 61) 
HC 
(N = 87) 
Visuospatial 
(Range 0-5) 
 
3.7 (1.2) 
 
3.6 (1.2) 
 
3.8 (1.4) 
 
3.6 (1.2) 
 
4.2 (0.9) 
 
4.4 (0.7) 
 
Attention 
(Range 0-6) 
 
4.9 (1.3) 
 
4.9 (1.2) 
 
4.9 (1.4) 
 
4.9 (1.4) 
 
5.2 (1.2) 
 
5.7 (0.7) 
 
Language 
(Range 0-6) 
 
4.9 (1.3) 
 
4.9 (1.4) 
 
4.9 (1.5) 
 
4.9 (1.4) 
 
5.1 (1.2) 
 
5.7 (0.7) 
 
Executive 
function 
(Range 0-2) 
 
1.2 (0.8) 
 
1.1 (0.8) 
 
1.4 (0.8) 
 
1.3 (0.8) 
 
1.3 (0.7) 
 
1.7 (0.6) 
 
Memory 
 (0-5) 
 
2.0 (1.5) 
 
2.4 (1.3) 
 
1.8 (1.5) 
 
1.7 (1.4) 
 
2.2 (1.6) 
 
3.1 (1.2) 
 
Orientation 
(0-6) 
 
5.7 (0.5) 
 
5.7 (0.5) 
 
5.7 (0.7) 
 
5.8 (0.5) 
 
5.7 (0.9) 
 
5.9 (0.5) 
 
Data are presented as mean (SD) 
Patients with HF had lower mean scores than the CAD or healthy control cohorts in all 
individual cognitive domains with the exception of orientation to time and place.  Between the 
three HF cohorts similar scores were found for the domains of attention, language and 
orientation.  The biggest difference between the three HF groups was found in the assessment 
of memory.  Patients with HF and AF had the lowest mean score in this domain (1.7 ± 1.4) 
followed by patients with non-ischaemic cardiomyopathy (1.8 ± 1.5) and ischaemic 
cardiomyopathy (2.4 ± 1.3).  Participants in the healthy control cohort had higher mean scores 
than any other group in all cognitive assessments. 
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7.3  Summary 
The Montreal Cognitive Assessment tool was easy and quick to administer and was well 
tolerated by study participants.  All participants recruited into this study completed the MoCA.  
The MoCA was initially developed to try to identify those patients with mild CI that may have 
previously been missed by other global cognitive assessment tools and has been shown to be 
a sensitive measure of CI in previous studies.161;203  When compared to RBANS, the MoCA failed 
to differentiate between the individual HF cohorts when assessing language and attention.  
Otherwise, a similar pattern was seen in the individual cognitive domains when assessed by 
MoCA and RBANS.  Patients with HF and AF had the poorest results for visuospatial awareness 
and memory when assessed by both the RBANS assessment tool and MoCA.  Those with cardiac 
disease (including HF and CAD) had poorer results than the healthy control cohort in all 
domains with less difference seen between the heart failure and cardiac control groups.   
In this study, using the more conservative cut-off value of <25 in our binary analyses, the MoCA 
identified almost 65% of all patients with HF and 13% of healthy control participants as having 
some degree of CI.  In an attempt to put these results into context, tables 7-6 to 7-8 compare 
total MoCA scores found in this study to other published studies which used MoCA to assess 
cognition. 
The initial validation study by Nasreddine et al, included 90 healthy control volunteers with a 
mean age comparable to that of our healthy control cohort (72.8 versus 70.3).160  A higher 
proportion of the initial validation cohort were female (40% versus 36.8%) with fewer average 
years of education (13.3 versus 14.8).  Despite these differences in study population 
demographics the overall mean MoCA scores were the same in the 2 healthy control cohorts as 
shown in table 7-6. 
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Table 7-6:  Total MoCA scores for healthy control populations 
 
MoCA 
Nasreddine et al160 
(N=90) 
CIHF HC 
(N=87) 
 
 
Age 
 
72.8 (7.0) 70.3 (6.7) 
Male sex (%) 36 (40.0) 55 (63.2) 
 
Years of education 
 
13.3 (3.4) 14.8 (3.6) 
 
Total MoCA 
 
26.9 (2.3) 26.8 (2.4) 
Data are presented as mean (SD) or N(%) 
Only 2 studies using MoCA as a cognitive assessment tool in patients with known CAD and no 
clinical HF were found.161;204  The results from these studies are compared to results from this 
study in table 7-7 below.  The MoCA was administered to 2,653 ethnically diverse subjects as 
part of a population based study of cardiovascular disease in Dallas, USA.204  The majority of 
patients included in that study were African American (52%) with 33% Caucasian, 11% 
Hispanic and 2% classified as “other”.  Although variation in cognition cannot be attributed to 
ethnicity per se there may be other related variables such as quality of education and culture 
which would make it difficult to compare those results directly to the results from this study. 
The second study by McLennan et al administered MoCA to 110 patients attending cardiology 
outpatient clinics in a large tertiary referral hospital in South Australia.161  The patients 
recruited into that study had fewer mean years of total education compared to our cardiac 
control cohort (10.5 versus 13.0) and they had lower total MoCA scores compared to this study 
(22.8 versus 24.1). 
 
 
 
 
164 
 
Table 7-7:  Total MoCA scores in patients with CAD compared to other studies 
MoCA 
Rossetti et al204 
(N=2,653) 
McLennan et al161 
(N=110) 
CIHF 
CAD CONT 
(N=61) 
 
Age 
 
 
50.3 (11.2) 
 
 
67.9 (11.7) 
 
67.5 (6.3) 
 
Male sex (%) 
 
 
1061 (40.0) 
 
 
44 (40.0) 
 
43 (70.5) 
 
Years of education 
 
13.4 (2.5) 
 
10.5 (3.2) 
 
13.0 (3.3) 
Total MoCA 23.4 (4.0) 
 
22.8 (3.8) 
 
24.1 (4.1) 
 
Data are presented as mean (SD) or N(%) 
When MoCA results from this study were compared to MoCA results from other studies 
assessing cognition in HF patients the results were similar.100;121;127   Table 7-8 describes the 
main demographic variables in 3 published HF studies which used the MoCA assessment tool 
and compares these to the HF patients recruited into this study.  As the published studies did 
not divide HF cohorts into those patients with AF, ischaemic cardiomyopathy or non ischaemic 
cardiomyopathy I have included MoCA scores for the total HF population in addition to the 
individual HF cohorts.    It can be seen that those patients with HF and AF had the lowest 
(worst) mean MoCA scores in this study - although this was still comparable with the total 
mean MoCA score found by Harkness et al. 
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Table7-8:  Total MoCA scores in patients with HF compared to other studies 
 
 
 
 
 
 
 
 
 Data are presented as mean (SD) or N(%) 
 
  
 
 
MoCA 
 
Athilingham et 
al121 
(N=90) 
Gallagher et 
al127 
(N=128) 
Harkness et 
al100  
(N=100) 
CIHF 
HF CAD 
(N=70) 
CIHF 
HF no CAD 
(N=51) 
CIHF 
HF AF 
(N=75) 
CIHF 
All HF 
(N=196) 
 
 
Age  
 
62.2 (9.2) 
 
80.7 (11.5) 
 
72.4 (9.8) 71.0 (8.1) 69.4 (7.5) 71.0 (8.6) 70.6 (8.1) 
 
Male sex (%) 
  
59 (65.6) 
 
71 (55.5) 
 
68 (68) 49.0 (70.0) 32.0 (62.7) 56.0 (74.7) 137.0 (69.9) 
 
Years of 
education 
 
13.8 (2.8) N/A N/A 11.6 (3.4) 11.8 (3.7) 12.6 (4.0) 12.0 (3.7) 
 
Total MoCA 
 
24.9 (2.8) 
 
24.6 (3.5) 
 
22.2 (4.5) 23.4 (3.7) 23.2 (4.2) 22.6 (3.3) 23.0 (3.7) 
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CHAPTER EIGHT 
 
MINI MENTAL STATE EXAMINATION 
 
 
167 
 
8.1  Introduction 
The mini-mental state examination (MMSE) is a 30-point questionnaire that has been used 
extensively in clinical and research settings to measure cognitive impairment.  The MMSE has 
been described previously in chapter 3 and a copy of the MMSE is shown in appendix VII. 
The MMSE was the third neuropsychological assessment tool to be administered and took 
approximately 10 minutes for participants to complete.  Although recognised as a measure of 
global cognition, the MMSE questionnaire does categorise tasks according to the particular 
cognitive domain being studied.  Tasks within each individual domain are individually marked 
and then totalled to give a score for each domain.  These scores are then combined to give a 
total score out of 30.  The maximum possible scores for each category are shown in table 8-1.  
Upon completion, the MMSE scores for each domain were totalled to give the overall score by 
Dr Rosalind Lees.  A random 20% of the sample was re-scored by 2 independent consultant 
neuropsychologists (Dr Niall Broomfield and Dr John Sharp) for quality assurance.  Any 
disagreements in marking were referred to a third arbitrator (Professor Jonathan Evans).   
In this chapter, the MMSE scores for each domain will be given in addition to the total scores 
for each study cohort.  Any differences found between the five study cohorts will also be 
described.  Significance testing was only performed for certain pre-specified variables.  At the 
end of this chapter the results presented here will be compared to other published results in 
an attempt to put these results into context. 
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Table 8-1:  Domains assessed by mini mental state examination 
Category 
 
Possible points 
 
Orientation 
10 
 
Learning 
6 
 
Language 
8 
 
Attention and calculation 
5 
 
Concentration 
1 
 
 
8.2  Results 
 
8.2.1  MMSE total score 
 
  8.2.1.1  MMSE total score results 
The mean (SD), median and range of MMSE scores are shown in table 8-2 for each study cohort.  
The healthy control group had the highest mean score of 29.1 ± 1.3 out of a possible maximum 
score of 30.  Patients with non-ischaemic cardiomyopathy, ischaemic cardiomyopathy and the 
CAD control cohort had similar mean scores (27.5 ± 3.1 versus 27.5 ± 2.2 versus 27.9 ± 2.5).  
Those with HF and AF had the lowest mean MMSE scores of 26.9 ± 2.8.   
Table 8-2:  Mini mental state examination total scores 
 
 
 HF 
CAD 
(n=70) 
HF 
no CAD 
(n=51) 
HF 
AF 
(n=75) 
CAD 
CONT 
(n=61) 
HC 
 
(n=87) 
 
Mean (SD) 
 
27.5 (2.2) 27.5 (3.1) 26.9 (2.8) 27.9 (2.5) 29.1 (1.3) 
 
Median 
 
28.0 29.0 27.0 29.0 30.0 
 
Range 
 
(21.0, 30.0) (16.0, 30.0) (17.0, 30.0) (20.0, 30.0) (23.0, 30.0) 
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The same models were used in adjustment as described in table 6-2.  Patients with HF had an 
increased risk of CI detected by MMSE when compared to healthy control participants (effect 
estimate, -1.82; 95% confidence interval [CI], -2.41 to -1.23; p<0.0001).  This statistically 
significant relationship persisted even after adjustment for age and sex.  When co-morbidity 
count and level of education were adjusted for, this statistical significance was lost (p=0.1057).  
Patients with HF were at increased risk of CI when compared to the cardiac control cohort (as 
detected by MMSE), however this association was not statistically significant (0.1002).  These 
results are demonstrated in tables 8-3 and 8-4. 
 
Table 8-3:  Mini Mental State Examination total scores for HF cohort versus 
healthy controls 
Outcome Model Total N Effect estimate (95%CI) p-value 
All HF vs Healthy controls 0 283 -1.82 (-2.41, -1.23) <0.0001 
All HF vs Healthy controls 1 283 -1.79 (-2.39, -1.2) <0.0001 
All HF vs Healthy controls 2 283 -0.89 (-1.98, 0.19) 0.1057 
All HF vs Healthy controls 3 271 -1.3 (-2.36, -0.24) 0.0173 
All HF vs Healthy controls 4 268 -0.9 (-2.04, 0.24) 0.1214 
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Table 8-4:  Mini Mental State Examination total scores for HF cohort versus CAD 
controls 
Outcome Model Total N Effect estimate (95% CI) p-value 
All HF vs CAD controls 0 257 -0.64 (-1.39, 0.12) 0.1002 
All HF vs CAD controls 1 257 -0.51 (-1.27, 0.25) 0.1913 
All HF vs CAD controls 2 257 -0.32 (-1.06, 0.43) 0.4066 
All HF vs CAD controls 3 248 -0.48 (-1.21, 0.25) 0.1984 
All HF vs CAD controls 4 244 -0.5 (-1.34, 0.34) 0.2474 
 
The effect of anticoagulation on MMSE scores and the overall distribution of scores are shown 
in figures 8-1 and 8.2. 
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Figure 8-1:  Mini mental state examination total scores for the heart failure and 
atrial fibrillation cohort 
 
Figure 8-2:  Mini mental state examination total scores distributions by cohort 
8.2.1.2  MMSE total score results:  Binary analyses 
In addition to ordinal analysis, total MMSE scores were also analysed using the following three 
cut-off values taken to represent cognitive impairment:  26, 27 and 28 out of 30.  These 3 cut-
off values were chosen as they are the cut-off values most commonly used in clinical practice.  
The proportion of subjects identified as having impaired cognition varied significantly 
depending on which value was used.  These results are shown in table 8-5. 
When a threshold value of 28 was used, over half of those patients with HF and AF were 
categorised as having CI (53.3%) compared to a proportion of 29.3% classified as cognitively 
impaired when the lower cut-off of <26 was used.  Using the cut-off value of <26, patients with 
HF were at increased risk of CI when compared to the healthy control cohort (odds ratio, 13.01; 
95% confidence interval [CI], 3.08 to 55.03; p=0.0005).  This cut-off score classified 2.3% of the 
healthy control cohort as having CI with a higher proportion of the CAD control group 
showing impairment of cognition (16.4%). 
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Table 8-5:  Binary analyses of mini mental state examination total scores 
Variable 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
MMSE binary 
(<26 vs ≥26) 
   Normal 57 (81.4%) 39 (76.5%) 53 (70.7%) 51 (83.6%) 
 
85 (97.7%) 
 
   Abnormal 13 (18.6%) 12 (23.5%) 22 (29.3%) 10 (16.4%) 
 
2 (2.3%) 
 
MMSE binary 
(<27 vs ≥27) 
   Normal 53 (75.7%) 37 (72.5%) 46 (61.3%) 44 (72.1%) 
 
83 (95.4%) 
 
   Abnormal 17 (24.3%) 14 (27.5%) 29 (38.7%) 17 (27.9%) 
 
4 (4.6%) 
 
MMSE binary 
(<28 vs ≥28) 
   Normal 41 (58.6%) 33 (64.7%) 35 (46.7%) 42 (68.9%) 
 
77 (88.5%) 
 
   Abnormal 29 (41.4%) 18 (35.3%) 40 (53.3%) 19 (31.1%) 
 
10 (11.5%) 
 
Data are presented as N (%) 
8.2.2  MMSE individual domain scores 
Patients with HF had the lowest mean scores in subtests assessing attention and calculation – 
particularly patients with both HF and AF (3.9 ± 1.4).  Patients with CAD – either with or 
without HF also had reduced scores in this domain (4.2 ± 1.4), followed by those with non-
ischaemic cardiomyopathy (4.4 ± 1.4).  Similar scores were found in all domains between 
patients with CAD regardless of whether or not they had HF.  Performance in orientation, 
concentration and language were similar across all five cohorts.  These results are shown in 
table 8-6. 
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Table 8-6:  Mini mental state examination individual domain scores 
 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Orientation 
(0-10) 
9.6 (0.7) 9.5 (1.0) 9.6 (0.8) 9.6 (1.0) 
 
9.9 (0.4) 
 
Learning 
(0-6) 
5.3 (0.9) 5.2 (1.2) 5.0 (1.1) 5.3 (0.9) 
 
5.6 (0.8) 
 
Language 
(0-8) 
7.7 (0.6) 7.7 (0.8) 7.6 (0.8) 7.8 (0.5) 
 
7.9 (0.4) 
 
Attention and 
calculation 
(0-5) 
4.2 (1.4) 4.4 (1.4) 3.9 (1.4) 4.2 (1.4) 
 
4.7 (0.8) 
 
Concentration 
(0-1) 
0.8 (0.4) 0.8 (0.4) 0.8 (0.4) 0.9 (0.3) 
 
1.0 (0.2) 
 
Data are presented as mean (SD) 
8.3  Summary 
 
The MMSE defined lower proportions of participants as having mild CI compared to the other 
global cognitive assessment tools (RBANS and MoCA) – this is however affected by the cut-off 
values used in each cognitive assessment tool.  This assessment tool was quick and easy to 
administer and was well tolerated by study subjects.   
In an attempt to put these results into context, tables 8-7 to 8-9 compare the MMSE results 
from this study to MMSE results from other published studies. 
The original study by Folstein et al in 1974 administered MMSE to 63 healthy control 
participants in addition to their disease cohorts.155  This cohort was recruited from New York, 
USA and had a mean age of 73.9 years with the majority being female (57%).  The mean total 
MMSE score from this cohort was lower than the mean MMSE for our healthy control cohort 
(27.6 versus 29.1) however no information was available regarding the education level of the 
population studied.   
In an attempt to describe the population distribution of performance on the MMSE in a 
representative UK population, Huppert et al administered MMSE to 3,035 healthy 
participants.205  The mean total MMSE in that cohort was 28.3 (1.4) – a value slightly lower than 
the mean MMSE result in our sample.  Unfortunately however, no data were available on mean 
years of education for that sample for comparison. 
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Table 8-7:  Total MMSE scores for healthy control populations 
MMSE Huppert et al205 
(N=3,035) 
Folstein et al155 
(N=63) 
CIHF HC 
(N=87) 
 
 
Age 
 
72.4 
 
73.9 70.3 (6.7) 
 
Male sex (%) 
 
 
1328 (44) 
 
 
27 (43) 55 (63.2) 
 
Years of education 
 
N/A 
 
N/A 14.8 (3.6) 
 
Total MMSE 
 
28.3 (1.4) 
 
27.6 (1.7) 29.1 (1.3) 
Data are presented as mean (SD) or N(%) 
Two cross sectional studies were found which assessed cognition in patients with CAD and no 
HF using the MMSE.206;207  Similar total MMSE scores were seen in our cardiac control cohort 
as was found in these 2 studies as shown in table 8-8 below. 
 
Table 8-8:  Total MMSE scores in patients with CAD compared to other studies 
MMSE 
Swardfager et 
al207 
(N=81) 
Freiheit et al206 
(N=248) 
CIHF 
CAD CONT 
(N=61) 
 
Age 
 
62.5 (11) 
 
70.1 (5.8) 
 
67.5 (6.3) 
 
Male sex (%) 
 
 
70 (86.4) 
 
 
186 (75) 
 
43 (70.5) 
 
Years of education 
 
16.5 (3.4) 
 
13.2 (3.8) 
 
13.0 (3.3) 
Total MMSE 28.9 (1.7) 
 
27.6 (0.25) 
 
27.9 (2.5) 
 
Data are presented as mean (SD) or N(%) 
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MMSE has been employed in several HF studies to date as a method of assessing 
cognition.110;112;208  Table 8-9 shows results from some of these published studies and compares 
the total MMSE scores from those studies to the results found in this study.  As previous studies 
have not looked at individual HF cohorts e.g. HF with AF, non ischaemic cardiomyopathy, 
ischaemic cardiomyopathy results are presented from our total HF population in addition to 
each of the separate HF cohorts.  The mean MMSE from our total HF cohort was similar to the 
mean scores from 2 of these studies (27.2 versus 27.6)110;112 with the third total mean MMSE 
score being more in keeping with the mean MMSE from our HF plus AF cohort (26.9).208 
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 Table 8-9:  Total MMSE scores in patients with HF compared to other studies 
 
 
 
 
 
 
 
 
 
 
 Data are presented as mean (SD) or N (%)
MMSE 
 
Karlsson et 
al208 
(N=74) 
Bratzke -
Bauer et 
al112 
(N=47) 
Pressler et 
al110  
(N=249) 
CIHF 
HF CAD 
(N=70) 
CIHF 
HF no CAD 
(N=51) 
CIHF 
HF AF 
(N=75) 
CIHF 
All HF 
(N=196) 
 
 
Age  
 
 
76.0 (7.0) 
 
74.7 (8.9) 
 
 
62.9 (14.6) 71.0 (8.1) 69.4 (7.5) 71.0 (8.6) 70.6 (8.1) 
 
Male sex (%) 
  
 
41 (55.0) 
 
37.0 (79.0) 
 
 
158 (63.0) 49.0 (70.0) 32.0 (62.7) 56.0 (74.7) 137.0 (69.9) 
 
Years of 
education 
 
N/A 
 
13.8 (3.1) 
 
12.9 (2.8) 11.6 (3.4) 11.8 (3.7) 12.6 (4.0) 12.0 (3.7) 
 
Total MMSE 
 
 
26.9 (3.0) 
 
27.6 (1.9) 
 
27.6 (2.2) 27.5 (2.2) 27.5 (3.1) 26.9 (2.8) 27.2 (2.7) 
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CHAPTER NINE 
 
ADDITIONAL MEASURES OF EXECUTIVE 
FUNCTION 
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9.1  Introduction 
 
The domain of “executive function” is an umbrella term for cognitive processes that regulate, 
control and manage other cognitive processes such as planning, problem solving, mental 
flexibility, and initiating and monitoring of actions.52  Executive function is thought to be 
particularly important in patients with HF as this determines how a person can recognise novel 
situations and adapt to them appropriately. Neuropsychological assessments of executive 
function have been underused in studies of CI in HF to date.  Although executive function is 
assessed as part of the RBANS, additional measures of executive function including trails 
making tests parts A & B, controlled oral word association, Wechsler letter number sequencing, 
animal naming test and frontal assessment battery were included in this study to attempt to 
address this gap.   
The results from each of these additional measures of executive function are discussed in turn 
below.  Results of each individual test are presented in the order in which they were 
administered at return visit 1.  Statistical significance testing was only performed for certain 
pre-specified variables. 
9.2  Results   
 
9.2.1 Trails making test part A 
 
Trails making test A is shown in appendix X.  In this assessment of executive function, 
participants are asked to draw lines sequentially connecting 25 encircled numbers distributed 
on a sheet of paper.  The exercise is timed and the final score is the amount of time taken to 
complete the task.  This is the first of the additional “bolt-on” measures of executive function 
that each study subject was asked to complete.   
Normative values for this assessment tool have previously been discussed in chapter 3.  
Following completion of the task, scores were compared with published normative data and 
participants were stratified into percentiles based on their performance.  These results are 
shown in tables 9-1 and 9-2. 
All participants included in this study completed Trails making test part A.  There was a wide 
variation in the time taken to complete the test (ranging from 16 to 180 seconds).  The healthy 
control cohort had the lowest mean time of completion (36.3 ± 13.9 seconds) followed by the 
CAD cohort (39.1 ± 17.7 seconds).  Patients with HF took longer to complete this task.  Of the 
three HF groups those with AF took the longest (58.5 ± 27.7 seconds) followed by those with 
CAD (55.4 ± 23.4 seconds).  Patients with AF receiving formal anticoagulation (with either 
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warfarin or a NOAC) had a mean duration of 60.8 ± 28.7 seconds compared to 46.1 ± 17.9 
seconds in patients not receiving anticoagulation.  Patients with HF and no CAD had the 
shortest mean duration of the three HF groups (49.2 ± 21.2 seconds).  The majority of patients 
with HF fell below the 50th percentile when compared to published normative data (table 9-2). 
 
Table 9-1:  Results for trails making test part A 
 HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
 
Mean (SD) 
 
55.4 (23.4) 
 
49.2 (21.2) 
 
58.5 (27.7) 
 
39.1 (17.7) 
 
36.3 (13.9) 
 
 
Median  
 
52 
 
43 
 
52 
 
33 
 
34 
 
 
Range 
 
24, 140 
 
19, 110 
 
19, 180 
 
18, 90 
 
16, 120 
 
Data are presented in seconds. 
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Table 9-2:  Trails making test part A results by percentile 
 HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Percentile 
0-10 29 (41.4) 15 (29.4) 29 (39.2) 12 (20.0) 
 
3 (3.4) 
 
10-20 9 (12.9) 4 (7.8) 11 (14.9) 7 (11.7) 
 
11 (12.6) 
 
20-30 4 (5.7) 6 (11.8) 7 (9.5) 4 (6.7) 
 
9 (10.3) 
 
30-40 4 (5.7) 6 (11.8) 5 (6.8) 3 (5.0) 
 
6 (6.9) 
 
40-50 5 (7.1) 4 (7.8) 4 (5.4) 3 (5.0) 
 
12 (13.8) 
 
50-60 7 (10.0) 4 (7.8) 4 (5.4) 5 (8.3) 
 
11 (12.6) 
 
60-70 3 (4.3) 4 (7.8) 2 (2.7) 3 (5.0) 
 
4 (4.6) 
 
70-80 1 (1.4) 3 (5.9) 3 (4.1) 4 (6.7) 
 
11 (12.6) 
 
80-90 6 (8.6) 2 (3.9) 3 (4.1) 9 (15.0) 
 
7 (8.0) 
 
90-100 2 (2.9) 3 (5.9) 6 (8.1) 10 (16.7) 
 
13 (14.9) 
 
Data are presented as N (%) 
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9.2.2  Trails making test part B 
 
Trails making test part B is similar to Trails making test part A, however they are separate 
cognitive assessment tools and can be used independently of each other.  Trails making test 
part B involves drawing sequential lines alternating between numbers and letters and is shown 
in appendix X.  The final score is the time taken to complete the test (seconds). 
Participants were asked to complete Trails making test part B after they had completed part A.  
Only 2 participants did not complete this task - one patient with HF and AF and one patient 
with non-ischemic cardiomyopathy.  These were both due to difficulties visualising the 
assessment form.  The mean (SD), median and range of results are shown in table 9-3.  
Individual scores were then compared to published normative values and participants were 
classified into percentiles based on their performance.172  The number of participants in each 
percentile is shown in table 9-4.  
Patients with HF and AF on average took longer to complete this task than those participants 
in the other four cohorts.  The average time taken to complete Trails B was 144.2 ± 67.7 
seconds for those with HF and AF compared to 136.8 ± 67.7 seconds and 110.6 ± 57.6 seconds 
in patients with ischaemic cardiomyopathy and non-ischaemic cardiomyopathy, respectively.  
In patients with AF, those receiving anticoagulation with either warfarin or a NOAC had a 
longer mean time of completion (151.2 ±68.3 seconds) compared to those on antiplatelet 
therapy only (107.6 ± 52.7 seconds).   
The healthy control cohort had the shortest average time of completion (77.9 ± 30.2 seconds) 
followed by the CAD control cohort (97.4 ± 56.2 seconds).  A large proportion of patients with 
HF fell below the 10th percentile when compared with published normative data (table 9-4). 
In summary, results for trail making test B followed the same pattern as those for trail making 
test A with patients with both HF and AF having the poorest performance in these tests of 
executive function. 
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Table 9-3:  Results for trails making test part B  
 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 50) 
HF.AF 
(N = 74) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Mean (SD) 136.8 (67.7) 110.6 (57.6) 144.2 (67.7) 97.4 (56.2) 
 
77.9 (30.2) 
 
Median 120.0 101.0 125.5 79.0 
 
73.0 
 
Range 39, 320 41, 280 47, 296 37, 300 
 
31, 180 
 
Data are presented in seconds. 
Table 9-4:  Trails making test part B results by percentile 
 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 50) 
HF.AF 
(N = 74) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Percentile 
0-10 28 (40) 17 (34) 34 (47) 17 (28) 
 
13 (15) 
 
10-20 5 (7) 3 (6) 12 (16) 6 (10) 
 
2 (2) 
 
20-30 8 (11) 2 (4) 4 (6) 5 (8) 
 
6 (7) 
 
30-40 4 (6) 3 (6) 2 (3) 4 (7) 
 
4 (5) 
 
40-50 1 (1) 4 (8) 4 (6) 2 (3) 
 
8 (9) 
 
50-60 5 (7) 1 (2) 2 (3) 4 (7) 
 
3 (3) 
 
60-70 5 (7) 5 (10) 4 (6) 3 (5) 
 
13 (15) 
 
70-80 2 (3) 6 (12) 3 (4) 9 (15) 
 
7 (8) 
 
80-90 4 (6) 2 (4) 4 (6) 1 (2) 
 
6 (7) 
90-100 8 (11) 7 (14) 4 (6) 9 (15) 
25 (29) 
 
Data are presented as N (%) 
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Previous studies assessing CI in HF have also used trails making tests A and B as a measure of 
executive function.  In an attempt to put our results into context, tables 9-5 and 9-6 compare 
results from trails making tests A & B from this study to other published studies.   
Hoth et al performed the trails making test on 31 patients with CAD and no HF and 31 patients 
with HF (of any aetiology).209  The group found those patients with CAD (and no HF) had faster 
(better) completion times than those with HF for both trails making tests A and B – this is 
consistent with our findings.  Although the results from that study were similar to ours, 
patients recruited into our CAD control group had slightly longer (worse) results from Trails A 
and slightly faster (better) for Trails B. 
Table 9-5:  Results for Trails making tests A & B in CAD cohorts  
 
Trails A & B 
Hoth et al209 
CAD group 
 (N=31) 
CIHF 
CAD CONT 
(N=61) 
 
Age 
 
68.9 (8.5) 
 
 
67.5 (6.3) 
 
 
Male sex (%) 14 (45) 
 
43 (70.5) 
 
 
Years of education 
 
13.1 (2.7) 
 
13.0 (3.3) 
 
 
Trails A (s) 
 
34.7 (10.4) 39.1 (17.7) 
 
Trails B (s) 
 
99.7 (32.9) 97.4 (56.2) 
Data are presented as mean (SD) or N (%) 
A study by Bratzke-Bauer et al also used trails making test as a measure of executive function 
in HF patients.112  These results are displayed in table 9-6.  Although their results were similar 
to the results from this study, on average HF patients enrolled into this study took longer to 
complete trails A (worse) and a shorter time to complete trails B (better) compared to those in 
the Bratzke-Bauer study. 
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Table 9-6:  Results for Trails making tests A & B in HF cohorts 
 
Trails A & B 
Bratzke -Bauer et 
al112 
(N=47) 
Hoth et al209 
(N=31) 
CIHF 
All HF 
(N=196) 
 
Age 
 
74.7 (8.9) 
 
 
69.1 (8.5) 
 
70.6 (8.1) 
 
Male sex (%) 
 
37.0 (79.0) 
 
 
17.0 (54.0) 
 
137.0 (69.9) 
 
Years of education 
 
13.8 (3.1) 
 
 
12.9 (2.8) 
 
12.0 (3.7) 
 
Trails A (s) 
 
52.5 (24.2) 45.9 (28.8) 
 
55.0 (24.8) 
 
 
Trails B (s) 
 
134.0 (68.5) 143.2 (79.8) 
 
132.9 (66.3) 
 
Data are presented as mean (SD) or N (%) 
9.2.3  Controlled oral word association test 
 
The controlled oral word association test (COWA) is a test of phonemic verbal fluency and 
executive function.  This assessment tool is outlined in chapter 3 and the record sheet is shown 
in appendix XII. The number of words beginning with the same designated letter said by the 
participant in one minute is recorded.  The letters F, A and S were used in this study and the 
number of words for each letter were added together to give a total number of words given in 
3 minutes.  All study participants completed this task. 
Table 9-7 shows the mean (SD), median and range of total number of words given in three 
minutes in each of the study cohorts.  There was a large range in the number of words given in 
3 minutes (ranging from 5 to 71).  Patients with HF and AF had the lowest mean number of 
words (32 ± 12) and the healthy control participants had the highest (43 ± 12).  Patients with 
AF on anticoagulation had the poorest performance with an overall average of 31 ± 11 words 
compared to an average of 40 ± 14 words for those patients on antiplatelet therapy only. 
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Table 9-7:  Results of controlled oral word association test 
 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Mean (SD) 34 (11) 35 (12) 32 (12) 38 (14) 
 
43 (12) 
 
Median 32 34 31 37 
 
43 
 
Range 14, 60 13, 61 5, 64 8, 67 
 
13, 71 
 
Data are presented as number of words given in 3 minutes 
On review of the current literature, 2 studies were found which used COWA in cognitive 
assessment of HF patients.110;209  The results from these studies are shown in table 9-8 
alongside results for the total HF cohort from this study for comparison.  In these other 
published HF studies, the HF cohort was not divided according to underlying aetiology of HF 
nor presence of AF and so these results have been compared to the total HF cohort in this study.   
The total HF cohort in this study had a higher mean total number of words given in 3 minutes 
compared to the other studies suggesting an overall better performance on this assessment 
tool.  This was despite having a higher mean age of participant with lower average years of 
education. 
Table 9-8:  Results of controlled oral word association test in this study 
compared to other published HF studies 
 
COWA Hoth et al
209 
(N=31) 
Pressler et al110 
(N=249) 
CIHF 
All HF 
(N=196) 
 
Age 
 
69.1 (8.5) 62.9 (14.6) 70.6 (8.1) 
 
Male sex (%) 
 
17 (54.0) 158 (63.0) 137.0 (69.9) 
 
Years of education 
 
12.9 (2.8) 12.9 (2.8) 12.0 (3.7) 
 
COWA 
 
30.3 (13.1) 30.1 (11.9) 33.6 (11.8) 
Data are presented in mean (SD) or N (%) 
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For each participant, the reference age and education band into which they appeared was 
determined using published normative values.175  The total COWA scores for each individual 
were then compared to the relevant reference tables and the percentile into which they 
appeared was determined.  The assigned percentiles were compared across all subjects and 
are shown in table 9-9. 
Table 9-9:  Controlled oral word association test results by percentile  
 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Percentile 
0-10 10 (15) 7 (14) 13 (18) 9 (15) 
 
6 (7) 
 
10-20 6 (9) 4 (8) 8 (11) 2 (3) 
 
6 (7) 
 
20-30 3 (4) 6 (12) 8 (11) 9 (15) 
 
3 (4) 
 
30-40 11 (16) 6 (12) 8 (11) 9 (15) 
 
3 (4) 
 
40-50 6 (9) 5 (10) 4 (6) 9 (15) 
 
7 (8) 
 
50-60 7 (10) 6 (12) 7 (10) 7 (12) 
 
13 (15) 
 
60-70 9 (13) 5 (10) 9 (13) 5 (8) 
 
9 (11) 
 
70-80 4 (6) 4 (8) 3 (4) 2 (3) 
 
7 (8) 
 
80-90 4 (6) 6 (12) 8 (11) 5 (8) 
 
15 (18) 
 
90-100 9 (13) 6 (12) 4 (6 ) 9 (15) 
 
15 (18) 
 
Data are presented as N (%) 
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9.2.4  Wechsler letter number sequencing 
 
The Wechsler letter number sequencing test assesses attention and executive function.  This is 
frequently used as part of the Wechsler Adult Intelligence Scale (WAIS) which is composed of 
15 individual subtests.  These individual subtests can then be totalled together to give an 
overall score.  On review of current literature, no prior HF studies were found which used this 
test as a method to assess cognition. 
In this test, examinees are read a series of numbers and letters and are asked to arrange these 
into numerical and alphabetical order before repeating them back to the examiner.  A copy of 
the Wechsler letter number sequencing is shown in appendix VII.  There is a maximum total 
score of 30.   
Table 9-10 shows the mean (SD), median and range in results for each study cohort.  There was 
a striking reduction in the mean and median results in patients with HF for this particular test 
compared to both the cardiac and healthy control cohorts.  All study participants completed 
this assessment tool.  Total scores ranged from 0 to 25 out of 30.  The lowest mean scores were 
found in patient with HF and AF.   
Table 9-10:  Results of Wechsler letter number sequencing test 
 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Mean (SD) 10.9 (6.1) 12.1 (6.7) 10.2 (6.3) 14.4 (5.9) 
 
17.2 (5.1) 
 
Median 12 13 10 17 
 
18 
 
Range 0, 22 0, 22 0, 22 1, 24 
 
1, 25 
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9.2.5  Animal naming test 
 
The animal naming test assesses executive function using verbal fluency.  Individuals are asked 
to generate as many names as possible from a specified category in one minute.  The category 
chosen in this study was animals.  This assessment tool is discussed in more detail in chapter 
3 and a copy of the scoring sheet is shown in appendix VII. 
The minimum number of animal names given in one minute was 3 and the maximum was 30.  
Overall, the healthy control cohort had the highest mean score (19.2 ± 4.2) followed by the CAD 
control cohort (17.8 ± 4.6).  There was a striking reduction in median scores of HF patients 
compared to the cardiac and healthy control cohorts in this particular test.  Of the 3 HF cohorts, 
those with AF had the lowest mean score (14.4 ± 4.8), followed by those with ischaemic 
cardiomyopathy (14.9 ± 4.8) and non-ischaemic cardiomyopathy (15.1 ± 4.8).  Individual 
scores were then compared to published normative data and participants were categorised 
into percentiles.175  These results are shown in tables 9-11 and 9-12. 
Table 9-11:  Results of animal naming test 
 HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Mean (SD) 14.9 (4.8) 15.1 (4.8) 14.4 (4.8) 17.8 (4.6) 
 
19.2 (4.2) 
 
Median 15 14 14 19 
 
20 
 
Range 3, 30 7, 25 3, 25 9, 30 
 
7, 29 
 
Data are presented as number of animals given in 1 minute 
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Table 9-12:  Animal naming test results by percentile 
 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Percentile 
0-10 14 (20) 12 (24) 22 (31) 7 (12) 
 
5 (6) 
 
10-25 13 (19) 5 (10) 15 (21) 7 (12) 
 
10 (12) 
 
25-50 14 (20) 15 (30) 7 (10) 9 (15) 
 
12 (14) 
 
50-75 16 (23) 6 (12) 14 (19) 17 (28) 
 
18 (21) 
 
75-90 6 (9) 8 (16) 9 (13) 16 (27) 
 
27 (32) 
 
90-100 6 (9) 4 (8) 5 (7) 4 (7) 
 
13 (15) 
 
Data are presented as N (%) 
On review of current literature, one previous study was found that used the animal naming test 
in the cognitive assessment of HF patients.210  The animal naming test results from that study 
are compared to the results from this study in table 9-13.  The HF patients recruited into this 
study were on average older with fewer years of education compared to the cohort studied by 
Garcia et al.  By comparison, the total HF cohort in this study had a lower mean number of 
animals (14.8 versus 19.9) suggesting a poorer performance on this assessment tool in our 
study cohort. 
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Table 9-13:  Animal naming test results compared to other HF studies 
 
Animal naming test Garcia et al
210 
(N=41) 
CIHF 
All HF 
(N=196) 
 
Age 
 
68.3 (8.4) 70.6 (8.1) 
 
Male sex (%) 
 
27.0 (66.0) 137.0 (69.9) 
 
Years of education 
 
13.6 (3.0) 12.0 (3.7) 
 
Number of animals 
 
19.9 (4.99) 14.8 (4.8) 
Data are presented as mean (SD) or N (%) 
9.2.6  Frontal assessment battery 
 
The frontal assessment battery (FAB) was the final additional measure of executive function 
that was given to study participants.  It took approximately 10 minutes to administer and all 
study participants completed this assessment tool.  The FAB is described in chapter 3 and a 
copy of the questionnaire is shown in appendix XII.  The results of the raw scores are presented 
in table 9-14.  There was a similar range in results found between all study cohorts with similar 
mean and median results between groups.   
In addition to the ordinal analysis a binary analysis was also performed.  A cut-off score of <12 
was taken as being abnormal.  This is based on previously published data.176  Based on results 
from this analysis, 17% of those with patients with HF and AF were categorised as cognitively 
impaired compared to 3% of the healthy control cohort.  
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Table 9-14:  Results of frontal assessment battery 
 
HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 51) 
HF.AF 
(N = 75) 
CAD.CONT 
(N = 61) 
HC 
(N = 87) 
Mean (SD) 15 (3) 16 (3) 15 (3) 16 (2) 
 
17 (2) 
 
Median 16 17 15 17 
 
17 
 
Range 6, 18 9, 18 6, 18 8, 18 
 
7, 18 
 
N (%) with 
score <12 
9 (13) 4 (8) 13 (17) 3 (5) 
 
3 (3) 
 
 
On review of current literature, only one previous study was found that used the frontal 
assessment battery in the cognitive assessment of HF patients.210  The results from that study 
are shown in table 9-15.  Results from the HF cohort recruited into this study were similar to 
the FAB results from the study by Garcia et al (15.0 versus 15.9). 
 
Table 9-15:  Frontal assessment battery results compared to other HF studies 
 
Frontal assessment 
battery 
Garcia et al210 
(N=41) 
CIHF 
All HF 
(N=196) 
 
Age 
 
68.3 (8.4) 70.6 (8.1) 
 
Male sex (%) 
 
27.0 (66.0) 137.0 (69.9) 
 
Years of education 
 
13.6 (3.0) 12.0 (3.7) 
 
Frontal assessment 
battery score 
15.9 (2.46) 15.0 (2.8) 
Data are presented as mean (SD) or N (%) 
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9.3  Summary 
 
This chapter described the main findings from the additional measures of executive function 
used in this study.  In addition to the three global cognitive assessment tools, six additional 
measures of executive function were employed.  These additional measures were added as 
executive function has been understudied in previous studies looking at cognitive impairment 
in heart failure.  In general, these additional tests were well tolerated and completed by the 
majority of study participants. 
The study of executive function is relevant to the clinical management of patients with HF.  
Central to the treatment of chronic heart failure is complex pharmacological therapy requiring 
careful monitoring in the community which often involves patient self-monitoring for signs 
indicative of clinical decline e.g. weight gain.  It is important that patients can recognise a 
change in their clinical condition, process this information and react to it accordingly e.g. 
reduce their fluid intake.  This ability may be jeopardised if patients have impaired executive 
function. 
With the exception of the frontal assessment battery, the other 5 tests of executive function 
showed the same pattern in their results.  .  Patients with both HF and AF had the poorest 
overall results suggesting the greatest degree of executive dysfunction.  Of the patients with 
AF, those on treatment with formal anticoagulation (either warfarin or a NOAC) had lower 
scores than those who were not.  All patients included in this study who had a history of AF 
and who were not formally anticoagulated, were receiving treatment with an antiplatelet 
agent.    .  Patients with HF had poorer scores than either the ischaemic heart disease control 
cohort or the age and sex matched healthy control participants.   
Of the other HF cohorts (ischaemic cardiomyopathy in sinus rhythm and non-ischaemic 
cardiomyopathy in sinus rhythm), those with a confirmed diagnosis of CAD had poorer 
performances in each of the six individual neuropsychological tests.  Patients with no clinical 
history of HF and a preserved ejection fraction with a history of CAD had poorer performances 
in each of these tests than age and sex matched healthy controls but still had better results than 
patients with HF.  Of the six tests employed, the animal naming test and the Wechsler letter 
number sequencing test showed the greatest difference in scores between patients with HF 
(poorer scores) and those with no HF.   
The frontal assessment battery showed a different pattern of results.  In this subtest, there was 
less of a difference seen between patients with HF and AF versus ischaemic cardiomyopathy.  
This test appeared to differentiate more between patients with ischaemic cardiomyopathy 
versus non ischaemic cardiomyopathy. 
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The results discussed in this chapter confirm that patients with HF have greater executive 
dysfunction compared to those patients without HF.  Apart from one of the tests employed all 
of these cognitive assessment tools showed the same pattern of results with the combination 
of HF and AF resulting in the greatest degree of impairment compared to patients in sinus 
rhythm.  This is clinically relevant as we know that executive function is the broad description 
of a set of processes involved in higher cortical function, particularly in goal formation, self-
monitoring and planning – all of which are involved in a patients ability to recognise changes 
in their clinical conditions and react appropriately.   
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Chapter 10:  Other measures 
10.1 Introduction  
 
In addition to the previously discussed measures of cognition, several other questionnaires 
were also given to study participants.  These questionnaires were given at return study visit 1 
and patients returned these by post once completed.  Results from each of these are discussed 
in turn below. 
10.2 Results 
 
10.2.1 Kansas city cardiomyopathy questionnaire 
 
The KCCQ is a commonly used disease specific health related quality of life questionnaire and 
so was only applicable to patients with HF included in this study.  The KCCQ is described in 
more detail in chapter 3 and shown in appendix XVII. 
Out of 196 patients with HF 177 completed and returned the KCCQ.  The results of the overall 
KCCQ summary score, clinical summary score and their individual components are presented 
in table 10-1. 
The overall summary score has a maximum score of 100 and assesses functional ability.  A low 
score reflects poor self-reported levels of functioning.  The clinical summary score assesses 
symptom burden and has a maximum value of 100.  Low scores indicate a high burden of 
symptoms.   
Patients with HF and CAD reported the highest burden of symptoms and poorest level of 
functioning, followed by those with HF and AF.  Patients with non-ischaemic cardiomyopathy 
reported fewest symptoms and the best levels of functional ability.  Patients reporting the 
highest symptom burden and poorest functional ability also reported most social limitation.  
Despite this however, patients with ischaemic cardiomyopathy had the highest scores for 
questions pertaining to quality of life and self-efficiency. 
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Table 10-1:  Results of Kansas city cardiomyopathy questionnaire 
 HF.CAD 
(N = 65) 
HF.NOCAD 
(N = 45) 
HF.AF 
(N = 67) 
KCCQ physical 
(0-100) 
54.9 (28.4) 
 
57.8 (30.2) 
 
55.1 (25.5) 
KCCQ symptom 
(0-100)  
67.6 (25.9) 
 
70.3 (26.2) 
 
70.6 (23.7) 
KCCQ self-efficacy 
(0-100) 
76.5 (21.9) 
 
73.9 (22.3) 
 
77.1 (23.2) 
KCCQ quality of life 
(0-100) 
60.9 (25.8) 
 
59.6 (28.4) 
 
58.1 (25.4) 
KCCQ social limitation 
(0-100) 
50.8 (27.4) 
 
54.9 (32.7) 
 
55.5 (31.9) 
KCCQ clinical summary 
score 
(0-100) 
61.3 (24.8) 
 
64.3 (26.1) 
 
63.2 (23.1) 
KCCQ overall summary 
score 
(0-100) 
58.7 (23.8) 
 
61.0 (26.5) 
 
59.8 (24.0) 
Data are presented as mean (SD) 
To help put our results from the disease specific quality of life questionnaire into context, table 
10-2 presents KCCQ clinical and overall summary scores from other HF studies.34;211-213  The 
heart failure cohort investigated in this study had similar results for both summary scores 
suggesting our sample population were fairly representative of the wider HF population. 
Table10-2:  Kansas city cardiomyopathy questionnaire summary scores from    
           heart failure studies 
 SHIFT34 RED-HF212 STICH211 Heart Mate 
II213 
CIHF 
Clinical 
Summary Score  
(Max. 100) 
68 59 64 34 63 
Overall 
Summary Score  
(Max. 100) 
65 56 54 27 59 
Data are presented as means.  SHIFT, systolic heart failure treatment with the If  inhibitor 
ivabradine trial; RED-HF, reduction of events with darbopoetin alfa in heart failure trial; STICH, 
surgical treatment for ischaemic heart failure; CIHF, cognitive impairment in heart failure 
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10.2.2 Self-care of heart failure index 
 
The SCHFI was given to all patients with HF in this study and a copy of the questionnaire is 
shown in appendix XVIII.  173 out of 196 patients completed and returned this assessment 
form and the results are shown in table 10-3.   
This questionnaire asks about symptom recognition and daily interventions that patients can 
employ to improve their clinical status.  A score ≥70 is used as the cut-point to judge adequate 
self-care.   
Patients with non-ischaemic cardiomyopathy had the lowest scores for questions assessing 
ability to adhere to lifestyle modifications for HF treatment (e.g. eating a low salt diet).  They 
also had the poorest scores for self-management of HF however they had the highest scores of 
confidence in managing their condition.  From the results below it appears that the HF cohort 
enrolled into this study had poor HF self-care. 
Table 10-3:  Results of the self-care of heart failure index 
 HF.CAD 
(N = 62) 
HF.NOCAD 
(N = 45) 
HF.AF 
(N = 66) 
SCHFI 
maintenance 
(0-100) 
53.3 (14.9) 51.6 (13.9) 56.6 (14.7) 
 
SCHFI 
management 
(0-100) 
47.7 (19.9) 42.0 (24.1) 46.0 (22.0) 
 
SCHFI confidence 
(0-100) 
53.6 (20.8) 55.5 (23.5) 52.9 (23.3) 
 
Data are presented as mean (SD) 
10.2.3 EuroQol five dimensions questionnaire 
 
The EQ-5D is a standardised instrument for use as a measure of health outcome and was given 
to all study participants.  A copy of the EQ-5D is shown in appendix XVII.  A total of 328 
participants completed and returned this assessment form.  A single index value is given as a 
measure of health status (with a maximum score of 1) and a visual analogue scale records the 
respondents self-rated health status from 0-100.  Similar results were found across the 3 HF 
cohorts with a mean of 65 out of 100 on the visual analogue scale for both patients with 
ischaemic and non-ischaemic cardiomyopathy.  Of the 3 HF cohorts, patients with AF reported 
the poorest health status on the visual scale.  The results of the EQ-5D for each cohort are 
presented in table 10-3. 
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Table 10-3:  Results of EuroQol five dimensions questionnaire 
 HF.CAD 
(N = 67) 
HF.NOCAD 
(N = 45) 
HF.AF 
(N = 75) 
CAD.CONT 
(N =58 ) 
HC 
(N = 83) 
 
EQ-5D utility 
(0-1) 
 
 
0.62 (0.32) 
 
0.69 (0.26) 
 
0.66 (0.27) 
 
0.73 (0.25) 
 
0.89 (0.13) 
 
 
EQ-5D visual 
scale 
(0-100) 
 
 
65 (17) 
 
65 (20) 
 
62 (20) 
 
74 (19) 
 
88 (8.8) 
Data are presented as mean (SD) 
10.2.4 Hospital anxiety and depression scale 
 
The mood assessment tool used in this study was the HADS questionnaire.  This was given to 
each study participant at return study visit 1.  The questionnaire was completed at home and 
returned by 330 participants.  A copy of the questionnaire is shown in appendix XVII and the 
results are presented in tables 10-4 and 10-5. In clinical practice, a score of 0-7 out of a 
maximum score of 21 is normal.  A score of 8-10 out of 21 represents mild mood disorder.  A 
score of 11-14 defines moderate mood disorder and 15-21 defines severe mood disorder. 
Patients with HF had the highest scores for both the anxiety and depression subscale of HADS.  
Patients with non-ischaemic cardiomyopathy had the highest mean score on the anxiety scale 
while patients with ischaemic cardiomyopathy had the highest mean depression score. Overall 
19% of HF patients were categorised as significantly anxious (defined as scores >10 out of 21) 
and 13% of HF patients were categorised as significantly depressed (defined as scores >10 out 
of 21) on binary analyses – these results are shown in table 10-6. 
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Table 10-4:  Results of hospital anxiety and depression scale anxiety subscale 
(Range 0-21) 
 HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 46) 
HF.AF 
(N = 73) 
CAD.CONT 
(N =59) 
HC 
(N = 82) 
Mean 6.5 (5.2) 6.7 (4.4) 5.1 (3.7) 5.6 (4.6) 
 
3.9 (3.1) 
 
Median 5.0 6.0 4.0 4.5 
 
3.0 
 
Range 0, 20 0, 15 0, 16 0, 17 
 
0, 18 
 
 
 
Table 10-5:  Results of hospital anxiety and depression scale depression                   
subscale (Range 0-21) 
 HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 46) 
HF.AF 
(N = 73) 
CAD.CONT 
(N =59) 
HC 
(N = 82) 
Mean 
5.7 (3.9) 5.6 (4.1) 5.0 (3.2) 4.4 (4.3) 
 
2.3 (2.1) 
 
Median 
5.0 5.0 4.0 3.0 
 
2.0 
 
Range 
0, 15 0, 15 1, 15 0, 17 
 
0, 10 
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Table 10-6:  Results from binary analyses of the hospital anxiety and depression 
questionnaire 
 HF.CAD 
(N = 70) 
HF.NOCAD 
(N = 46) 
HF.AF 
(N = 73) 
CAD.CONT 
(N =59) 
HC 
(N = 82) 
Non-
anxiety 51 (72.9%) 37 (80.4%) 65 (89%) 50 (84.5%) 
 
79 (96.3%) 
 
Anxiety 
19 (27.1%) 9 (19.6%) 8 (11%) 9 (15.5%) 
 
3 (3.7%) 
 
Non-
depressed 60 (85.7%) 38 (82.6%) 66 (90.4%) 54 (91.5%) 
 
82 (100%) 
 
Depressed 
10 (14.3%) 8 (17.4%) 7 (9.6%) 5 (8.5%) 
 
0 (0%) 
 
Data are presented as N (%).  Cut-off defined as >10 out of 21 representing anxiety / depression 
10.2.5 Zarit burden interview 
 
The Zarit burden interview was administered to family members or friends of all enrolled 
participants.  This questionnaire was used as a measure of care giver strain and was given at 
return visit 1.  The questionnaire was completed by a relative of the participant at home and 
returned by post.  A copy of the questionnaire is shown in appendix XIX. 
146 questionnaires were returned by relatives caring for patients with HF.  53 forms were 
completed for the relatives of those in the cardiac control group and 80 for the healthy 
volunteers.  Lowest scores (reflecting less burden) were given regarding the healthy control 
group followed by the cardiac control group and non-ischaemic cardiomyopathy group.  
Relatives of patients with HF and AF gave the highest scores with 7.3% reporting moderate to 
severe levels of strain.  No completed questionnaires gave a total score falling into the “severe 
strain” category.  These results are shown in tables 10-7 and 10-8.  The cut-off values used in 
the binary analyses were taken from recently published guidelines.214 
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Table 10-7:  Results of the Zarit burden interview (Range 0-88) 
 HF.CAD 
(N =50 ) 
HF.NOCAD 
(N =41) 
HF.AF 
(N =55) 
CAD.CONT 
(N =53) 
HC 
(N =80) 
Mean 
13.5 (11.4) 12.1 (12.9) 14.1 (13.1) 11.4 (12.7) 
 
3.6 (5.3) 
 
Median 
10.5 8.0 11.0 8.0 
 
2.0 
 
Range 
0, 46 0, 60 0, 45 0, 46 
 
0, 24 
 
 
 
Table 10-8:  Binary analysis of Zarit burden interview results 
 HF.CAD 
(N=50) 
HF.NOCAD 
(N=41) 
HF.AF 
(N=55) 
CAD.CONT 
(N=53) 
HC 
(N=80) 
 
 
No- little 
burden 
(0-21) 
 
37 (74) 33 (80.5) 43 (78.2) 43 (81.1) 78 (97.5) 
 
Mild-
moderate 
burden 
(21-40) 
 
12 (24) 6 (14.6) 8 (14.5) 6 (11.3) 2 (2.5) 
 
Moderate – 
severe 
burden 
(41-60) 
 
1 (2) 2 (4.9) 4 (7.3) 4 (7.5) 0 (0) 
 
Severe 
burden 
(61-88) 
 
0 (0) 0 (0) 0 (0) 0 (0) 0(0) 
Data are presented as N (%) 
 
 
 
 
202 
 
10.2.6 Informant questionnaire on cognitive decline in the elderly 
 
This questionnaire uses informant reports as an alternative way to measure cognitive decline 
from a pre-morbid level.  A copy of the IQCODE is shown in appendix XVI and the questionnaire 
is described in more detail in chapter 3.  In this questionnaire the informant is asked to 
comment on any perceived change in cognition over the past 10 years.  A copy of the 
questionnaire was given at return visit 1, completed at home and returned by post.  This 
questionnaire has a range of scores of 1-5 with scores 0-3 representing “no change”, a score of 
4 representing “a bit worse” and 5 representing “much worse”. 
The largest perceived change in cognition was reported for patients with HF and AF with 16.4% 
of participants reporting cognitive decline in their relative.  Only one relative of a healthy 
volunteer reported that they saw a change in the cognitive function of their relative. 
Table 10-8:  Results of the informant questionnaire on cognitive decline in the 
elderly (Range 1-5) 
 HF.CAD 
(N =58) 
HF.NOCAD 
(N =42) 
HF.AF 
(N =61) 
CAD.CONT 
(N =56) 
HC 
(N =80) 
 
Mean 3.1 (0.5) 3.1 (0.4) 3.2 (0.4) 3.1 (0.5) 
 
3.1 (0.3) 
 
 
Median 3.0 3.0 3.1 3.1 
 
3.0 
 
 
Range 1.1, 4.2 1.6, 4.3 1.1, 4.2 1.0, 3.9 
 
1.0, 3.8 
 
 
Normal 
N (%) 
53 (91.4%) 38 (90.5%) 51 (83.6%) 50 (89.3%) 
 
79 (98.8%) 
 
 
Abnormal  
N (%) 5 (8.6%) 4 (9.5%) 10 (16.4%) 6 (10.7%) 
 
 
1 (1.2%) 
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10.3 Summary 
 
This chapter has shown results from questionnaires assessing disease specific quality of life, 
disease self-management and mood.  The results from two questionnaires given to 
participants’ relatives assessing care giver strain and perceived cognitive changes are also 
presented for each study cohort. 
The results presented from the KCCQ confirm that the HF population recruited into this study 
are representative of the wider HF population by comparing their summary scores to those 
from other clinical HF trials.  Despite having low scores in the self-care of HF index (suggesting 
poor levels of self-care) patients with HF were confident in managing their condition.   
Patients with HF had the lowest scores for self-reported health outcomes.  Healthy control 
participants had the best results for self-reported health outcomes.  HF patients reporting the 
highest burden of symptoms (those with HF are coronary artery disease) also reported the 
poorest levels of daily functional ability.  Almost one fifth of the HF population had scores 
indicative of clinically relevant anxiety with a lower proportion (13%) reporting clinically 
relevant depressive symptoms. 
Overall there was a low level of care giver burden reported.  Relatives of patients with HF and 
AF reported the highest level of care giver strain but none of these fell into the “serious” 
category.  Of relatives who reported care giver strain, most was classified as mild.  In addition 
to reporting care giver strain, relatives of those patients with AF also reported the highest 
perceived level of cognitive decline. 
In summary, the HF patients recruited into this study had a relatively high symptom burden 
and reduced functional ability but despite this reported confidence in the management of their 
condition and continued reasonable quality of life.  In general, anxiety was more common than 
depression and overall there was not a huge burden of mood disorder.  Despite relatives and 
caregivers being aware of cognitive decline in these patients there were low overall levels of 
caregiver strain reported. 
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CHAPTER ELEVEN 
 
CONCLUSIONS 
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11.1  Discussion and main findings of the study 
      
It is estimated that 1-2% of the adult population in developed countries have HF with the 
prevalence increasing to ≥10% among patients aged over 70 years.  HF admissions account for 
5% of all medical admissions (making it the commonest cause of unscheduled admissions in 
older adults).  Societal and demographic changes, including ageing of the general population 
and improved survival from heart disease will increase the prevalence of HF with a potential 
doubling in HF prevalence within the next 40 years.   
The estimated prevalence of CI / dementia in the UK in adults over the age of 65 years old is 
7.1% (based on 2013 data).  For the reasons outlined above the total number of people living 
with dementia in the UK is also forecast to increase to over 1 million by 2025 and over 2 million 
by 2051 if age-specific prevalence remains stable.  Figure 11-1 shows the rising incidence of 
HF and rising prevalence of dementia in two community based populations. 
 
Figure 11-1:  Incidence of heart failure within the Framingham cohort and prevalence of 
dementia by age and sex (pooled from 5 centres of the Medical Research Council 
cognitive function and ageing study).  Reproduced with permission.215 
 
The term “cardiogenic dementia” was first coined in an editorial published in the Lancet in 
1977 and so the co-existence of HF and “brain failure” has been recognised for decades.  
Although the idea of concomitant CI and HF will be familiar to most clinicians the topic has 
received relatively little research interest compared with other aspects of cardiac disease.  
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The systematic literature review presented in chapter 2 found disparate and inconsistent 
literature, characterised by small sample sizes, heterogeneity and multiple potential biases.  
This heterogeneity resulted from differences in study designs, case mix and cognitive 
assessments employed.   
This study has provided a comprehensive evaluation of cognition in a well-defined population 
of patients with HF, ischaemic heart disease and age- and sex- matched healthy controls.  The 
tolerability of performing these cognitive assessment tools has been demonstrated.  
Differences in the prevalence of CI identified with the various cognitive assessment tools have 
been demonstrated.  This study has therefore achieved its main aims. 
Of the 817 potential participants screened, 344 were included in this study.  The study cohort 
included 196 patients with HF, 61 patients with ischaemic heart disease and no HF and 87 
healthy control participants.  The HF cohort consisted of 70 patients with HF and coronary 
artery disease in sinus rhythm, 51 patients with no coronary artery disease in sinus rhythm 
and 75 patients with HF and atrial fibrillation.   
All patients with HF had evidence of HF-REF with a LVEF <45% on transthoracic 
echocardiography.  The majority of the cohort was male and elderly.  HF patients with AF were 
more likely to have multiple co-morbidities.  Despite this the majority lived independently at 
home and were stable, community-dwelling HF patients who had not been recently discharged 
from hospital. 
Patients recruited from cardiac rehabilitation clinics had proven coronary artery disease, no 
clinical HF and a LVEF >55%.  The ischaemic heart disease group were relatively well matched 
to healthy controls who had no previous diagnosis of any chronic illness, prescribed no regular 
medication and also had a LVEF >55%.  All participants underwent the same baseline 
investigations and there were no obvious differences in baseline demographics between each 
of the cohorts. 
Many potential confounding variables are relevant to cognition assessment in these cohorts of 
participants.  Our stringent exclusion criteria along with baseline investigations including 
detailed biochemical and haematological laboratory testing, urinalysis, electrocardiography 
and echocardiography aimed to reduce the possibility of confounding from other pathological 
processes.  To minimise the chance of any change in clinical condition of the participant, the 
return visit for neuropsychological assessment was held within 10 days of the initial screening 
visit. 
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The majority of participants completed all cognitive assessment tools (with the exception of 2 
participants who did not complete trails making test part B).  This detailed cognitive 
assessment took approximately 90 minutes to perform and was generally well tolerated.  The 
instruments used to assess cognition were administered in the same order to each participant 
and additional questionnaires assessing quality of life, self-care of HF and mood were 
completed at home by participants and their carers and returned by post. 
Nine individual tests of cognition were administered to 344 study participants.  In addition to 
the nine direct cognitive tests, an informant based interview was also performed to assess 
perceived change in cognitive function over time.  Three questionnaires were used to assess 
quality of life, one assessment tool to assess mood and one questionnaire to assess caregiver 
strain.   
The prevalence of CI in this sample of stable HF outpatients varied from 20-80% depending on 
the cognitive assessment tool and threshold value used.  The most commonly used cognitive 
screening test in clinical practice is the MMSE.  Using a recognised threshold of <26 out of 30, 
24% of HF patients were categorised as cognitively impaired compared to 44% when a higher 
threshold value of <28 was used.  The second global assessment tool used was the MoCA.  This 
reported a prevalence of CI of 65% in the HF cohort when a threshold of <25 was used 
compared to 80% using the higher threshold of <27.  The RBANS categorised 19% of HF 
patients as cognitively impaired using a threshold of <70 and 70% when a threshold of <90 
was used.   
Using the more conservative cut-off scores outlined above, the MoCA detected most cognitive 
changes, followed by the MMSE and then RBANS.  This is in keeping with the clinical 
applications of these neuropsychological assessment tools.  MoCA and MMSE being designed 
as global screening tools whereas RBANS being a more specific domain specific cognitive 
assessment tool.  
Regardless of the cognitive assessment tool used or the cut-off value taken to define CI the 
results always followed the same pattern.  Patients with a combination of HF and AF (either 
permanent or paroxysmal) had poorer cognition than those with HF and no history of AF.  
Patients with cardiac disease (either HF or ischaemic heart disease and no HF) always had 
poorer scores than the age- and sex- matched healthy control population and less of a 
difference was seen between the HF and ischaemic heart disease control group. 
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At the start of this study, we made the following three hypotheses: 
 1. Patients with a combination of HF and AF (either permanent or   
 paroxysmal) will have poorer cognition than those with HF and no   
 history of AF. 
 2. HF patients will attain lower cognitive scores than age and sex matched  
 cardiac control participants. 
 3. Patients with HF will attain lower cognitive scores than the age- and   
 sex- matched healthy control participants.   
The results generated from this study support hypothesis 1 and 3 but do not support 
hypothesis 2. 
 
11.2  Strengths of the study 
 
The major strength of this study is the inclusion of a cardiac control cohort which has been 
missing from previous other studies as outlined in chapter 2.  The inclusion of a cohort of 
patients with confirmed ischaemic heart disease and preserved left ventricular ejection 
fraction with no clinical HF allows us to make an assessment of whether HF per se is associated 
with CI, rather than the underlying atherosclerotic risk factors.    
The second major strength of this study is the extensive battery of neuropsychological tests 
employed.  Routine screening for CI in patients with HF is not recommended in current HF 
guidelines and this is in part due to a lack of standardised assessment tools.  By using a 
comprehensive battery of tests I not only thoroughly investigated cognition (and its individual 
domains) but was also able to compare global assessment tools and their ability to detect subtle 
changes in cognition.   
All enrolled patients have consented to re-contact for future study visits to further investigate 
the potential mechanistic basis that may underlie CI in HF.  All patients have also consented to 
be “flagged” with the Information Services Division of the Scottish Health Service.  This will 
allow accurate mortality data to be obtained by linking the study database to information on 
deaths, held by the General Registrar’s Office for Scotland. 
I employed several techniques to ensure that all data collected and processed in this study were 
robust.  Data collected from the neuropsychological tests used were marked by a blinded 
independent reviewer trained in neuropsychology (Dr Rosalind Lees).  A random 20% of the 
study booklets were then re-marked by two consultant neuropsychologists (Dr John Sharp and 
Dr Niall Broomfield), with any discrepancy in marking referred to a third Professor of 
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neuropsychology (Professor Jonathan Evans).  The creation of an electronic database held at 
the Robertson Centre for Biostatistics at the University of Glasgow ensured quality control of 
the data processed.  Although data were manually entered into this database, these were 
independently checked by two database managers.  At completion, this study was randomly 
selected for an independent audit by the NHS Greater Glasgow and Clyde Research and 
Development Governance Team (appendix XX).  The positive outcome from this rigorous audit 
process also confirms the robust nature of the data gathered.  
11.3  Limitations of the study 
 
This was a cross-sectional design study which aimed to look at the prevalence of CI in HF.  I 
therefore do not have any serial measures of cognition which would allow me to have some 
assessment of the incidence of CI in HF and the rate of cognitive decline.  To answer this 
question, prospective follow up of a cohort of HF patients free from CI at inception would be 
required.  Few studies to date have utilised this study design. 
Reports published in 2001 noted that the visuospatial/constructional and delayed memory 
indexes of RBANS tend to over classify deficits in healthy older adults.217  Common to the 
assessment of these two domains is the figure copy sub-test of RBANS which involves 
participants copying a complex geometric drawing (shown in appendix XXI).  At the end of the 
RBANS assessment the participant is then asked to draw the same shape from memory as an 
assessment of delayed memory.  An examination of a subsample of these tests showed that 
strict adherence to the scoring criteria presented in the RBANS manual resulted in lower than 
expected raw scores in these two subtests (figure copy and figure copy recall).217  Following 
suggestions from the RBANS developer the scoring criteria for figure copy and figure copy 
recall were then modified to reflect less stringent adherence to the manual’s scoring criteria.196  
Examples of these modifications included:  less exact measurements, emphasising the majority 
of correct elements and discouraging the use of a ruler for measuring.  These minor 
modifications led to scores that more closely approximated that of the original standardisation 
sample.167  Despite these modifications and clear scoring guidelines there does remain some 
subjectivity in the scoring of these two subtests of the RBANS.   
In this study I aimed to control for AF by having patients with HF in both sinus rhythm and AF.  
I did not however include a cohort of patients with AF free from HF.  Although patients in the 
HF in sinus rhythm cohort had no clinical history of AF and no previous objective 
documentation of AF, I did not routinely perform ambulatory cardiac monitoring to look for 
occult AF. 
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11.4  Future research relating to this study 
 
Additional funding has been secured to allow continuation of this existing body of work.  The 
first additional exploratory study is using neuroimaging to describe the pathophysiology of 
cognitive decline in HF.  I aim to compare the ordinal and quantitative markers of cerebral 
small vessel disease across the individual study cohorts.  Although this study shows that CI is 
prevalent in patients with HF the underlying mechanism of this association is poorly 
understood.   
Through investigator initiated funding I have performed cerebral MRIs on patients with HF 
and AF (N=25) and healthy controls (N=16).  Additional funding recently secured will now 
allow me to add neuroimaging of a third comparator group – HF with limited concomitant 
cardiovascular disease (non-ischaemic cardiomyopathy).  
The neuropathological processes of interest have specific neuroimaging signatures, these are - 
stroke: focal flair lesions; small vessel disease: white matter disease and microbleeds; 
Alzheimer’s disease: focal and hippocampal atrophy. Neuroimaging sequences include:  T1, T2, 
FLAIR, DWI, SWI MRI spectroscopy [two regions of interest per hemisphere] and diffusion 
tractography. Assessments will use both ordinal assessments scales (Fazekas, Scheltens) and 
quantitative measures of regions/lesions of interest.   The primary analyses will assess the 
relationship of differing neuroimaging findings to participant group, using Kruskal-Wallis 
testing to test ordinal and quantitative data for potential between group differences. Other 
potential differences between groups will be explored with univariate and multivariate 
models. 
The second additional study relating to the work contained in this thesis aims to assess if 
cognitive screening measures can predict non-compliance with medication in HF.  Stored urine 
samples for each study participant are being analysed for metabolites of commonly used HF 
medications (as a means of identifying whether these medications have been ingested by the 
patient).  By identifying a subgroup of patients with HF and CI and linking this to poorer 
medication adherence I would highlight the need for better supportive strategies in the 
community (e.g. nursing and pharmacy assistance) to improve adherence and this may in turn 
help improve patient outcomes. This additional study will allow us to tie together the demographic, 
echocardiographic and neuropsychological data with the “real-life” clinical implications of CI in HF. 
The third additional area of interest arising from this original study is regarding the potential 
relationship between plasma immune/inflammatory markers and CI.  A major strength of this 
study is the extensive phenotyping of all enrolled participants allowing comparisons of the 
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clinical characteristics between groups.  There is literature indicating a role for 
immune/inflammatory markers in CI and so I have stored stored EDTA and SST samples for 
each study participant to allow immunophenotyping of those patients who display CI versus 
those who do not.216  One possible “real life” consequence of CI is non-compliance with 
medication.  As a measure of medication adherence I am also performing urinalysis to look for 
metabolites of common HF medications and comparing any differences between those with CI 
and those without. 
11.5  Conclusion 
 
CI was common in this cohort of stable, community dwelling patients with chronic HF.  Up to 
80% of those patients with HF and AF showed some degree of mild CI on formal 
neuropsychological testing and this association persisted after adjustment for vascular 
comorbidities common to both conditions.  Patients with both HF and AF have poorer cognition 
than those with HF only.  Patients with cardiac disease (including HF or ischaemic heart disease 
with no HF) have poorer cognition than age and sex matched healthy adults.  There is less 
difference in cognition between patients with HF versus those with proven coronary artery 
disease and no HF. 
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Appendix I 
NHS Greater Glasgow and Clyde Health Board 
Glasgow Royal Infirmary & Western Infirmary Glasgow 
Cardiology Department 
 
Enquiries to Dr Jane Cannon 
Telephone:  0141 330 2237 
 
Cognitive Impairment in Heart Failure 
 
Patient Information Sheet 
 
We would like to invite you to take part in a research study looking at the link between heart 
problems and difficulty with memory/thinking skills. Before you decide you need to understand 
why the research is being done and what it would involve for you. Please take time to read the 
following information carefully. Talk to others about the study if you wish. Ask us if there is anything 
that is not clear or if you would like more information.  
 
Who is conducting the research? 
The research is being carried out by Dr Jane Cannon, Professor John JV McMurray, Professor 
Matthew Walters and Dr Karen Hogg from the Department of Cardiology and Cardiovascular 
Research at the University of Glasgow. 
 
What is the purpose of the study? 
Heart failure is a debilitating condition which occurs when the heart muscle becomes damaged and 
its ability to pump blood around the body becomes reduced.  There is evidence that this is linked to 
poorer thinking skills (cognitive impairment) in some people.  Cognitive impairment usually presents 
as memory difficulties and these people appear to be at increased risk of dementia in later life.  We 
aim to study patients with and without heart failure, and compare them with healthy volunteers, to 
see if the patients with heart failure show an increased risk of cognitive impairment compared to 
those without.  If we identify that this is the case then we will investigate the possible causes behind 
this.  Cognitive impairment in heart failure is an important predictor of disability, poor quality of 
life, increased hospital admissions and death.  By highlighting groups of people who are more likely 
to be at risk of cognitive impairment, it may be possible to intervene and provide extra support to 
these types of patients and so improve their quality of life.  This study does not involve taking any 
extra tablets or new medication. 
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Why have I been invited? 
We are recruiting 5 groups of people: 
 Group 1: Patients with heart failure caused by coronary artery disease  
 Group 2: Patients with coronary artery disease but no signs of heart failure 
 Group 3: Patients with heart failure not caused by coronary artery disease 
 Group 4: Healthy control participants with no history of heart failure, coronary   
     artery disease, or any other chronic inflammatory disease 
 Group 5:   Patients with heart failure of any cause and atrial fibrillation 
You have been invited to consider taking part in this study as you fall into one of the groups described 
above. 
 
Do I have to take part? 
It is up to you to decide. We will describe the study and go through this information sheet, which we 
will then give to you. You will be asked to sign a consent form to show you have agreed to take part. 
You are free to withdraw at any time, without giving reason. This would not affect the standard of 
care you receive or your future treatment. 
 
What does taking part involve? 
If you are interested in taking part in the study a member of the research team will go through this 
information sheet with you and, if you decide to take part, you will be asked to sign a consent form 
in the presence of the research doctor.  There are two stages to this study, and you will only be asked 
to participate in stage 2 providing the results of the blood tests (taken in stage 1) are satisfactory. 
 
Stage 1 
The first part of this study will last approximately 30 minutes and will be held at the Clinical 
Research Unit at the British Heart Foundation Glasgow Cardiovascular Research Centre (GCRC) 
which is located at the Western Infirmary.  This meeting will involve the following: 
 
 Medical History and Examination:  Speaking to a doctor about any symptoms/previous 
illnesses.  You will be examined for any signs of heart failure. 
 We will seek your permission to view your medical notes.  Any information gathered is only 
available to the doctors running the study. 
 A blood sample:  20mls of blood (four teaspoons) will be taken to check for any signs 
of infection/inflammation, thyroid function, kidney function, liver function, glucose, 
vitamin B12, folate and a special blood test to check for any signs of heart failure 
(BNP).  Having blood taken can be uncomfortable and some people may feel faint.  
There is a small risk of bleeding or bruising at the puncture site following the blood 
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being taken.  This blood sample will be taken in exactly the same way as other blood 
samples you would have had taken before. 
 Electrocardiograph:  This is a commonly used, noninvasive procedure for recording 
electrical changes in the heart. The record, which is called an electrocardiogram 
(ECG), shows the series of waves that relate to the electrical impulses which occur 
during each beat of the heart. The results are printed on paper.  You will be asked to 
disrobe from the waist up, and electrodes (tiny wires in adhesive pads) are applied to 
specific sites on the arms, legs, and chest. It takes approximately 10 minutes and no 
complications have been observed from this procedure. 
 
If the results of these tests meet the criteria required for inclusion in the study, a further 
appointment to take part in the second stage of the study will then be arranged with you (see 
stage 2 below).    
If any of the results of these tests exclude you from taking part in the second stage of the 
study then we would like to thank you for taking the time to read about and take part in this 
study. 
 
Stage 2 
If you remain agreeable to participating in the study, you will be asked to attend a further visit lasting 
up to 60 minutes.  This will be to the British Heart Foundation Glasgow Cardiovascular Research 
Centre (GCRC) which is located at the Western Infirmary.   
The visit will involve: 
 
 Hospital Anxiety and Depression Scale:  This is a brief 14 question self rating scale which 
can detect the presence and severity of mild degrees of mood disorder, anxiety and 
depression. 
 Geriatric Depression Scale:  This is a 15 point questionnaire comprising of yes/no answers 
which is used as a screening test for depression.  It is quick and easy to complete. 
 Kansas City Cardiomyopathy Questionnaire:  This questionnaire will be completed only by 
patients with heart failure.  This aims to show the ways that heart failure and its treatments 
can affect key physical, emotional, social and mental dimensions of a persons’ life. 
 Neuropsychological Testing:  These are scoring tests/questionnaires which allow us to assess 
short and long term memory, language, attention and IQ among other aspects of cognition. 
 
A taxi to and from these appointments will be provided free of charge if needed. 
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We may also decide to look in the near future at the cause of Cognitive Impairment using Magnetic 
Resonance Imaging (MRI) of your heart and head, and ask for your permission to contact you to 
invite you to take part in this. 
 
What happens to the information? 
Your identity and personal information will be completely confidential and known only to the 
researcher. The information obtained will remain confidential. The data is held in accordance with 
the Data Protection Act, which means that we keep it safely and cannot reveal it to other people, 
without your permission.  
 
What are the possible benefits of taking part? 
It is hoped that by taking part in this research, you will be providing valuable information regarding 
the link between these two common medical conditions (heart failure and cognitive impairment).  
Heart failure is one of the leading causes of hospital admissions and death in Western countries.  Due 
to the aging population the number of cases of heart failure is set to rise.  We aim to identify if there 
is a link between heart failure and cognitive impairment which may make these individuals at 
increased risk of dementia in later life.  If we identify a link then we will investigate the reasons 
behind this and so allow for early detection and intervention in the future.  The aim is to improve the 
treatment of these patients by improving our understanding of the conditions and the link between 
the two.  We will keep the blood samples for future ethically approved research, or in case future 
tests become available to perform which would help with our research topic. 
 
If the research doctor discovers during the study that you have another medical condition of which 
you were previously unaware, you will be referred to the appropriate doctor for the treatment of this 
condition. 
 
Who has reviewed the study? 
This study has been reviewed by one of the committees of the West of Scotland Research Service 
(WoSRES).  
 
If you have any further questions? 
We will give you a copy of the information sheet and signed consent form to keep. If you would like 
more information about the study and wish to speak to someone not closely linked to the study, 
please contact Professor Scott Muir. 
Professor Scott Muir 
Consultant Physician & Clinical Director ECMS West Glasgow 
Western Infirmary 
Glasgow 
G11 6NT 
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Telephone:  0141 211 2575. 
Email:  Scott.Muir@glasgow.ac.uk 
 
If you have a complaint about any aspect of the study? 
If you are unhappy about any aspect of the study and wish to make a complaint, please contact the 
researcher in the first instance but the normal NHS complaint mechanisms is also available to you. 
 
 
Thank-you for your time and co-operation 
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Appendix II 
Department of Cardiovascular Research    
British Heart Foundation 
Glasgow Cardiovascular Research Centre 
106 University Place 
Glasgow  
G12 8TA 
 
Enquiries to Dr Jane Cannon 
Telephone:  0141 330 2237 
 
Cognitive Impairment in Heart Failure 
 
Participant Information Sheet 
 
We would like to invite you to take part in a research study looking at the link between heart problems 
and difficulty with memory/thinking skills.  Before you decide you need to understand why the 
research is being done and what it would involve for you. Please take time to read the following 
information carefully. Talk to others about the study if you wish. Ask us if there is anything that is 
not clear or if you would like more information.  
 
Who is conducting the research? 
The research is being carried out by Dr Jane Cannon, Professor John JV McMurray, Professor 
Matthew Walters and Dr Karen Hogg from the Department of Cardiology and Cardiovascular 
Research at the University of Glasgow. 
 
What is the purpose of the study? 
Heart failure is a debilitating condition which occurs when the heart muscle becomes damaged and 
its ability to pump blood around the body becomes reduced.  There is evidence that this is linked to 
poorer thinking skills (cognitive impairment) in some people.  Cognitive impairment usually presents 
as memory difficulties and these people appear to be at increased risk of dementia in later life.  We 
aim to study patients with and without heart failure, and compare them with healthy volunteers, to 
see if the patients with heart failure show an increased risk of cognitive impairment compared to 
those without.  If we identify that this is the case then we will investigate the possible causes behind 
this.  Cognitive impairment in heart failure is an important predictor of disability, poorer quality of 
life, increased hospital admissions and death.  By highlighting groups of people who are more likely 
to be at risk of cognitive impairment, it may be possible to intervene and provide extra support to 
these patients and so improve their quality of life.  This study does not involve taking any extra 
tablets or new medication. 
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Why have I been invited? 
We are recruiting 5 groups of people: 
 Group 1: Patients with heart failure caused by coronary artery disease  
 Group 2: Patients with coronary artery disease but no signs of heart failure 
 Group 3: Patients with heart failure not caused by coronary artery disease 
 Group 4: Healthy control participants with no history of heart failure, coronary   
     Artery disease, or any other chronic inflammatory disease 
 Group 5: Patients with heart failure of any cause and atrial fibrillation 
You have been invited to consider taking part in this study as you fall into group 4. 
 
Do I have to take part? 
It is up to you to decide. We will describe the study and go through this information sheet, which we 
will then give to you. You will be asked to sign a consent form to show you have agreed to take part. 
You are free to withdraw at any time, without giving reason.   
 
What does taking part involve? 
If you are interested in taking part in the study, a member of the research team will go through this 
information sheet with you and, if you decide to take part, you will be asked to sign a consent form 
in the presence of the research doctor.  There are two stages to this study, and you will only be asked 
to participate in stage 2 providing the results of blood tests (taken in stage 1) are satisfactory. 
 
Stage 1 
The first part of this study will last approximately 30 minutes and will be held at the Clinical Research 
Unit at the British Heart Foundation Glasgow Cardiovascular Research Centre (GCRC) which is 
located at the Western Infirmary Glasgow.  This meeting will involve the following: 
 
 Medical History and Examination:  Speaking to a doctor about any symptoms/previous 
illnesses.  You will be examined for any signs of heart failure. 
 We will seek your permission to view your medical notes.  Any information gathered is only 
available to the doctors running the study. 
 A blood Sample:  20mls of blood (four teaspoons) will be taken to check for signs of 
infection/inflammation, thyroid function, kidney function, liver function, glucose, vitamin 
B12, folate and a special blood test to check for any signs of heart failure (BNP).  Having 
blood taken can be uncomfortable and some people may feel faint.  There is a small risk of 
bleeding or bruising at the puncture site following the blood being taken.   
 Electrocardiograph:  This is a commonly used, noninvasive procedure for recording 
electrical changes in the heart. The record, which is called an electrocardiogram 
(ECG), shows the series of waves that relate to the electrical impulses which occur 
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during each beat of the heart. The results are printed on paper.  You will be asked to 
disrobe from the waist up, and electrodes (tiny wires in adhesive pads) are applied to 
specific sites on the arms, legs, and chest. It takes approximately 10 minutes and no 
complications have been observed from this procedure. 
If the results of these tests meet the criteria required for inclusion in the study, a further appointment 
to take part in the second stage of the study will then be arranged with you (see stage 2 below).   
If any of the results exclude you from taking part in the second stage of the study, then we would 
like to thank you for taking the time to read about and take part in this study. 
 
Stage 2 
If you remain agreeable to participating in the study you will be asked to attend a further visit lasting 
60 minutes.  This will be to the Clinical Research Unit at the British Heart Foundation Glasgow 
Cardiovascular Research Centre (GCRC) which is located at the Western Infirmary Glasgow.  The 
visit will involve: 
  
 Hospital Anxiety and Depression Scale:  This is a brief 14 question self rating scale which 
can detect the presence and severity of mild degrees of mood disorder, anxiety and 
depression. 
 Geriatric Depression Scale:  This is a 15 point questionnaire comprising of yes/no answers 
which is used as a screening test for depression.  It is quick and easy to complete. 
 Neuropsychological Testing:  These are scoring tests/questionnaires which allow us to assess 
short and long term memory, language, attention and IQ among other aspects of cognition.  
These may be similar to previous cognitive assessments carried out through Generation 
Scotland. 
A taxi to and from these appointments will be provided free of charge if needed. 
 
We may also decide to look in the near future at the cause of cognitive impairment using Magnetic 
Resonance Imaging (MRI) of your heart and head, and ask for your permission to contact you to 
invite you to take part in this. 
 
What happens to the information? 
Your identity and personal information will be completely confidential and known only to the 
researcher. The information obtained will remain confidential. The data is held in accordance with 
the Data Protection Act, which means that we keep it safely and cannot reveal it to other people, 
without your permission.  This study data can be linked to the Generation Scotland Data 
anonymously for future research proposals.  All potential proposals will be reviewed by the existing 
Generation Scotland Access Committee. 
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What are the possible benefits of taking part? 
It is hoped that by taking part in this research, you will be providing valuable information regarding 
the link between these two common medical conditions (heart failure and cognitive impairment).  
Heart failure is one of the leading causes of hospital admissions and death in Western countries.  Due 
to the aging population the number of cases of heart failure is set to rise.  We aim to identify if there 
is a link between heart failure and cognitive impairment which may make these individuals at 
increased risk of dementia in later life.  If we identify a link then we will investigate the reasons 
behind this and so allow for early detection and intervention in the future.  The aim is to improve the 
treatment of these patients by improving our understanding of the conditions and the link between 
the two.  We will keep the blood samples for future ethically approved research, or in case future 
tests become available to perform which would help with our research topic.  If the research doctor 
discovers during the study that you have a medical condition of which you were previously unaware, 
you will be referred to the appropriate doctor for the treatment of this condition. 
 
Who has reviewed the study? 
This study has been reviewed by one of the committees of the West of Scotland Research Service 
(WoSRES).  
If you have any further questions? 
We will give you a copy of the information sheet and signed consent form to keep. If you would like 
more information about the study and wish to speak to someone not closely linked to the study, 
please contact Professor Scott Muir. 
 
Professor Scott Muir 
Consultant Physician & Clinical Director ECMS West Glasgow 
Western Infirmary 
Glasgow 
G11 6NT 
Telephone:  0141 211 2575. 
Email:  Scott.Muir@glasgow.ac.uk 
 
If you have a complaint about any aspect of the study? 
If you are unhappy about any aspect of the study and wish to make a complaint, please contact the 
researcher in the first instance but the normal NHS complaint mechanisms is also available to you. 
 
 
Thank-you for your time and co-operation 
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Appendix III 
Cognitive Impairment  
in Heart Failure 
 
 
 
 
 
 
British Heart Foundation Cardiovascular Research 
Centre 
126 University Place 
University of Glasgow 
Glasgow 
G12 8TA 
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Dear ..................................................................................... 
 
Thank you for agreeing to take part in this Heart Failure Study. 
An appointment has been made for you at the BHF Glasgow Cardiovascular 
Research Centre on:  
....................................  at  .......................... 
 
Transport will / will not be organised by us.  If you are arriving with your 
own transport please see the map for directions. 
 
When you arrive please report to the reception and someone will take 
you through to the clinic area.  The visit should last no more than 45 
minutes. 
 
Please bring your medicines with you. 
 
Kind regards, 
Dr Jane Cannon 
 
 
  For appointment queries or to change the date or time, 
please contact a member of the research team on 0141 330 
2237 
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BHF Glasgow 
Cardiovascular 
Research centre 
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British Heart Foundation Cardiovascular 
Research Centre 
126 University Place 
University of Glasgow 
Glasgow 
G12 8TA 
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Appendix IV 
Department of Cardiovascular Research 
British Heart Foundation 
Glasgow Cardiovascular Research Centre 
106 University Place 
Glasgow 
G12 8TA 
 
Cognitive Impairment in Heart Failure Consent Form                      Please inital boxes
                                                                                                            
I confirm that I have read and understand the information sheet dated 21/01/2013  
for the above study and have had the opportunity to ask questions 
 
 
I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being 
affected.  
  
I understand that sections of my medical notes may be looked at by the research 
team where it is relevant to my taking part in the research. I give my permission 
for the research team to have access to my records. 
 
I agree to my details being entered into the database at Information Services 
Division of NHS Scotland for use during this study and future ethically approved 
research.  
 
 
I agree to take part in the above study 
 
           YES            NO 
I agree to be contacted within the next 12 months regarding taking part 
in further research related to this study. 
 
 
---------------------------------------               -----------------         ---------------------------------- 
Name of Patient           Date      Signature 
 
 
 
---------------------------------------               -----------------          --------------------------------- 
Name of Researcher           Date       Signature 
 
 
1 copy to the patient, 1 copy to the researcher, 1 original for the patients’ notes 
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Appendix V 
Department of Cardiovascular Research 
British Heart Foundation 
Glasgow Cardiovascular Research Centre 
106 University Place 
Glasgow 
G12 8TA 
 
Cognitive Impairment in Heart Failure Consent Form                                      Please initial  boxes
      
 
 
 
        
I confirm that I have read and understand the information sheet dated 21/01/2013  
for the above study and have had the opportunity to ask questions 
 
 
I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being 
affected.  
 
I understand that sections of my medical notes may be looked at by the research 
team where it is relevant to my taking part in the research. I give my permission 
for the research team to have access to my records. 
 
I agree to anonymous linkage of this data to the data already held by Generation 
Scotland 
 
 
I agree to take part in the above study 
 
           YES           NO 
I agree to be contacted within the next 12 months regarding taking part 
in further research related to this study. 
 
 
---------------------------------------               -----------------         ---------------------------------- 
Name of Participant           Date      Signature 
 
 
 
---------------------------------------               -----------------          --------------------------------- 
Name of Researcher           Date       Signature 
 
 
 
1 copy to the participant, 1 copy to the researcher, 1 original for the patients’ notes 
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NHS Greater Glasgow & Clyde 
Research & Development Department 
 
 
Research and Development Department 
NHS Greater Glasgow and Clyde 
 
 
 
 
38 Church Street 
Tennent Institute 
R&D Management Offices 
Western Infirmary 
Glasgow 
G11 6NT 
 
Dr Jane Cannon 
University of Glasgow 
126 University Place 
Glasgow 
 
 
jane.cannon@glasgow.ac.uk 
  
Enquiries to: 
 
 
 
 
 
Extension:  
Direct Line: 
Date: 
  
Ms Eileen McCafferty, Auditor 
Eileen.McCafferty2@ggc.scot.nhs.uk 
 
Mrs Jane Alexander, Co-ord Assistant 
Jane.Alexander@ggc.scot.nhs.uk 
 
5 2207 
0141 211 2207 or 0141 211 8550     
23.06.2015                  
 
Investigator: Dr Jane Cannon 
Site: Glasgow Royal Infirmary 
Subject: Audit of: Non Commercial  (Academic) Study 
Sponsor: NHS Greater Glasgow & Clyde  
Title: Cognitive Impairment in Heart Failure 
Acronym: n/a 
R&D Reference: GN12CA384 
 
 
Dear  Dr Cannon 
 
In order to comply with the Research Governance Framework for Health and Community Care 2006 (as amended) 
http://www.cso.scot.nhs.uk/nrs/research-governance/, NHS Greater Glasgow & Clyde is obliged to have 
oversight of all research conducted on NHS premises.  
 
Part of this process includes systematic audit of Investigator site files.  The above study is registered on our 
Research and Development (R&D) database and has been selected for internal audit by the R&D Governance Team. 
 
The aim of the audit will be to review essential documentation within your site file(s).  I anticipate the audit will take a 
few hours to conduct. 
 
I would therefore be grateful if you could: 
 
1. Confirm a suitable date from below for me to conduct the audit 
 
 13 July – 31 July 2015 
If these dates are unsuitable, please indicate an alternative date.  Please also advise a time which is convenient for 
you. 
 
2. Confirm site to visit is as shown above. 
 
3. Ensure the site file(s), which includes data collection forms and consent forms, are available for audit and there 
is dedicated space available for the audit to be undertaken.  Please note, casenotes and x-rays will not be 
required. 
 
4. Ensure either you or a member of your study team is available at the start and end of the audit. 
 
 
In the meantime, please do not hesitate to contact me prior to the audit if I can be of any assistance. 
 
Kind regards 
 
 
 
 
 
 
Eileen McCafferty 
Research Audit Facilitator 
Appendix XX 
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